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Opening remarks
NOTE: The hard copy you are reading is for archival purposes only, and does not
contain all of the information in the thesis. It has been printed from the hypertext
to meet faculty requirements. Please use the hypertext version.
In 1998, the University of Sydney Academic Board (AB 11.3.98) made provision for
the electronic submission of PhD theses. This thesis is presented in hypertext
format, primarily because of the advantage of being able to include various
resources, such as interactive three dimensional molecular data and multiple colour
images, impossible within traditional media. Other advantages include rapid and
cheap dissemination and the preservation of numerical data in a readily useable
form. Effort has been made to make the work as general and standard for long-term
accessibility as possible. The interface is designed to be simple and self-explanatory.
The thesis is world readable via the web server
http://gabacus.pharmacol.usyd.edu.au/thesis and will be cut onto CD-ROM plus
hard copy of the text for storage by the university. While it is possible to print the
text, the work is intended to be read electronically.
Chapters 2, 3, 6 and 8 have previously been published through electronic
conferences, and also via the print journal J. Molecular Structure (Theochem), or the
electronic Internet Journal of Chemistry. Most of the other material has been
presented through conference posters and talks.
Links to all required software for browsing on various platforms are included in the
software directory to assist archival. The text is presented in Hypertext Markup
Language (.htm) and is designed to be browsed using any standard web browser on
any platform, Netscape 2.x or higher, Internet Explorer 3.x or higher. Images are in
standard formats (.jpg, .gif). Molecules are presented mostly as Cambridge Protein
Data Bank (.pdb) format, some are offered in an alternative X-Mol cartesian co-
ordinates (.xyz) format. In order to view molecular structures, a viewer such as
Rasmol or preferably the browser plugin MDL's Chemscape Chime should be
installed (see the software directory for a copy). In some instances, use has been
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made of the Chime format <embed> tag to call molecular data within the text or
tables.
The search facility included with the thesis is a PERL script which requires that it be
served from an appropriately configured web server; this feature may not operate
from an archival copy on an isolated machine. The MIME types associated with
interactive molecules may also require client and server configuration in order for
them to be recognised by a molecular browser should the thesis be mounted on a
new site, however the numerical data will still remain readable. While these
features of the thesis may become more difficult to access from an archival copy,
they are over and above those available in hard copy.
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1. Introduction
1.1 Preamble
1.2 Guide to chapters
1.3 Key references
1.1 Preamble
This thesis is primarily concerned with a class of chemical compounds known as
pyridazinediones, being 6-membered aromatic rings containing two adjacent
nitrogen atoms (pyridazine), doubly substituted with oxygen. In particular, the
work focuses on pyridazine-3,6-diones, derivatives of maleic hydrazide (1).
Understanding of the chemistry of these compounds is extended, using theoretical
and synthetic techniques.
Scheme 1.1 maleic hydrazide (1)
This thesis is also concerned with two very important classes of receptors which
bind amino acids in the brain: firstly, the inhibitory GABA receptor, which binds -
aminobutyric acid (GABA) (2) in vivo, and for which muscimol (3) is an agonist of
the GABAA subclass; secondly, Excitatory Amino Acid (EAA) receptors, which bind
glutamate (4) in vivo, and in particular the AMPA subclass, for which (S)-2-amino-3-
(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) (5) is an agonist.
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-aminobutyric acid (GABA) (2) muscimol (3)
glutamate (4) AMPA (5)
Scheme 1.2 important amino acids
The connection between pyridazinediones and amino acid receptors is the design,
synthesis, and evaluation of structures based on pyridazinediones as potential
GABA and EAA receptor ligands. Techniques of theoretical chemistry, molecular
modelling, synthetic chemistry, and in vitro pharmacology are used to explore
pyridazine-3,6-dione derivatives as ligands.
1.2 Guide to chapters
Chapter 1 (this chapter) describes the way in which the other stand-alone chapters
are linked, and provides some background.
Chapter 2 is concerned with an exhaustive theoretical investigation into the
tautomerism of the four isomeric pyridazinone N-oxides, and pyridazine 1,2-
dioxide, positional isomers of maleic hydrazide (1). It also describes aspects of the
structure and pKa behaviour of these isomers, and their conjugate bases. Whereas
the tautomerism of (1) and other diazine diones is well studied, the structure and
tautomerism of these compounds has been previously considered only briefly. High
level quantum computational techniques are used, and compared with experiment
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where possible. Tautomerism is an important chemical study in its own right, has
long been a challenge to computational and experimental techniques. It is also
important for understanding the way that heterocycles behave biologically, as a
prelude to medicinal chemistry.
Chapter 3 extends the study in Chapter 2 to the four isomeric pyridazinediones,
including maleic hydrazide (1), capable of very highly complex tautomerism.
Previous theoretical studies on (1) are improved upon, and the tautomerism and
properties of the conjugate bases of these isomers is examined for the first time.
Since pyridazinediones are acidic in solution, and predominantly ionised at
physiological pH, the study of their anionic forms is of particular interest as
background to the medicinal chemistry of their derivatives.
Chapter 4 introduces the GABA and EAA receptors with a brief discussion of their
history and therapeutic importance. The role that 3-isoxazolols such as muscimol
(3) and AMPA (5) et al. have had in defining these receptors is described. The
rationale for examining pyridazinedione derivatives as ligands for these receptors is
discussed, with the aid of molecular modelling. A set of twelve target compounds
to be evaluated is presented.
Chapter 5 describes synthetic efforts to produce the twelve compounds described in
Chapter 4: glycino-, alanino-, aminomethyl-, and tetrahydropyrido- derivatives of
(1), and their N-methyl substituted counterparts. Several stumbling blocks were
encountered, leading to the abandonment of the synthesis of the glycino-
pyridazinediones. An unexpected synthetic result yielded another test compound.
Chapter 6 concerns one aspect of the synthesis of pyridazinone amino acid
analogues: free-radical bromination by N-bromosuccinimide (NBS) as described in
Chapter 5. A crucial step in the synthesis, this reaction is difficult to control, and
often produces mixtures or unexpected products. In this chapter, several NBS
reactions on methyl pyridazinones are investigated using techniques from
theoretical chemistry. A rapid method of predicting the results of the reaction is
developed, increasing understanding of the reaction.
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Chapter 7 describes the pharmacological experiments performed to evaluate the ten
analogues synthesised in Chapter 5 for activity. The guinea-pig ilium is used to test
muscimol and THIP analogues for GABAA activity, and xenopus oocytes are used
to test for GABAC activity. The rat cortical wedge preparation is used to test the
AMPA analogues for EAA (NMDA and AMPA receptor) activity.
Chapter 8 concerns the AMPA receptor, and in particular, the types of oxygen-
substituted heterocycles which may act as bioisosteres for the -carboxylate group
of glutamate at this receptor. A range of heterocycles producing AMPA analogues
of varying activity are submitted to theoretical investigation, including the study of
their tautomerism and pKa behaviour. The tested pyridazinones are evaluated and
compared with other bioisosteres, and predictions are made about the nature of
AMPA receptor binding and the future direction of medicinal chemistry in this
area.
1.3 Key references and background
Familiarity with chemical nomenclature is assumed throughout. Reasonable
familiarity with organic chemistry, molecular modelling, applied ab initio and semi-
empirical quantum theory are assumed for Chapters 2, 3, 4, 6, and 8. A basic
understanding of synthetic heterocyclic chemistry is assumed in Chapters 5 and 6.
Chapters 4, 7, and 8 assume a basic understanding of drug design and
pharmacology.
The following key references provide much of the necessary background for the
material presented
Molecular modelling and applied ab initio quantum theory:
• JB Foresman, A Frisch, Exploring Chemistry with Electronic Structure Methods,
2nd Ed., Gaussian Inc., (1995-6).
• WJ Hehre, Practical Strategies for Electronic Structure Calculations,
Wavefunction Inc., (1995)
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Heterocyclic tautomerism:
• J Elguero, C Marzin, AR Katritzky, P Linda, The Tautomerism of
Heterocycles, Advances in Heterocyclic Chemistry, Supplement 1 (1976)
Pyridazine synthetic chemistry:
• RN Castle, Pyridazines, The Chemistry of Heterocyclic Compounds, Wiley
Interscience, 28, (1973)
Pyridazine medicinal chemistry:
• G Heinisch, H Frank, Progress in Medicinal Chemistry, 27, 1 (1990)
• G Heinisch, H Frank, Progress in Medicinal Chemistry, 29, 141 (1992)
Bioisosterism in drug design:
• T Fujita, Similarities in bioanalogous structural transformation patterns
among various bioactive compound series, Biosci. Biotech. Biochem., 60(4),
557-566 (1996)
• GA Patani, EJ LaVoie, Bioisosterism: A rational approach in drug design,
Chem. Rev., 96, 3147-3176 (1996).
• CA Lipinkski, Bioisosterism in drug design, Ch 27, Annual reports in
Medicinal Chemistry, 21, (1986)
GABA receptor medicinal chemistry and pharmacology:
• SJ Enna, NG Bowery, The GABA Receptors, Humana Press (Totowa, NJ), 2nd
ed. (1997)
• P Krogsgaard-Larsen, B Frølund, FS Jørgensen and A Schousboe. GABAA
receptor agonists, partial agonists, and antagonists. Design and therapeutic
prospects, Journal of Medicinal Chemistry 37(16), 2489-2505 (1994)
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• DIB Kerr and J Ong, GABA agonists and antagonists, Medicinal Research
Reviews, 12(6) 593-636 (1992).
• GAR Johnston, GABAA agonists as targets for drug development, Clinical and
Experimental Pharmacology and Physiology, 19, 73-78 (1992)
Excitatory Amino Acid receptor medicinal chemistry and pharmacology:
• G Vaccarella, Synthesis and activity of Pyridazine analogues of glutamic acid, PhD
thesis, Department of Pharmacology, University of Sydney (1998)
• DT Monaghan, R Wenthold, The Ionotropic Glutamate Receptors, Humana
Press (Totowa, NJ), 2nd ed. (1997)
• P Krogsgaard-Larsen, B Ebert, TM Lund, H Bräuner-Osborne, FA Sløk, TN
Johansen, L Brehm, U Madsen, Design of excitatory amino acid receptor
agonists, partial agonists and antagonists: ibotenic acid as a key lead
structure, European Journal of Medicinal Chemistry 31, 515-537 (1996)
• JJ Hansen, P Krogsgaard-Larsen, Structural, Conformational, and
Stereochemical Requirements of Central Excitatory Amino Acid Receptors,
Medicinal Research Reviews, 10(1), 55-94 (1990)
Medical applications:
• P Krogsgaard-Larsen, Amino acid neutrotransmitters in Alzheimer's disease:
focus on AMPA and GABAA receptors, European Journal of Pharmaceutical
Sciences, 2, 59-61 (1994)
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2. Tautomerism of hydroxy pyridazines: the N-oxides.
Abstract
A comprehensive theoretical study of the structure and tautomerism of the four isomeric
hydroxy pyridazine N-oxides, as well as pyridazine-1,2-dioxide is presented. Gas phase
properties are modelled with high-level ab initio calculations employing large basis sets (6-
311++G(3df,3pd)) and quadratic configuration interaction treatment of electron correlation
(QCISD(T)). Since these acidic heterocycles are of interest as novel carboxylate bio-isosteres, their
anionic conjugate bases are also examined. Aqueous solution-phase properties are investigated
using the isodensity polarised continuum model (IPCM) , and the semi-empirical AM1-SM2 and
PM3-SM3 models, and relative acidities compared. The calculated properties are generally in
good agreement with existing experimental data, indicating that the 1-hydroxy tautomer
predominates both in the gas phase and in solution in the case of the 6- substituted system, and
that hydroxy 1-oxide tautomers predominate in the 3- and 5- substituted systems. The behaviour
of the 4-substituted isomer is less clear, with non-planar 1-hydroxy and planar 4-hydroxy
tautomers being similar in stability.
"Tautomerism of hydroxy pyridazines: the N-oxides" JR Greenwood, HR
Capper, RD Allan, GAR Johnston. Journal of Molecular Structure (Theochem)
419, 97-111 (1997)
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2.1 Introduction
As a class, the pyridazines are the least studied and understood of the six-
membered diazine heterocycles, both experimentally, and theoretically [1]. With the
resurgence of interest in pyridazine derivatives as novel bio-active molecules [2,3,4]
and with the close structural similarity of some hydroxy pyridazines to better
known systems such as uracil, these compounds are expected to be the subject of
further synthetic and medicinal study. In particular, being relatively strong acids
and having comparatively large dipoles, these heterocycles show promise as novel
carboxylate bio-isosteres.
Pyridazine-1,2-dioxide 1, and 3-, 4-, and 5-hydroxy pyridazine 1-oxides 2, 3, 4, are
known synthetically [5,6,7,8]. Various ring-substituted derivatives of 6-hydroxy-
pyridazine 1-oxide 5 are also known [9], although the parent compound appears to
have eluded synthesis, despite the fact that its immediate precursors 6-chloro and 6-
methoxy pyridazine 1-oxide are known [10].
Experimental studies on the tautomerism of these compounds are few, and
apparently the subject has been neglected since the 1960s. Itai [11] suggests that 2c
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is favoured over 2b, 3a over 3d, 4d over 4b, and 5a over 5d, i.e. that hydroxy N-
oxides are preferred for 2 and 4, and N-hydroxy ketones for 3 and 5, citing
[6,8,9,12,13] as evidence. Igeta [6,14] has made a thorough study of 2, and based on
NMR and UV spectroscopic data has concluded the preference for the lactim form
2c, and found a pKa value of 4.1 for this system. 4 is also well studied by UV
spectroscopy by Okusa and Kamiya [8] who concluded that the phenolic 4d is
preferred. By contrast, 3 and 5 are poorly studied. Aspects of the chemistry of
derivatives of 5, such as facile demethylation of 6-methoxy pyridazine 1-oxides or
methyl migration to form 1-methoxy pyridazin-6(1H)-ones [15], along with
comparisons with other better-studied N-hydroxy alpha-oxo heterocyles (e.g. 9,
[37]), may be taken to support the hypothesis of the predominance of 1-hydroxy
tautomers in the absence of direct studies. The tautomerism of 3 and its derivatives
is even less well studied; certainly alkylation and acylation yield 1-OR derivatives
[7] suggesting 3a, but this is not conclusive, as kinetics or thermodynamics may
render alkylation favourable or unfavourable regardless of tautomer prevalence.
The conclusions of Itai [11] would seem valid in the case of the solution-phase
behaviour of 2 and 4, and open to further investigation in the case of 5 and
particularly 3.
The hydroxy-pyridazine 1-oxides are apparently previously unstudied
theoretically. Pyridazine 1,2-dioxide 1 has received limited attention as the subject
of semi-empirical MINDO/2, CNDO/2 and other calculations [16,17]. The closely
related 3- and 4-hydroxy-pyridazines 12, 13 are better studied. Fabian [18,19]
reports a semi-empirical (AM1, PM3, MNDO, MINDO/3) and ab initio (HF/3-21G)
study of these compounds, in conjunction with 3,6-pyridazinedione 15 (maleic
hydrazide) and 3,5-pyridazinedione 14, concluding inter alia that PM3 handles these
systems better than other low-cost methods. La Manna et al. [20,21] report
calculations to HF/6-31G(d)//3-21G, finding 3(2H)-pyridazinone and 4(1H)-
pyridazinone to be favoured tautomers. Lapinski et al. [22,23] studied the 3-hydroxy
pyridazine 12 system at HF/3-21G and SCF-MBPT(2)/DZ(d,p) theories, in
conjunction with IR experiments, and predicted 3(2H)-pyridazinone to be heavily
favoured, in agreement with experiment. Maleic hydrazide 15, being perhaps the
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best known pyridazine derivative and a commercial plant-growth inhibitor, and
having been determined as preferring the somewhat unusual lactam-lactim
structure in numerous experiments [24], has been more thoroughly studied, and
attempts made to include solvation effects. In addition to the work of Fabian [18,19],
Hofmann et al. [25] studied maleic hydrazide tautomerism up to HF/6-31G(d), and
calculated the free-energy of solvation of the favoured lactam-lactim tautomer to be
-12.2 Kcal, via Tomasi's polarisable continuum model (PCM) [26]. A more extensive
treatment was performed by Burton et al.. [27], who conducted gas-phase
calculations to MP4/6-31G(d,p)//6-31G(d,p), made comparisons with experiments
based on the pKas of known methyl-derivative model compounds, and estimated
solvent effects by three methods: molecular dynamics simulation (free-energy
perturbation, FEP), self-consistent reaction field (SCRF) in an ellipsoidal cavity, and
the PCM model.
The aim of this study of hydroxy pyridazine 1-oxides 2, 3, 4, 5 is to describe the
complex tautomerism of these molecules by applying and building on the
theoretical methods previously applied to similar systems. Additionally, the same
methods are applied to their anionic conjugate bases, likely to be present at
physiological pH. In order to lay theoretical ground for medicinal chemistry
studies, aqueous solution-phase modelling is performed, including semi-empirical
methods not previously applied to pyridazines, but described in detail for the
tautomerism of 5-isoxazolols by Cramer and Truhlar [28]. For completeness and
comparison, the non-acidic non-tautomeric pyridazine-1,2-dioxide 1 is also
included in this study.
2.2 Methods and Results
Following the description of heterocyclic tautomerism given by Elguero et al.. [24], a
set of all possible tautomers and their conjugate bases were generated. Firstly, non-
substituted ring carbons were assumed to be at least singly protonated. This defines
the four anions 2-, 3-, 4-, 5-. To each of these, the addition of a proton to the
unsubstituted nitrogen, either of the two oxygens, or to a carbon - to an oxygen
substituent (forming a methylene), defines a complete set of structures; five neutral
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tautomers for 2, six for 3, five for 4, and four for 5. No tautomerism is possible, nor
may an anion be formed of 1 under this system. Chart 2.1 provides a key to these
structures.
Initially, all structures were built with planar geometry. Rotation of 180° about the
carbon-oxygen bond generates two distinct conformers in the case of hydroxy
tautomers. Optimisations of both conformers of each hydroxy tautomer were
performed at HF / 6-31G(d), and the results summarised in Table 2.1. The higher
energy conformer of each hydroxy tautomer was discarded from the study set.
Optimisation and frequency calculations were performed at HF / 6-31G(d) on all
tautomers, including the recommended scaling factor of 0.8929 for frequencies and
thermochemistry calculated at 298.15K. Structures 3a, 3f, and 5c were found to have
imaginary frequencies at this level, and were re-optimised in C1 symmetry. A high
energy minimum for structure 5c was found in C1 symmetry at HF / 3-21G, but
optimisation failed to find a minimum at HF / 6-31G(d). In addition, methylene-
containing tautomers 2d, 2e, 3c and 4c were found to have particularly small lowest
vibrational frequencies, e.g. 34 cm-1 for 2d, indicating very soft bending of the
methylene out of the ring plane at this level of theory and basis set. Minima and
energies are presented in Table 2.2.
Tautomers whose energies were greater than 25 Kcal above that of the lowest
energy tautomer at HF / 6-31G(d), i.e. 3b, 3e, 3f, 5b and 5c, were then discarded
from the set as being very unlikely to contribute significantly to tautomerism (cf
[25]). A second form of 3a, the planar structure 3a', found to be a transition
structure at this level, was added to the set for further study on account of the very
small difference between the energies of the Cs and C1 structures. The remaining set
of structures was optimised at MP2 / 6-31G(d,p), and this geometry was used in all
subsequent ab initio calculations.
Ideally, high accuracy gas-phase energies would be obtained from a compound
method such as G2 theory, or alternately a complete basis set method such as CBS-
Q, but such calculations were too expensive to apply to each system. Instead, single
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point energies were calculated at MP2 theory with the large basis set 6-
311++G(3df,3pd). The extra diffuse functions and high angular momentum
functions are employed to treat as far as possible on equal footing anions and
neutral species, and atoms of differing hybridisation, known to present problems
for calculations of heterocyclic tautomerism [28]. Higher order correlation effects
were considered by performing single point energy calculations at QCISD(T) / 6-
31G(d,p). Compound energies were then calculated by correcting the MP2 / 6-
31g(d,p) energy as follows, and are presented in Table 2.3.
E0 = ZPE{HF/6-31G(d)}*0.8929 + E{MP2/6-311++G(3df,3pd)} + E{QCISD(T)/6-
31G(d,p)} - E{MP2/6-31G(d,p)}
The basis set for the base energy of this method is intermediate in size between the
G2(MP2,SVP) theory of Smith and Radom, and Curtiss et al.. [29,30] i.e. 6-31G(d),
and G2(MP2) theory [31] i.e. /6-311G(d,p). Both these methods include an empirical
EHLC term in the calculation of E0, to correct for residual basis set deficiencies. Since
this term is a linear combination of the number of alpha and beta electrons, which
are identical for all of the isomeric structures considered, this term cancels for
relative energies, and has not been included. Relative energies calculated by the
above means are expected to be more accurate than G2(MP2,SVP) theory, but
probably not better than the more expensive G2(MP2) theory, despite the larger
basis set correction term employed. In particular, poor or inconsistent treatment by
MP2 at the base level of calculation is a possible source of error.
From the scaled thermochemical properties calculated at HF / 6-31G(d), gas phase
relative free energies of tautomerism and of proton loss at 298.15K were calculated,
and these values are included in Table 2.3.
Since the compound E0 values and free energies calculated for 3a, 3a', and 3d were
found to be very similar, a series of higher level calculations were performed on
these three structures, summarised in Table 2.4. Modified and extended G2 and
G2(MP2) energies were calculated, and relative free energies at 298.15K calculated
from the compound energy derived from the highest level calculations available.
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The high cost of the MP4/6-311G(2df,p) calculation has prevented the direct
calculation of G2 energies for the C1 symmetry structure 3a. For comparison, this
energy is approximated as follows: the unknown effect of higher level (MP4 vs
MP2) correlation on 3a at 6-311G(2df,p) is estimated as the known effect on the Cs
symmetry conformer 3a', corrected by the known difference between these two
effects calculated with the smaller basis set 6-311G(d,p).
Free energies of aqueous solvation were estimated by three different theories, and
the results presented in Table 2.5. Firstly, the isodensity polarised continuum model
(IPCM) [32], an extension to the PCM model used previously for solvation of
pyridazinones [25,27], was used to calculate single point energies at MP2 / 6-
31G(d,p), using a solvent dielectric constant of 78.4 and the recommended
isodensity value of 0.001, from which were subtracted the gas-phase energies at this
level. Secondly, both single point energies at the MP2 / 6-31G(d,p) geometries and
optimisations were performed using the semi-empirical AM1, and AM1-SM2
aqueous solvation model of Truhlar and Cramer [33], and free energies of solvation
determined as the difference between the two. Single point energies may be more
reliable than optimised calculations, due to poor semi-empirical geometries,
however both types of calculation are presented for comparison. For several
optimisations, maximum gradients remained large, a known tendency of aromatic
systems in this model [40]. Thirdly, the same calculations were performed using the
PM3-SM3 model [34]. The PM3-based semi-empirical calculations are of interest in
light of the known superior treatment of pyridazinediones by PM3 vs. AM1 [19,35].
The alternative AM1-SM1a model which requires explicit declaration of atom type,
suggested by Cramer and Truhlar for the calculation of heterocyclic tautomerism
[28], was not used because of the ambiguous hybridisation of certain atoms in the
set, particularly with respect to anions.
Addition of the free-energies of solvation to the gas-phase free energies gives an
estimate of the relative free energies of tautomers in aqueous solution at 298.15K.
For two tautomers in equilibrium, if the free energies in solution are known to a
sufficient degree of accuracy, the tautomeric ratio may be calculated:
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HA1 <=> HA2 ; K2,1 = [HA2]/[HA1] = exp((G1-G2)/RT)
From the relative free energies, normalised tautomer ratios (neglecting tautomers of
very low concentration) have been calculated by this method, and are presented in
Table 2.6.
In principle, assuming one acid produces one base in solution, pKa or pKb can be
calculated ab initio by modelling the following reactions in the gas phase, and
correcting with free energy of solvation for each species
HA + H2O <=> H3O
+ + A- ; pKa = -log(exp(- G/RT))
HA + OH- <=> A- + H2O ; pKb = -log(exp(- G/RT))
The latter reaction has the attraction of equal numbers of charged species on both
sides, thus minimising systematic error. Unfortunately, the difficulty of treating
different anions equally in the gas phase, and in particular the difficulty of
modelling the hydroxide ion, and the difficulty of obtaining sufficiently precise and
consistent treatment of G of aqueous solvation across all species preclude the
accurate ab initio calculation of pKa by this approach at present.
By making the assumption that systematic errors are consistent across similar
systems, we may write the following:
pKa = k - log(exp((GHA - GA-)/RT))
where k is assumed to be constant across a series of closely related acid-base pairs,
and is the sum of systematic errors and free energy terms of neglected species.
Given the tautomeric proportions ai calculated as above, if a single base gives rise to
multiple acid tautomers, this may be extended:
pKa = k - a1*log(exp((GHA1 - GA-)/RT)) - a2*log(exp((GHA2 - GA-)/RT)) - ...
Estimations of relative pKas by this method are given in Table 2.7.
Some literature pKa values of closely related systems are given in Table 2.8 for
comparison.
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Figures
The anions and low energy tautomers optimised at MP2/6-31G(d,p) for each
system are presented as spheres of the van der Waals radii. Gas phase free energies
of tautomers relative to the anion are indicated in pink, calculated at 298.15K from
compound energies (Table 2.3) Electrostatic potential-derived charges from the
Merz-Kollman-Singh scheme are overlayed on atoms in yellow. Dipoles are
indicated by overlayed vectors, with units of 1 debye corresponding to distances of
1 angstrom.
Figure 2.1 pyridazine-1,2-dioxide
Figure 2.2 3-hydroxypyridazine 1-oxide
Figure 2.3 4-hydroxypyridazine 1-oxide
Figure 2.4 5-hydroxypyridazine 1-oxide
Figure 2.5 6-hydroxypyridazine 1-oxide
A key to structures referred to in the text is given in Chart 2.1, and the optimised
geometries indexed as .pdb files.
2.3 Discussion
In order to evaluate these results, discussion of the major sources of error is in
order. Smith and Radom [29], and Curtiss et al. [30] compare gas phase energies
calculated by G2(MP2) and G2(MP2,SVP) with experiment for a large test suite of
small acyclic species, including dissociation and ionisation energies, and electron
and proton affinities. The relative gas phase energies calculated by the compound
method described here should be intermediate in accuracy between G2(MP2) and
G2(MP2,SVP). While we are actually considering proton affinities in this work, the
test suite only concerned cations in this regard. Hence, electron affinities,
incorporating inherently less reliable calculations on anions, are probably a better
indication of accuracy. The results obtained were mean absolute deviations (MAD)
from experiment of 0.6 Kcal and 0.7 Kcal for the two methods respectively for
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proton affinities, and 1.9 and 2.1 Kcal respectively for electron affinities. This gives
an indication of the magnitudes of error in comparing the gas-phase acidities of
different systems. The accuracy of the relative gas phase free energies of
tautomerism, being between neutral tautomeric species within a single system, is
likely to be handled somewhat better than this.
Energy calculations on these heterocycles are slow to converge with increasing basis
set and correlation method; a glance at Table 2.4 shows variation in qualitative
predictions to the highest levels trialed. Very high levels of theory may be necessary
to evaluate relative energies to the degree required for accurate prediction of
tautomer proportions; a difference of only 1.36 Kcal corresponds to a ten-fold
difference in tautomeric ratio. None the less, other than for 3, we are confident that
the required level of accuracy has been attained for qualitative prediction of gas
phase tautomerism.
The highest level calculations performed have been unable to resolve the issue of
which tautomer of 3 is preferred in the gas phase. Both the N-hydroxy 3a and 4-
hydroxy 3d structures are low in energy. The qualitative predictions vary with basis
set, correlation treatment, and compound method employed. The issue of whether
the planar 3a' or non-planar 3a is preferred is also unresolved; larger basis sets seem
to favour planar geometry, while better treatment of electron correlation favours
non-planar. Optimisation with a larger basis set, i.e. at 6-311+G(d,p) seems to make
a small difference, but between structures so close in energy, perhaps a significant
one. The inference from these results is that any difference in energy between 3a
and 3d is sufficiently small to indicate the likely presence of both structures in the
gas phase. Entropy and thermal terms appear to favour 3a over 3d slightly.
Concerning the structure of 3a: if the planar 3a' actually represents a local
maximum (saddle point), as indicated by the HF/6-31G(d) frequency calculation,
then the energy barrier of inversion of conformation is exceedingly small.
Conversely, if 3a' is lower in energy than 3a as suggested by compound theories,
and is a truly a local minimum, then either the hydroxyl rotation out of the plane
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and ring puckering is an exceedingly soft vibrational mode, or the compound will
display significant populations in both non-planar and planar minima.
By contrast, the energies of tautomers of 2, 4, and 5 are sufficiently separated to
allow confident prediction of tautomerism. The 3-substituted system 2 shows a
clear preference of 3.3 Kcal in the gas phase for the 3-hydroxy tautomer 2c over the
NH oxo-oxo tautomer 2b, in accordance with the predictions of Itai [11], with all
other tautomers being substantially less significant. Also predicted was the
preference of 4 for the 5-hydroxy 1-oxide tautomer 4d over the NH oxo-oxo
tautomer 4b, and this is indeed found to be the case by 6.5 Kcal at 0K. However, it is
the N-hydroxy-oxo tautomer 4a which is found to be next lowest in energy, being
4.3 Kcal relative to 4d. The comparative stability of 4a was not suggested in Okusa's
experimental study [8], and stands in contrast to the much less favoured analogous
N-hydroxy-oxo tautomer 2a. 3.3 Kcal separates the N-hydroxy-oxo tautomer 5a
from the 6-hydroxy 1-oxide 5d, in accordance with literature predictions, with no
other significant contributing tautomers. Strong intramolecular hydrogen bonding
is observed for this species, affecting the conformation, and reversing the normal
preference for the HONN dihedral to be 0°. This bonding would also be likely to
have implications for physical properties, e.g. solid state where hydrogen bonded
dimers are recorded for similar systems, and acidity.
It is also noteworthy that while none of the methylene-containing tautomers appear
to contribute significantly to tautomerism - Elguero [24] suggests these are more
important in five-membered heterocyclic rings than six - none the less, some
methylene tautomers are less unfavourable than expected. For example, 4(3H)-
pyridazinone 1-oxide 3c is more stable than the NH isomer, 4(2H)-pyridazinone 1-
oxide 3b.
The accurate prediction of solution-phase properties is a much more challenging
task than the prediction of gas phase properties, particularly for an aqueous system
such as this one, for which hydrogen bonding interactions in the first solvation
sheath are likely to be crucial. Of the commonly used methods, molecular dynamics
(FEP) treatments generally ignore the effects of solute polarisation, and to a large
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extent, solvent polarisation [28], while giving fair treatment of first solvation sheath
effects. Conversely, continuum model (SCRF) treatments neglect first solvation
sheath effects, but potentially consider polarisation effects accurately. The
improvement of continuum models to include a cavity defined by an isodensity
surface (IPCM) is recent in origin, and little data exists to indicate how well it
handles these kinds of systems. Concern also exists about the suitability of IPCM for
calculations on anions due to "charge leakage" which occurs with truncation of
wavefunctions as the isodensity cavity is contracted. The semi-empirical SMx
models hold the attraction of consideration of both polarisation terms, and through
empirical atomic parametisation, first solvation sheath effects, and are therefore the
methods of choice for this problem.
Across the different solvation methods trialed, the estimates of G are generally in
fair agreement, with some anomalies (Table 2.5). As expected, the IPCM method
shows greater variability, while the semi-empirical models are more concordant.
Certain qualitative trends are reversed for IPCM, e.g. the comparison of 3a and 3a',
which alters the predicted preferred structure in solution; IPCM predicts the non-
planar structure, while SMx more credibly predicts the stabilisation of the planar
structure. The solvation energies of the anions also appear to be under-estimated by
IPCM compared with semi-empirical methods, as is the solvation of 1, and non-
hydroxy tautomers in general. Despite the variablility of these figures, the
qualitative predictions of tautomer distribution (Table 2.6) remain substantially
similar across all methods, with the exception of 3. The quoted [40] RMS errors for
neutral species and ions using AM1-SM2 and PM3-SM3, are 0.9 and 4.0, and 1.2 and
5.6 respectively. The indication is that qualitative comparisons from these
treatments between tautomers in the aqueous phase are probably valid, except
where tautomers lie very close in energy (3). Quantitative estimates, taking into
account both gas phase and solution phase errors, may easily be in error by an
order of magnitude or more. Comparisons of aqueous acidities between systems,
requiring consistent treatment of different anions vs. neutrals, are unlikely to be
accurate within 5 Kcal/mol at best. Given that a difference of only 5 Kcal translates
to a pKa difference of 3.7, the quantities in Table 2.7 should be viewed with a great
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deal of scepticism; current models are simply unable to make quantitative
predictions by this means. The literature only contains a single pKa value for a
hydroxy pyridazine N-oxide with which to judge these results - that of 2, which has
been determined to be 4.1 [6]. This would imply pKa values of well below zero for 3
and 4, according to the semi-empirical solvation methods, which seems unlikely to
be correct. On the other hand, all methods trialed gave the same qualitative
predictions of the order of acidity, i.e. pKa 4 > 3 > 5 > 2. This prediction can be
compared with experimental pKa values of closely related hydroxy heterocycles
(Table 2.8.) Comparing 12 with 13, and 14 with 15 indicates increased acidity of a
hydroxyl in the 4- vs. the 3- position of pyridazine, which is consistent with the
prediction of 3 and 4 to be more acidic than 2 and 5. N-oxidation of hydroxy-
pyridines causes a substantial drop in pKa, of between 2.3 and 5.7 units, and N-
oxidation of 12 to 2 causes a drop of 5.8 units, thus the N-oxides of 13, i.e. 3 and 4,
are expected to be strongly acidic, in accordance with these qualitative predictions.
The pKa of 10, having a hydroxyl meta- to an N-oxide, is 0.5 units higher than that
of the ortho- and para- isomers 9 and 11. This is in accordance with the prediction
that 4 is more acidic than 3, and 5 is more acidic than 2. Note also, that the predicted
relative acidity of 5 increases from the gas phase to solution, compared with other
tautomers. This is to be expected if the extra stability of strong intramolecular
hydrogen bonding of the neutral species in the gas-phase is diminished in aqueous
solution, allowing easier dissociation.
2.4 Conclusion
The literature experimentally-based predictions of the tautomerism of 3-, 5-, and 6-
hydroxy-pyridazine 1-oxides 2, 4, 5 are confirmed by theory. The hydroxy N-oxide
tautomers are predicted to be substantially favoured in the case of 2 and 4, both in
solution and in the gas phase. The N-hydroxy-oxo tautomer of 5 is predicted to be
substantially favoured in both phases, a result suggested by experiments on similar
structures. No firm conclusion has been reached regarding 4-hydroxy-pyridazine 1-
oxide 3, nor has sufficient experimental data been found with which to make
comparisons. However, it seems likely that in solution both planar N-hydroxy and
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4-hydroxy tautomers are present in significant quantities. Likewise, in the gas
phase, both N-hydroxy and 4-hydroxy tautomers are likely to be significant,
although the preferred structure of the N-hydroxy compound remains unresolved.
2.5 Calculation details
MP4 and QCISD(T) energies were calculated using Molpro 96 [39]. AM1-SM2 and
PM3-SM3 were performed using AMSOL 5.4 [40]. All other calculations were
performed using Gaussian 94 [41]. Platforms used were SGI R10000 Power
Challenge and IBM RS6000.
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Table 2.1. Discrimination of favourable conformers at RHF/6-31G(d)
 Name  Energy (a.u.)  Name  Energy
 2a -412.29334  4a  -412.29453
 2a' -412.27514  4a' -412.28151
 2c  -412.30854  4d  -412.29677
 2c'  -412.29831  4d'  -412.29640
 3a (C1)  -412.30633  5a  -412.32359
 3a' (Cs) -412.30307  5a'  -412.31483
 3d  -412.28906  5d  -412.30545
 3d'  -412.28834  5d'  -412.28316
N.B. All structures are minima in Cs symmetry, apart from 3a/3a'; see text for
further details.
Table 2.2. Relative (absolute) energies of all possible tautomers at
RHF / 6-31G(d) in Kcal (a.u.)
 Name  Symmetry  Energy  Name  Symmetry  Energy
 1  C2v  (-412.20302)  3e  Cs  -323.91
 2-  Cs  (-411.75091)  3f  C1  -280.94
 2a  Cs  -340.38  4-  Cs  (-411.75740)
 2b  Cs  -350.01  4a  Cs  -337.05
 2c  Cs  -349.92  4b  Cs  -335.17
 2d  Cs  -335.60  4c  Cs  -326.34
 2e  Cs  -337.44  4d  Cs  -338.46
 3-  Cs  (-411.74632)  4e  Cs  -331.45
 3a  C1  -351.41  5-  Cs  (-411.73895)
 3a'  Cs  -349.37  5a  Cs  -366.87
3b  Cs  -318.57  5b  Cs  -324.99
 3c  Cs  -330.02  5c  C1  Not optimised
 3d  Cs  -340.57  5d  Cs  -355.48
3a': One imaginary frequency at RHF / 6-31G(d); see text
5c: High energy minimum found at RHF / 3-21G in C1 symmetry, but not at RHF /
6-31G(d)
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Table 2.3. Structures1, relative (absolute) compound energies2, and
relative (absolute) free energies3 of low energy tautomers
 Name E0  G  Name  E0  G
 1  (-413.88799)  (-413.91716)  3d  -327.79  -328.26
 2-  (-413.43647)  (-413.45429)  4-  (-413.43990)  (-413.46982)
 2a  -323.47  -331.33  4a  -320.75  -321.03
 2b  -330.51  -338.34  4b  -318.50  -319.01
 2c  -333.83  -341.46  4c  -315.95  -311.22
 2d  -315.83  -324.52  4d  -325.04  -325.16
 2e  -317.13  -325.41  4e  -313.10  -313.81
 3-  (-413.43020)  (-413.46017)  5-  (-413.43415)  (-413.46412)
 3a  -327.47  -328.03  5a  -339.88  -340.12
 3a'  -327.74  -328.09  5d  -336.59  -336.49
 3c  -311.77  -312.72    
Notes
1. All structures optimised at MP2 / 6-31G(d,p)
2. Compound energies: E0 = E{MP2 / 6-311++G(3df,3pd)} + E{QCISD(T) / 6-
31G(d,p)} - E{MP2 / 6-31G(d,p)} + 0.8929*ZPE{HF / 6-31G(d)}
Relative energies in Kcal with respect to conjugate base anion.
Absolute energies in Hartree in parentheses.
Lowest energies shown in bold
3. Gibbs free energies calculated at 298.15K by correcting E0 with thermochemical
data calculated at HF / 6-31G(d) scaled by 0.8929.
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Table 2.4: High level gas-phase calculations of 4-hydroxy-pyridazine
1-oxide tautomers. Absolute energies (a.u.)1.
Name
 MP2 /
6-31G
(d,p)
 MP2 /
6-311G
(d,p)
 MP2 /
6-311+G
(d,p)
 opt MP2 /
6-311+G
(d,p) 1.
 MP2 /
6-311G
(2df,p)
 MP2 /
6-311+G
(3df,2p)
 MP2 /
6-311++G
(3df,3pd)
 3a(C1)  -413.52188  -413.68659  -413.70682  -413.70710  -413.90550  -413.94931  -413.95751
 3a'(Cs)  -413.52180  -413.68609  -413.70589  -413.70610  -413.90587  -413.94962  -413.95781
 3d  -413.52619  -413.68815  -413.70965  -413.70983  -413.91033  -413.95566  -413.96405
Name
 MP4 /
6-311G(d,p)
 MP4 /
6-311+G(d,p)
 MP4 /
6-311G(2df,p)
 QCISD(T)/
6-31G(d,p)
 QCISD(T)/
6-311G(d,p)
 3a(C1)  -413.77684  -413.79797  -414.004565.  -413.59872  -413.76735
 3a'(Cs)  -413.77589  -413.79657  -414.00449  -413.59795  -413.76622
 3d  -413.77544  -413.79785  -414.00621  -413.59720  -413.76318
Name
 E0
compound2.
 G2(MP2,**)3.
 G2(MP2,++)4
.  G2(**)
3.  G2(++)4.
 Best free
energies6.
 3a(C1)  -413.95206  -414.05278  -413.95598  -414.03891  -413.94211  0 Kcal
 3a'(Cs)  -413.95248  -414.05327  -413.95646  -414.03902  -413.94221  0.13 Kcal
 3d  -413.95256  -414.05320  -413.95659  -414.03885  -413.94224  0.00 Kcal
Notes
1. All calculations performed using MP2/6-31G(d,p) geometry except MP2/6-
311+G(d,p) optimisation. Lowest energies (Hartree) indicated in bold.
2. E0 compound: Modified G2(MP2,SVP) theory neglecting EHLC. As used for all
other structures. See Table 2.3. for definition
3. ** Modified G2 and G2(MP2) theories: Geometries at MP2/6-31G(d,p) substituted
for MP2(full)/6-31g(d) throughout. EHLC = -0.105 for all structures
4. ++ Extended G2 and G2(MP2) theories: Geometries at MP2/6-31G(d,p).
E{MP2/6-311++G(3df,3pd)} substituted for E{MP2/6-311+G(2df,p)}. EHLC is
neglected.
5. Calculation of energy of 3a at MP4/6-311G(2df,p) prohibitively expensive.
Approximation used:
E{3a,MP4/6-311G(2df,p)} ~ E{3a,MP4/6-311G(d,p)} +E{3a,MP2/6-311G(2df,p)} -
E{3a,MP2/6-311G(d,p)} -E{3a',MP2/6-311G(2df,p)} +E{3a',MP2/6-311G(d,p)}
+E{3a',MP4/6-311G(2df,p)} -E{3a',MP4/6-311G(d,p)}
6. Relative gas phase free energies at 298.15K in Kcal, from HF/6-31G(d)
thermochemistry and G2(++) theory
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Table 2.5. Free energies of solvation (Kcal/mol)
Name  IPCM1
 AM1-SM2//
MP2/6-
31G(d,p)2
 AM1-SM23
 PM3-SM3//
MP2/6-
31G(d,p)4
 PM3-SM35
 1  -6.66  -14.52  -16.28  -14.63  -16.10
 2-  -63.56  -68.92  -68.27  -65.65  -65.23
 2a  -13.73  -15.80  (-17.18)6  -14.44  -15.00
 2b  -8.68  -9.30  (-9.53)6  -11.73  -12.25
 2c  -11.54  -13.72  (-13.09)6  -13.63  -13.89
 2d  -9.93  -11.60  -11.89  -15.92  -16.57
 2e  -10.34  -10.51  -11.13  -13.29  (-14.76)6
 3-  -60.08  -68.52  -68.70  -66.99  (-68.14)6
 3a  -16.79  -14.06  -12.47  -15.20  -12.90
 3a' -10.96  -14.20  -14.33  -15.03  -14.61
 3c  -7.18  -10.99  -11.41  -14.51  -16.07
 3d  -16.18  -14.95  -14.78  -15.74  -16.28
 4-  -58.53  -66.32  -66.48  -65.74  -66.06
 4a  -9.31  -13.48  (-14.25)6  -14.37  (-14.22)6
 4b  -12.77  -14.03  (-14.88)6  -18.07  -17.11
 4c  -8.06  -12.03  -12.64  -17.61  -17.51
 4d  -14.59  -14.49  -14.02  -15.34  -15.75
 4e  -7.20  -8.48  -8.74  -11.51  -13.04
 5-  -61.15  -74.44  -74.59  -71.95  -72.66
 5a  -8.62  -11.18  (-14.75)6  -11.60  -14.08
 5d  -7.45  -14.21  -14.90  -13.54  -16.66
Notes:
1. Isodensity polarised continuum model: Dielectric constant = 78.4. Isodensity
value = 0.001.
G = E{MP2/6-31G(d,p) , IPCM // MP2/6-31G(d,p)} - E{MP2/6-31G(d,p)}
2. AM1-SM2 model: G = Hf (AM1-SM2) - Hf (AM1) , single point energies at
MP2/6-31G(d,p) geometries
3. AM1-SM2 model: G = Hf (AM1-SM2) - Hf (AM1) , full electronic and geometry
relaxation.
4. PM3-SM3 model: G = Hf (PM3-SM3) - Hf (AM1) , single point energies at
MP2/6-31G(d,p) geometries
5. PM3-SM3 model: G = Hf(PM3-SM3) - Hf (AM1) , full electronic and geometry
relaxation.
6. AM1-SM2 or PM3-SM3 geometry optimisation failure. Energies stable, but
maximum gradients remain above cutoff. Probably not significant.
44
Table 2.6. Estimated normalised tautomer ratios1 in gas phase and
aqueous solution.
Name Gas phase  IPCM
AM1-SM2//
MP2/6-31G(d,p)
 AM1-
SM2
PM3-SM3//
MP2/6-31G(d,p)
 PM3-
SM3
  1 1.  1. 1.  1. 1.  1.
 2a 3.7E-08  1.5E-6 1.3E-06  3.8E-5 1.47E-07  2.5E-7
 2b 0.0052  4.1E-5 3.0E-06  1.3E-5 2.1E-4  3.3E-4
 2c 0.9948 0.99996 1. 0.99995 0.99979  0.9997
 2d 3.8E-13  2.5E-14 1.1E-14  5.0E-14 1.8E-11  3.5E-11
 2e 1.7E-12  2.2E-13 7.6E-15  6.3E-14 9.5E-13  7.5E-12
 3a 2 0.59  0.65 0.27  0.27 0.34  0.046
 3c 1.7E-12  3.6E-19 3.7E-15  1.0E-14 3.4E-13  2.8E-12
 3d 0.41 0.35 0.73  0.73 0.66  0.954
 4a 9.4E-4  1.3E-7 1.7E-04  1.4E-3 1.8E-4  7.1E-5
 4b 3.1E-05  1.4E-6 1.5E-05  1.3E-4 0.0031  3.1E-4
 4c 6.1E-11  9.9E-16 9.6E-13  5.9E-12 2.8E-09  1.2E-9
 4d 0.9990  1. 0.99981  0.9985 0.9967  0.9996
 4e 4.8E-09  1.8E-14 1.9E-13  6.5E-13 7.5E-12  4.9E-11
 5a 0.9978  0.9996 0.74  0.997 0.946  0.86
 5d 0.0022  3.0E-4 0.26  2.8E-3 0.054  0.14
Notes:
1. [HA2]/[HA1] = exp((G1 - G2)/RT) ; G = G298.15,gas + Gsolv
2. The planar conformer of 1-hydroxy-3(1H)-pyridazinone 3a' is predicted to be
favoured in solution by AM1-SM2 and PM3-SM3, and the non-planar conformer 3a
by IPCM. The figures given are the sum of the predicted proportions of both
conformers.
Table 2.7. Estimated relative1 pKas of isomers.
Isomer gas phase  IPCM
AM1-SM2//
MP2/6-31G(d,p)
 AM1-SM2
PM3-SM3//
MP2/6-31G(d,p)
 PM3-SM3
 2 0.  0. 0.  0. 0.  0.
 3 -9.8  -3.6 -8.7  -8.9 -9.3   -10.1
 4 -11.9  -6.0 -9.5  -10.0 -10.8  -11.2
 5 -1.0  -1.4 -7.0  -4.4 -7.2  -6.4
Notes:
1. Calculated relative to isomer 2; pKa = [- 0.4343* i{ai*(GHAi-GA-)/RT}]
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Table 2.8. Literature pKas of related structures
Name Structure pKa Reference
2-hydroxy pyridine 6 11.6 [36]
3-hydroxy pyridine 7 8.7 [36]
4-hydroxy pyridine 8 11.1 [36]
2-hydroxy pyridine 1-oxide 9 5.9 [37]
3-hydroxy pyridine 1-oxide 10 6.4 [37]
4-hydroxy pyridine 1-oxide 11 5.9 [37]
3-hydroxy pyridazine 12 10.5 [36]
4-hydroxy pyridazine 13 8.7 [36]
3,5-dihydroxy pyridazine 14 4.8 [38]
3,6-dihydroxy pyridazine 15 5.7 [36]
3-hydroxy pyridazine 1-oxide 2 4.1 [6]
Figure 2.1 pyridazine 1,2-dioxide
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Figure 2.2 3-hydroxypyridazine 1-oxide
Figure 2.3 4-hydroxypyridazine 1-oxide
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Figure 2.4 5-hydroxypyridazine 1-oxide
Figure 2.5 6-hydroxypyridazine 1-oxide
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Chart 2.1: All structures referred to in Chapter 2
Optimised geometries at HF / 6-31G(d) and MP2 /6-31G(d,p) linked.
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Index of optimised geometries from chapter 2.
1 HF/6-31G(d) (12-34566.pdb)
1 MP2 / 6-31G(d,p) (12-3456m.pdb)
2a HF/6-31G(d) (13-14566.pdb)
2a MP2 / 6-31G(d,p) (13-1456m.pdb)
2a' HF/6-31G(d) (13-1456a.pdb)
2b HF/6-31G(d) (13-24566.pdb)
2b MP2 / 6-31G(d,p) (13-2456m.pdb)
2c HF/6-31G(d) (13-34566.pdb)
2c MP2 / 6-31G(d,p) (13-3456m.pdb)
2c' HF/6-31G(d) (13-3456a.pdb)
2d HF/6-31G(d) (13-44566.pdb)
2d MP2 / 6-31G(d,p) (13-4456m.pdb)
2- HF/6-31G(d) (13-456-6.pdb)
2- MP2 / 6-31G(d,p) (13-456-m.pdb)
2e HF/6-31G(d) (13-45666.pdb)
2e MP2 / 6-31G(d,p) (13-4566m.pdb)
3a HF/6-31G(d) (14-13561.pdb)
3a' HF/6-31G(d) (14-1356s.pdb)
3a MP2 / 6-31G(d,p) (14-135m1.pdb)
3a' MP2 / 6-31G(d,p) (14-135ms.pdb)
3b HF/6-31G(d) (14-23566.pdb)
3c HF/6-31G(d) (14-33566.pdb)
3c MP2 / 6-31G(d,p) (14-3356m.pdb)
3d HF/6-31G(d) (14-34566.pdb)
3d MP2 / 6-31G(d,p) (14-3456m.pdb)
3d' HF/6-31G(d) (14-3456a.pdb)
3e HF/6-31G(d) (14-35566.pdb)
3- HF/6-31G(d) (14-356-6.pdb)
3- MP2 / 6-31G(d,p) (14-356-m.pdb)
3f HF/6-31G(d) (14-35666.pdb)
4a HF/6-31G(d) (15-13466.pdb)
4a MP2 / 6-31G(d,p) (15-1346m.pdb)
4a' HF/6-31G(d) (15-1346a.pdb)
4b HF/6-31G(d) (15-23466.pdb)
4b MP2 / 6-31G(d,p) (15-2346m.pdb)
4c HF/6-31G(d) (15-34466.pdb)
4c MP2 / 6-31G(d,p) (15-3446m.pdb)
4d HF/6-31G(d) (15-34566.pdb)
4d MP2 / 6-31G(d,p) (15-3456m.pdb)
4d' HF/6-31G(d) (15-3456a.pdb)
4- HF/6-31G(d) (15-346-6.pdb)
4- MP2 / 6-31G(d,p) (15-346-m.pdb)
4e HF/6-31G(d) (15-34666.pdb)
4e MP2 / 6-31G(d,p) (15-3466m.pdb)
5a HF/6-31G(d) (16-13456.pdb)
5a MP2 / 6-31G(d,p) (16-1345m.pdb)
5a' HF/6-31G(d) (16-1345a.pdb)
5b HF/6-31G(d) (16-23456.pdb)
5- HF/6-31G(d) (16-345-6.pdb)
5- MP2 / 6-31G(d,p) (16-345-m.pdb)
5d HF/6-31G(d) (16-34566.pdb)
5d MP2 / 6-31G(d,p) (16-3456m.pdb)
5d' HF/6-31G(d) (16-3456a.pdb)
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3. The tautomerism of pyridazinediones
Abstract
Pyridazine-3,6-dione, maleic hydrazide (3), is one of the best known pyridazine derivatives, and
has been the subject of several theoretical investigations. Its three positional isomers, pyridazine-
3,4-dione (1), pyridazine-3,5-dione (2), and pyridazine-4,5-dione (4), while apparently known
synthetically, have received comparatively little attention. These isomers, being relatively strong
acids, are potential heteroaromatic carboxylate bioisosteres, and of interest in the design of novel
bioactive agents. Both the isomers and their conjugate base anions may potentially exist in a
large number of tautomeric forms: ten acid and five basic forms of 1, fifteen and six of 2, nine
and three of 3, and nine and three of 4, respectively, many of which are potentially
conformationally flexible. This chapter presents a thorough theoretical investigation of the four
systems, employing extended basis set G2(MP2,SVP) theory ab initio calculations to model gas
phase behaviour, and Isodensity Polarised Continuum Model and semi-empirical AM1-SM2 and
PM3-SM3 calculations to model aqueous and pKa behaviour. Existing solid-phase data are
compared with theoretical predictions, and found to be in good agreement. The well-
documented lactam-lactim form of 3 predominates, and the lactam-hydroxy tautomer of 2 is
prominent, the hydroxyl proton being most acidic in both cases. However, in the gas phase, a
non-aromatic diketo 4,4 diprotonated tautomer of 2 is found to be relatively stable, and in
aqueous phase, AM1-SM2 theory predicts the stability of a 1-hydro, lactim-keto zwitterionic
tautomer of 2. Hydroxy-keto tautomers are found to predominate in both gas phase and
aqueous phase for 4, with a zwitterionic 1-hydro, 4-hydroxy form preferentially stabilised in
aqueous phase. Strong intramolecular hydrogen bonding is observed, with preferential loss of
the labile ring proton to form the base of 4. The tautomerism of 1 is found to be particularly
complex, although again, hydroxy-keto acid forms are favoured in both gas and aqueous phases,
zwitterions being preferentially stabilised in water. Hydroxyl proton loss from 1 is favoured in
both phases, although intramolecular hydrogen bonding stabilises a hydroxy-keto anion in the
gas phase. 2 is predicted to be the strongest acid of the series, but no confident prediction of the
relative acidities of 1, 3 and 4 can be made, other than that they are of similar pKa. Comparisons
with the known pKa behaviour of series of closely related pyridazinones and pyridones are
made.
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3.1. Introduction
As a class, the pyridazines are the least well studied and understood of the six-
membered diazines [1]. One of the best known pyridazine derivatives is maleic
hydrazide, or 6-hydroxy-3(2H)-pyridazinone 3, due to its ease of synthesis and
commercial use as a plant-growth inhibitor [1,2]. Its unusual lactam-lactim
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tautomeric behaviour has been the subject of several experimental studies and
reviews [1,3-10] and has long been a favoured test case for theoretical methods [11-
15].
By comparison, the three positional isomers of 3, those pyridazines having two
potential hydroxy groups in positions 3,4 (1), 3,5 (2) and 4,5 (4), have received little
attention. The synthesis of 2, its pKa, and X-ray crystal structure, have been
extensively studied by Wagner et al. [16], but only low level ab initio (HF / 3-21G)
and semi-empirical gas phase theoretical studies have been conducted on this
system [12,13]. Less well known still are 1 and 4, which are previously unstudied
theoretically, other than a cursory treatment of 4 by Gastmans et al. [11]. Both the
synthesis [17] and biosynthesis [18] of 4 as a metabolite of pyridazine have been
described, but its structure and tautomerism have remained unexplored. While the
synthesis of 1 has been claimed in a patent [19], the lack of physical data, and of
other references to 1 in the literature, cast doubt on this claim. Near derivatives of 1
such as its 2-methyl derivative [20] and the immediate precursor, 4-chloro-3(2H)-
pyridazinone [21,22] are known.
The pyridazinones are of increasing interest as frameworks for novel bioactive
molecules [23,24]. Isosterism for biochemical bases, phenyl groups, and acids have
led to applications as wide ranging as antibiotics [25], insecticides [26], plant-
growth regulators [2], herbicides [27] and neuroactive agents [28-30] to name a few.
The interest in these structures here stems from observations [31], [Chapters 7, 8],
that several derivatives of 3(2H)-pyridazinone show activity at subtypes of
Excitatory Amino Acid (glutamate) neuroreceptors, the pyridazinone base anion
forming a carboxylate bioisostere.
The tautomerism of oxygen-substituted azines is a long studied field in its own
right, as well as being of importance to the understanding of the many bioactive
materials which fall into this class [3]. The tautomeric behaviour of the
pyridazinediones is particularly rich and complex on account of the many potential
structures which 1 to 4 may adopt (Charts 3.1, 3.2, 3.3 and 3.4).
53
This study employs methods pioneered by Cramer et al. [32] for treatment of
heterocyclic tautomerism of this kind, with emphasis on the need for high level ab
initio calculations to consistently treat atoms of varying hybridisation, and the
relative success of semi-empirical solvation models for probing the aqueous
behaviour of tautomers.
The existing ab initio calculations on maleic hydrazide 3 [12-15] are extended to
higher levels of theory and larger basis sets, and these methods are applied to the
positional isomers 1, 2 and 4. Semi-empirical and isodensity polarised continuum
models (I-PCM) of aqueous solvation are used, where previous work has modelled
solvation using an ellipsoidal Onsage cavity model, free energy perturbation
(molecular dynamics simulation), and polarised continuum models [14,15]. No
theoretical work appears to have previously examined the anionic conjugate bases
of these structures, 1- to 4-, themselves capable of tautomerism. These are
considered here, on account of their likely prevalence at physiological pH, and
hence biological importance.
Chapter 2 reported high-level ab initio gas phase and semi-empirical aqueous phase
modelling of the four closely related potential hydroxy pyridazine 1-oxides 15, 16,
17, 18 , their conjugate base anions, and pyridazine 1,2-dioxide 19 [33], discussing
the methods used here and their limitations in some detail. This treatment of 1 to 4
completes the series of theoretical studies on the nine doubly oxygen-substituted
pyridazines.
3.2. Methods and Results
Ab initio Hartree-Fock theory, and electron correlated methods, second order
Møller-Plesset perturbation theory (MP2), and Quadratic Configuration Interaction
theory (QCISD(T)) [34] were used to probe the gas-phase structure and
tautomerism of 1 to 4 and their conjugate bases. Aqueous phase behaviour was
studied by both ab initio (Isodensity Polarised Continuum Model (I-PCM) [35] and
semi-empirical (AM1-SM2 and PM3-SM3) [36] solvation models.
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3.2.1 Generation of neutral and conjugate base anion tautomers and conformers
Following the description of heterocyclic tautomerism given by Elguero et al. [3], a
complete set of tautomers of 1 to 4 and their conjugate bases were generated. All
structures were initially built with planar geometry. Firstly, each pair of non-
substituted pyridazine ring carbons were assumed to be at least singly protonated.
Addition of a single proton to either ring nitrogen, either oxygen substituent, or any
carbon located - to an oxygen substituent (forming a methylene), neglecting
repetition through symmetry, generates all possible anionic tautomers: 1-a to 1-e, 2-
a to 2-f, 3-a to 3-c, 4-a to 4-c (see Charts 3.1, 3.2, 3.3, 3.4). Addition of a second
proton to remaining unsubstituted nitrogens, oxygens, or - ring carbons of each of
these anions, and neglecting repetition through symmetry, generates all possible
neutral tautomers 1a to 1j, 2a to 2o, 3a to 3i, 4a to 4i (see Charts 3.1 to 3.4).
Structures containing one or two hydroxyls are capable of conformational
flexibility. Two to four initial structures with hydroxyls rotated 180º were generated
respectively in these cases (indicated as ', '',''' in Charts 3.1 to 3.4) for a complete set
of planar conformers.
3.2.2 Discrimination of preferred conformers and low energy tautomers
Optimisations of all conformers and tautomers were attempted at the HF / 6-
31G(d) level, initially with planar geometry, with frequency calculations to
determine minima. Those structures not at a minimum (having at least one
imaginary frequency) were re-optimised with reduced symmetry, with optimisation
failures occurring for six structures: 1h", 3-b', 3c, 3f, 3f' and 4i'. The results are
summarised in Table 3.1 and Table 3.2. In the case of 3c, no stable ring closed form
could be found, the system optimising to an open ketene in both planar and
unrestricted geometries, under both Berny and Fletcher-Powell optimisation
schemes. In the cases of 3f and 3f', no stable pyridazine structure could be found,
ring contraction to a bicyclic system occurring in both planar and unrestricted
geometries under optimisation. The other optimisation failures were the result of
the conformation specified being a maximum, and optimising to a lower energy
conformation in unrestricted symmetry.
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All conformers with energies above the minimum energy conformer for each
tautomer at this level of theory and basis set were discarded from the set of
structures under investigation. Likewise, those anionic or neutral tautomers with
energies greater than 25 Kcal/mol above the lowest energy anion or neutral
tautomer respectively were also discarded as being unlikely to play a significant
role in tautomerism, [14,33].
3.2.3 Calculation of gas phase geometries
The remaining tautomers were optimised at MP2 / 6-31G(d,p). Inclusion of electron
correlation causes substantial differences in the preferred structures of certain
tautomers. In order to test for geometry convergence with respect to basis set, 3-a,
3a, 3b and 3h were optimised at MP2 / 6-311+G(2d,p), and compared with MP2 /
6-31G(d) optimised structures in Table 3.3. The differences were found to be very
small for 3-a, 3b and 3h, and somewhat larger in the case of 3a (RMS change = 0.015
Å). All calculated geometries are accessible via Charts 3.1, 3.2, 3.3 and 3.4, and the
index of geometries.
Tables 3.4 and 3.5 show a comparison of the calculated and experimental (X-ray
crystal) geometries of tautomers 2h [16] and 3b [37, 38]. The positions of heavy
atoms are in good agreement (RMS = 0.030 Å for 2h, and RMS = 0.028 Å and 0.029
Å for the polymorphs MH2 and MH1 of 3b described).
3.2.4 Calculation of high level gas phase energies
Table 3.2 includes the base level energies of optimised structures at MP2 / 6-
31G(d,p). Those anionic and neutral tautomers found to be in excess of 20 Kcal/mol
higher in energy relative to minimum energy anionic or neutral tautomers
respectively were again discarded from the set as being unlikely to contribute
significantly to tautomerism. The remaining structures were subjected to single
point energy calculations, both with a large basis set employing both high angular
momentum and diffuse functions on all atoms (MP2 / 6-311++G(3df,3pd)) and with
a higher level treatment of electron correlation (QCISD(T) / 6-31G(d,p)). The
combination of these two corrections to the base energy, with the addition of the
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scaled zero point energy calculated at HF / 6-31G(d) gives a compound gas phase
energy E0. This method is comparable [33] to G2(MP2) [39] and G2(MP2,SVP) [40]
theories, although neglecting the higher level correlation energy, EHLC, a term
which cancels for relative energies calculated for the structures under investigation.
Thermochemistry calculated at HF / 6-31G(d,p) was then used to calculate free
energies at 298.15K. These results are shown in Table 3.2, and summarised in Figure
3.1.
In addition, the same high level gas phase calculations were conducted on 3-a, 3a,
3b and 3h, optimised at MP2 / 6-311+G(2d,p), to test for the effect of increased basis
set optimisation on single point energies. This was found to be insignificant (0.19
Kcal/mol maximum change in relative energies). These results are shown in Table
3.3.
3.2.5 Calculation of free energies of aqueous solvation, and solution phase
properties
Free energies of aqueous solvation (Table 3.6) were calculated by five methods:
Single point energies using the I-PCM model [35] with an isodensity cutoff of 0.001
and a dielectric constant of 78.4, and the semi-empirical solvation methods AM1-
SM2 and PM3-SM3 [36], with and without geometry optimisation. Addition of free
energies of solvation to gas phase free energies at 298.15K gives free energies in
solution, from which were estimated tautomer ratios by normalising equilibrium
constants separately for both neutral and basic tautomers (Table 3.7). Aqueous
tautomerism is summarised in Figure 3.1. Combining tautomer ratios with free
energies gives overall free energy differences between neutral acidic tautomer
systems and their anionic conjugate bases, from which may be estimated relative
pKa values (Table 3.8).
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3.3. Key to charts, tables and figures, and geometries
Chart 3.1 3,4-substituted structures, 1
Chart 3.2 3,5-substituted structures, 2
Chart 3.3 3,6-substituted structures, 3
Chart 3.4 4,5-substituted structures, 4
Chart 3.5 related structures
Table 3.1 Unfavourable conformers
Table 3.2 Gas phase tautomer energies
Table 3.3 Effect of large basis set optimisation on 3
Table 3.4 Comparison of 2h with X-ray structure
Table 3.5 Comparison of 3b with X-ray structures
Table 3.6 Free energies of solvation
Table 3.7 Estimated tautomer ratios
Table 3.8 Equilibrium free energies and pKa
Table 3.9 Experimental pKas
Figure 3.1 Summary of tautomeric behaviour
Figure 3.2 Formal structures of 3c, 3f, and 3f'
Figure 3.3 Resonance of 2-b
Index of geometries Brookhaven .pdb format
Figure 3.1 Tautomerism of dioxopyridazines
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3.4. Discussion
3.4.1 Conformation
Considering first conformational preferences of hydroxy tautomers calculated at HF
/ 6-31G(d) (Table 3.1 vs 3.2) we note the following:
Steric hindrance causes certain conformations to fail to converge as minima, i.e. 4i',
3-b' and 1h".
Where opportunity exists for an intramolecular hydrogen bond, i.e. hydroxy
tautomers of 1 and 4, deviation from this conformation involves a large energy cost
(e.g. 4c' = 10 Kcal/mol, 1f' = 8 Kcal/mol).
A hydroxyl - to an unsubstituted nitrogen (tautomers of 1, 2, and 3) generally
prefers an HOCN dihedral of 0º, there being an increased energy in the 180º
position due to extra steric interaction between hydrogens and lone pair repulsion
between the oxygen and the nitrogen, as opposed to the energy lowering effect of
proton interaction with the nitrogen lone pair. In the case of 3h, this effect is around
8 Kcal/mol in magnitude per rotation. For 1-c' and 1b', this offsets the energy
lowering effect of the intramolecular hydrogen bond, and in the case of 1i, where
the hydrogen bond acceptor strength of the 4-oxygen is weakened by 5,5
diprotonation, exceeds it. Conversely, a hydroxyl - to a protonated nitrogen
generally prefers the 180º position, presumably because of a weak intramolecular
hydrogen bond formed between the oxygen and the N- proton, although the effect
is not as great (e.g. 3e' = 2 Kcal/mol).
In the absence of the above effects, in the case of 2d, 2h, 2k, 5-hydroxy substituents
prefer to align such that the 5-oxygen lone pairs lie away from the 3-oxygen
substituent. The effect may be a result of intramolecular dipole effects, and is
particularly subtle in the case of 2k'' (= 0.5 Kcal/mol) which does not contain a
carbonyl group.
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3.4.2 Structure determination
It is apparent that optimisation at HF / 6-31G(d) is inadequate for determination of
gas phase geometries for these systems. Comparing geometries optimised at HF /
6-31G(d) with geometries optimised at MP2 / 6-31G(d,p), differences are noted for
several structures, including changes in symmetry. A number of methylene-bridge
containing tautomers in particular, seem to be handled differently post-SCF, with
slightly puckered to very puckered ring systems predominating, vs. more planar
structures at HF / 6-31G(d), for example 1g, 1i, 2-d, 2g and 2j.
Of particular note is the way in which certain optimisations involving methylene
tautomers have failed to produce pyridazines (Table 3.2). After considerable
searching, it may be confidently asserted that either local minima which are
pyridazines do not exist for these structures, or if they do, they are very high in
energy. Firstly, 3f and 3f' undergo a ring contraction to a high-energy pyrazole.
What makes this interesting is the known tendency of certain pyridazine-3(2H)-ones
to undergo ring contraction to pyrazole products when heated with aqueous base
[1]. Further study of this phenomenon may shed light on the mechanism of these
reactions. The fact that this tautomer undergoes a change in ring structure may be
understood by considering that no neutral or favourable zwitterionic formal
structure (i.e. one having a negative charge on an oxygen and a positive charge on a
tetravalent nitrogen) may be drawn for the structure, whereas bridging N1 - C5
creates a neutral structure.
Secondly, 3c undergoes ring opening to a high energy ketene, rather than optimise
as a pyridazine. Ring opening reactions of pyridazinones are apparently rare,
except under reducing conditions. Again, the ring opening may be understood in
terms of there being no neutral structure or sensible zwitterionic formal structure
able to be drawn, except by a bond order of zero between N1 and C6.
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Figure 3.2 Formal structures of 3c, 3f, and 3f'
Since substantial geometry changes are noted on proceeding from optimisation at
HF/6-31G(d) to MP2/6-31G(d,p), particularly in the case of non-aromatic
tautomers, this begs the questions: is the geometry converged at this level, and if
not, how will larger basis set optimisation affect single point energies and hence
tautomerism predictions? In particular, it is known that a satisfactory treatment of
the geometry around amide bonds using MP2 theory may require large triple-
basis sets, and this is an ongoing area of investigation [52]. Insufficient basis sets
tend to over-estimate the degree to which an amide nitrogen is pyramidal. The
limited set of optimisations and subsequent single point energies performed at 6-
311+G(2d,p), as reported in Table 3.3, were chosen to investigate these questions.
The set is comprised of the lactim-lactim 3h, lactim-lactam 3b, and lactam-lactam 3a
tautomers of the well-studied maleic hydrazide 3, vs. the preferred conjugate base
3-a. These structures are aromatic, semiaromatic and non-aromatic, and contain
zero, one and two amide linkages respectively, and thus should highlight
differences in the treatment of amidic and non-amidic nitrogens.
A number of conclusions may be drawn: Firstly, and most importantly, in no case
does the change in relative energy for a calculation exceed 0.19 Kcal/mol, and is
generally small. This means that errors caused by the deficiencies of optimisation
with the smaller basis set are unlikely to affect our predictions of tautomerism, and
are expected to be smaller than the deficiencies of the compound energy methods
used throughout; the G2(MP2) and G2(MP2,SVP) methods having a mean absolute
deviation of 1.58 Kcal/mol and 1.63 Kcal/mol respectively for the 125 systems in
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the G2 test suite [40]. Secondly, the alteration in geometry of the lactam-lactam
tautomer 3a, having pyramidal nitrogens in C2 symmetry, is substantially greater
than that of the other tautomers (RMS 0.015 Å vs 0.004-6 Å). The sum of the bond
angles around the nitrogen of the MP2/6-311+G(2d,p) optimised structure is 348.3º,
vs. 345.7º for MP2/6-31G(d), i.e. the previously noted flattening of amide pyramidal
quality with increased basis set size.
It may be concluded that while the use of the less expensive basis set optimisation
in the present work provides a satisfactory description, future workers with greater
computing resources employing more accurate methods should consider higher
level geometry optimisation, particularly if the precise geometry of the amide
linkage is of interest.
3.4.3 Gas phase tautomerism predictions
It has long been suggested that adjacent heteroatoms prefer to adopt different
hybridisations [3,15,41]. In the case of dihydroxy pyridazine tautomers, there would
clearly be an energy cost associated with repulsion of co-planar lone pairs of the sp2
hybridised nitrogens.
However, there is an energy cost associated with losing full aromatic character of
the pyridazine ring by proton substitution of a nitrogen to form a planar semi-
aromatic system. Furthermore, there is an energy cost associated with loss of
conjugation through ring puckering. On the other hand, constraint of a substituted
hydrazine to a planar conformation rather than its preferred twisted structure
involves an energy cost.
The interplay of these factors, lone pair repulsion vs. resonance energy, assists in
the interpretation of the calculated tautomer energies and distributions (Tables 3.2
and 3.7). The current results suggest, with the possible exception of 2k in the gas
phase, that fully aromatic dihydroxy tautomers to not appear to play a major role.
Likewise, 1,2-dihydro tautomers are conspicuously absent. The preferred structures
are a balance between lone pair repulsion, and resonance energy gain. Thus, keto-
hydroxy tautomers predominate. With respect to which oxygen takes which form,
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oxygens - to a nitrogen generally prefer a keto form in the gas phase, whereas the
- substituent adopts the hydroxy form. This may be compared with the behaviour
of 2-pyridone and 3-hydroxy-pyridine [3], and is in accordance with the analysis of
hydroxy-pyridazine 1-oxide tautomerism [33] (Chapter 2). Zwitterionic structures
are generally unfavourable in the gas phase, 4c being one of the more stable at 4.2
Kcal/mol above 4d at 298.15K. In summary, 1f, 2h, 3b, and 4d are predicted to be
the most favoured tautomers in the gas phase, in accordance with solution and
solid phase experiments in the cases of 2 and 3.
Particularly interesting is the low energy of the 4,4-diprotonated tautomer, 2g.
While it exceeds 2h in energy by 1.8 Kcal/mol at 0 K, inclusion of thermochemistry
at 298 K gives a free energy difference of only 0.6 Kcal/mol, sufficient for
substantial gas phase contribution. With the dihydroxy tautomer 2k also predicted
to be only 2.19 Kcal/mol above 2h and hence a possible contributor, 2 is worthy of
closer experimental study. Methylene containing azine tautomers are exceedingly
rare, compared with their 5-membered counterparts, the disruption to aromaticity
caused by carbon protonation incurring a large energy cost. It may be speculated
that the comparative stability of 5-membered methylene tautomers is a driving
force for the ring contraction behaviour noted above. However, meta- dioxo
substitution is one of the few known cases where six-membered nitrogen
heterocycles are known to adopt this kind of structure [3,42]. This underscores the
importance of not neglecting such tautomers when analysing hydroxy-azine
tautomerism. The only other theoretical examinations of this system, those of
Fabian [12, 13], while correctly predicting the stability of 2h over 2f, 2f', 2h', 2k, and
2k'' at HF /3-21G, failed to consider 2g et al. Semi-empirical calculations failed to
reproduce ab initio or experimental qualitative results.
The previous best gas phase calculations reported on maleic hydrazide 3 [15] were a
combination of the unscaled zero point energies calculated at HF / 3-21G and the
single point energies at MP4/6-31G(d,p)//6-31G(d,p). They found 3b favoured
over 3a by 3.3 Kcal/mol, and over 3h by 5.5 Kcal/mol. The results here at 0K show
a greater difference between these tautomers: 4.2 and 7.2 Kcal/mol respectively.
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This indicates that geometry optimisation with correlated treatments, large basis
sets, and high level treatment of electron correlation are required to approach
convergence for these systems even for neutral tautomers. Particularly where
tautomers lie close in energy, less expensive approaches may not give correct
qualitative results.
3.4.4 Solvation effects according to different models
An examination of Table 3.6 shows that free energies of solvation calculated by the
I-PCM method differ markedly from those calculated by either single point or
optimised semi-empirical calculations, which are fairly concordant. Generally, they
are lower, particularly for the anions, where the solvation energies are around 10
Kcal/mol smaller than for semi-empirical methods. The I-PCM method was used
here for comparison with semi-empirical methods, and because previous work
[14,15] has attempted to describe pyridazinone aqueous solvation using solvent
continuum models. Recently, Cramer described in detail the shortcomings of the I-
PCM method for determining the solvation of anions [43]. Firstly, diffuse electron
density associated with anions will tend to increase isodensity cavity size, causing a
decrease in solvation energy. Secondly, the so-called charge penetration problem,
whereby for an anion, a substantial proportion of the charge may lie outside the
cavity, and solvation energy is again underestimated.
With respect to neutral tautomers, it is worth noting differences in the order in
which I-PCM and semi-empirical methods rank the solvation energy of different
kinds of tautomers. All methods agree that the solvation of methylene tautomers is
generally less favourable than other kinds of tautomers. The semi-empirical
methods strongly favour the solvation of zwitterionic tautomers. Hydroxy-keto
tautomers which are not zwitterionic are less strongly solvated, as are hydrazide
dioxo tautomers, and dihydroxy tautomers are poorly solvated, in accordance with
chemical expectation. The I-PCM method on the other hand seems less consistent,
and in the best studied case, 3, actually reverses the order of preferential solvation,
i.e. G oxo-oxo (3a) > hydroxy-oxo (3b) > dihydroxy (3h).
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The choice of whether to use single point or optimised semi-empirical calculations
is unclear. Whereas single point calculations are more likely to be accurate for
neutral species due to poor semi-empirical geometries, they may be less accurate for
anions, because anionic geometry may alter significantly in the aqueous phase. The
aqueous modelling of anions remains a challenge.
3.4.5 Aqueous phase tautomerism
Table 3.7 and Figure 3.1 summarise the findings of the aqueous phase equilibrium
of the title compounds.
The effect of solvation on anionic ortho-substituted systems 1- and 4- is to reduce
the stability of intramolecular hydrogen bonded bases with respect to their N-
protonated counterparts, such that 4-a may play a greater role, and 1-c a lesser role
in the equilibrium. With respect to the neutral tautomers of these structures, there is
disagreement between AM1-SM2 and PM3-SM3, the proximity of the energies of
various tautomers being finer than the expected error range of the methods.
However it is clear that there is preferential solvation of the zwitterionic oxo-
hydroxy forms, and there may well be a mixture of tautomers in aqueous solution.
For system 2, the favourable gas phase tautomer 2g is poorly solvated, whereas the
zwitterionic 2b is well solvated, such that the former probably plays no role but the
later may in the aqueous equilibrium. 2h, the structure found in the solid phase,
remains highly favoured. Once again, small differences between treatment by AM1-
SM2 and PM3-SM3 cause large differences in the estimated equilibrium.
The qualitative aqueous phase findings for maleic hydrazide 3 are the same as in
the gas phase, i.e. 3b > 3h > 3a, despite better solvation of 3a tautomer according to
semi-empirical theories. Burton et al. [15] found that both free energy perturbation
calculations and an elliptical Onsage cavity model gave solvation energies in the
expected order 3a > 3b > 3h, in reasonable agreement with our calculations.
However, when combined with their gas phase energies, they considered 3a to be
close in energy to 3b in solution, a conclusion at odds with the findings here, and
unsupported by experimental data as far as is known. They also found the PCM
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method gave less credible results than the other methods trialed, and preferred
molecular dynamics to continuum models.
Semi-empirical methods hold the promise of superiority over both continuum
models and molecular dynamics for the treatment of aqueous solvation of
tautomeric systems, overcoming the neglect of electronic and polarisation effects by
the former, and first hydration shell hydrogen bonding effects by the latter [32].
Alternately, mixed quantum mechanical and molecular dynamics approaches may
become the method of choice for this kind of problem as they become further
developed.
3.4.6 Ab initio prediction of relative pKa
Turning now to the estimation of relative pKa presented in Table 3.8, compared
with the available data, it is immediately apparent that the methods used are not
providing consistent quantitative results. No method trialed gives good agreement
with the known experimental pKa difference between 2 and 3. While I-PCM comes
closest to a reasonable prediction in this regard, it is otherwise disconcordant with
the semi-empirical methods, and its relative treatment of anions is dubious. On the
other hand, all methods make the qualitatively correct prediction that 2 is more
acidic than 3. Moreover, all semi-empirical methods predict that 1, 3 and 4 are close
in acidity. Examining Table 3.9, The following trend may be discerned: for both
pyridines and pyridazines, structures with an oxygen meta- to a ring nitrogen (6,
14) are more acidic than structures with an oxygen ortho- to a ring nitrogen (5, 13).
Also, ortho- dioxo-substituted structures (8, 12, 18) tend to be generally less acidic
than their positional isomers, possibly because of the intramolecular hydrogen bond
which stabilises the acid form. Most pertinently, structures 8, 9, 10, and 12, are
pyridine analogues of 1, 2, 3, and 4 respectively. Here, 8, 10 and 12 are all close in
acidity, and higher in pKa than 9, in good qualitative agreement with the relative
pKas of 1, 3 and 4 vs 2 in Table 3.8.
It remains to explain the large predicted pKa difference between 2 and the other
isomers. The anion, 2-b, is predicted to be particularly low in energy in the gas
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phase, compared with its isomers, hence proton removal is favoured from the
neutral tautomers. This may be understood as being a result of the fact that this
meta- substituted anion has accessible to it two fully conjugated canonical
resonance forms, where its isomers do not:
Figure 3.3. Two conjugated resonance forms of 2-b
The likely errors in the aqueous phase calculations far outweigh those of the gas
phase, particularly for anions, so it is a fair assumption that the solvation models
are overestimating the differential solvation of 2- compared with its isomers.
3.5. Conclusion
In summary, fully aromatic dihydroxy tautomers of dioxopyridazines are
unfavourable in gas and moreso in aqueous phase, due to nitrogen lone-pair
repulsion. Hydrazine tautomers, constrained from their preferred conformation, are
similarly unfavourable, due to loss of aromaticity and conjugation. The most stable
structures in the gas phase are those having a conjugated neutral hydroxy-oxo
structure, and are rivalled in solution by those hydroxy-oxo structures which exist
as aromatic zwitterions. Ketones are favoured - to a ring nitrogen and hydroxyls
favoured -. Intramolecular hydrogen bonding is an important factor in the gas
phase, and less so in solution, both for neutral species and their conjugate bases.
Methylene tautomers should not be discounted when considering gas phase
tautomerism of oxo-azines, but are unlikely to contribute to aqueous equilibrium.
Gas phase calculations are approaching the required degree of accuracy to make
quantitative judgements on tautomer equilibria, while aqueous solvation models
remain qualitative. The ab initio prediction of relative pKa of aromatic heterocycles is
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qualitative at best. The results from methods used throughout have been in close
agreement with available experimental data.
3.6. Calculation details
QCISD(T) energies were calculated using Molpro 96 [44]. All other ab initio
calculations were performed using Gaussian 94, revision D.3 [45]. AM1-SM2
calculations were performed using AMSOL 5.4 [46]. Platforms used were SGI
R10000 Power Challenge (IRIX 6.2) and IBM RS6000 (AIX 3.2).
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Table 3.1. Relative energies of less favoured conformers.
Conforme
r
Symmetr
y
Bond
rotated
Relative energy a Conforme
r
Symmetr
y
Bond
rotated
Relative energy a
1-c' Cs 3-OH 6.35 3-b' Cs 
c 3-OH (7.71)
1-d' Cs 4-OH 15.34 3b' Cs 3-OH 6.90
1b' Cs 3-OH 4.56 3e' Cs 6-OH 2.14
1c' Cs 4-OH 13.82 3f' C1 
d 3-OH 7.21
1e' Cs 3-OH 16.07 3g' C1 3-OH 3.85
1f' Cs 4-OH 7.99 3h' Cs 3-OH
or 6-
OH
7.66
1h' Cs 4-OH 4.26 3h" C2v 3-OH
and 6-
OH
15.53
1h" Cs 
b 3-OH (15.32)
1h"' Cs 3-OH
and 4-
OH
7.41 4-c' Cs 4-OH 11.23
1i' Cs 3-OH 0.92 4c' Cs 4-OH 10.05
1j' C1 4-OH 20.88 4d' Cs 5-OH 8.94
4f' C1 4-OH 17.52
2-c' Cs 3-OH 5.61 4g' Cs 5-OH 5.49
2-e' Cs 5-OH 1.24 4i' C2v 
e 5-OH f (6.98)
2b' Cs 3-OH 3.09 4i" C2v 4-OH 
f 3.60
2d' Cs 5-OH 4.00
2f' C1 3-OH 5.30
2h' Cs 5-OH 2.56
2j' Cs 3-OH 9.08
2k' Cs 3-OH 8.04
2k" Cs 5-OH 0.51
2k"' Cs 3-OH
and 5-
OH
7.55
2l' Cs 3-OH 3.40
2m' C1 5-OH 2.69
2o' Cs 5-OH 3.60
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Notes:
a Energies relative to minimum energy conformer in Kcal/mol, at RHF/6-31G(d)
optimised geometries. See Table 3.2 for relative and absolute energies of minimum
energy conformers.
b 1h": Not a minimum. Two imaginary frequencies in Cs symmetry. Relaxing
symmetry constraints optimises structure to 1h.
c 3-b': Not a minimum. Two imaginary frequencies in Cs symmetry. Relaxing
symmetry constraints optimises structure to 3-b.
d 3f': Not a pyridazine: optimised structure shows ring contraction via bonding
between N1 and C5, to form a bicyclic system.
e 4i': Not a minimum. One imaginary frequency in C2v symmetry. Relaxing
symmetry constraints optimises structure to 4i.
f 4i': hydroxyl protons near. 4i": hydroxyl protons far.
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Table 3.2. Energiesa of all tautomers at RHF/6-31G(d) and selected
tautomers post-SCF.
Structur
e
Symmet
ry
E {HF/6-
31G(d)}
E {MP2/6-
31G(d,p)}
E0 (best) G298 (gas)
1-a Cs 20.51 20.26
1-b Cs (-411.83038) 1.11 (-413.50124) (-413.53167)
1-c Cs 3.98 (-413.04628) 0.27 0.60
1-d Cs 9.84 4.18 4.21 4.55
1-e C1 24.02 28.57
1a C1 -338.12 -331.83
1b Cs -347.11 -348.17 -331.78 -331.67
1c Cs -334.65 -342.94 -325.07 -324.83
1d C1 -312.45
1e Cs -338.32 -344.21 -325.49 -325.27
1f Cs -355.33 -356.30 -338.03 -337.89
1g C1 -345.46 -339.80 -320.22 -321.45
1h Cs -342.71 -345.65 -328.12 -328.00
1i C1 
b,c -327.92 -323.22
1j Cs -287.37
2-a Cs 34.37
2-b Cs (-411.84220) (-413.04904) (-413.50826) (-413.53911)
2-c Cs 10.99 6.46 7.73 8.20
2-d C1 
b,c 16.42 17.24 18.00 17.34
2-e Cs 25.10
2-f Cs 22.39 24.32
2a C1 -303.93
2b Cs -323.43 -334.74 -314.53 -314.18
2c Cs 
b -312.69
2d Cs -313.97
2e Cs -287.91
2f Cs -336.90 -338.63 -316.76 -316.60
2g C1 
b,c -346.37 -343.67 -322.95 -323.83
2h Cs -344.97 -348.20 -324.78 -324.51
2i Cs -300.73
2j C1 
b,c -326.84 -325.82
2k Cs -335.83 -342.20 -322.69 -322.32
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2l Cs 
b -316.18
2m C1 -310.67
2n C1 -320.56
2o Cs -314.92
3-a Cs (-411.82891) (-413.03899) (-413.49775) (-413.52771)
3-b Cs 15.51 8.00 9.43 9.28
3-c Cs 36.77
3a C2 -354.48 -348.64 -330.10 -330.23
3b Cs -356.44 -357.20 -337.30 -337.60
3c C1 
d -313.96
3d Cs 
b -280.98
3e Cs -322.28
3f C1 
e -304.10
3g C1 -317.56
3h C2v -349.34 -354.75 -334.30 -334.04
3i C2 -275.20
4-a Cs 20.30 17.67 15.21 14.92
4-b C1 20.35 27.31
4-c Cs (-411.81382) (-413.04001) (-413.49312) (-413.52311)
4a C2v -288.45
4b C1 -311.12
4c Cs -339.09 -345.99 -327.05 -327.14
4d Cs -349.77 -347.32 -331.21 -331.46
4e C1 -338.41 -325.83
4f Cs -293.75
4g Cs -328.62
4h Cs 
f -327.21 -313.82
4i Cs -343.38 -340.48 -324.97 -325.35
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Notes:
a Absolute energies of lowest energy anionic tautomer of each system are indicated
in parentheses, given in Hartree. Energies of lowest energy conformations of other
tautomers relative to these structures (1-b or 1-c, 2-b, 3-a, 4-c) are given in
Kcal/mol. Lowest energy neutral tautomers are displayed in bold.
E0 (best) = Eelec + 0.8929*ZPE{HF/6-31G(d)}
Eelec = E{MP2/6-311++G(3df,3pd)} + E{QCISD(T)/6-31G(d,p)} - E{MP2/6-31G(d,p)}
G298(gas) = Eelec + Ethermal,298 + RT - TS
b Minimum found in Cs symmetry at HF / 6-31G(d). One small real frequency,
indicating soft ring puckering vibrational mode and likely breaking of symmetry at
higher level of theory and larger basis set.
c Minimum found in C1 symmetry with substantial deviation from planarity at MP2
/ 6-31G(d,p).
d 3c: Not a pyridazine: optimised structure in Cs symmetry has two imaginary
frequencies, and shows lengthening of C6-N1 bond. C1 symmetry optimised
structure is a ring-opened ketene.
e 3f: Not a pyridazine: optimised structure shows ring contraction via bonding
between N1 and C5, to form a bicyclic system.
f 4h: Minimum is a puckered ring with a vertical plane of symmetry.
Table 3.3. Effect of large basis set optimisation on favoured tautomers
of 3
Optimisation level //MP2/
6-31G(d)
//MP2/
6-311+G
(2d,p)
//MP2
/ 6-
31G(d)
//MP2/
6-311+G
(2d,p)
//MP2/
6-31G(d)
//MP2/
6-311+G
(2d,p)
/MP2/
6-31G(d)
//MP2/
6-311+G
(2d,p)
Structures 3-a 3-a 3a 3a 3b 3b 3h 3h
MP2/
6-311++G
(3df,3pd)
-413.49747 -413.49772 -333.22 -333.43 -343.02 -343.06 -341.06 -341.02
QCISD(T)/
6-31G(d) -413.11014 -413.10985 -353.55 -353.39 -359.52 -359.68 -355.55
-355.60
Energiesa
E0 -413.49775 -413.49786 -330.10 -330.28 -337.30 -337.49 -334.30 -334.30
RMS geometry
change
0.005 Å 0.015 Å 0.004 Å 0.006 Å
 
Notes:
a Energies relative to 3-a in Kcal/mol (absolute energies of 3-a in italics in Hartree).
See Table 3.2 for definition of E0.
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Table 3.4. Comparison of 2h geometry with X-ray crystal structure.
lengths a X-ray
structure b
MP2 /
6-31G(d,p)
angles a X-ray
structure b
MP2 /
6-31G(d,p)
N(1)-N(2) 1.344 1.343 N(1)-N(2)-C(3) 125.7 129.1
H(2)-N(2) 0.881 1.012 H(2)-N(2)-C(3) 119.4 116.0
C(3)-N(2) 1.361 1.403 N(2)-C(3)-C(4) 116.7 112.5
O(7)-C(3) 1.268 1.233 O(7)-C(3)-C(4) 125.2 127.1
C(4)-C(3) 1.407 1.447 C(3)-C(4)-C(5) 119.1 120.2
H(4)-C(4) 0.958 1.083 H(4)-C(4)-C(5) 123.5 122.6
C(5)-C(4) 1.354 1.367 C(4)-C(5)-C(6) 118.7 119.8
O(8)-C(5) 1.325 1.360 O(8)-C(5)-C(6) 115.6 114.8
H(8)-O(8) 0.828 0.967 H(8)-O(8)-C(5) 113.3 108.9
C(6)-C(5) 1.428 1.429 C(5)-C(6)-N(1) 122.9 122.6
H(6)-C(6) 0.964 1.080 H(6)-C(6)-N(1) 115.3 116.6
N(1)-C(6) 1.297 1.316 C(6)-N(1)-N(2) 115.9 115.9
Notes:
a Bond lengths in Å, bond angles in degrees.
b Crystal structure of hydrogen-bonded coplanar dimers described by Wagner et al.
[16]
Table 3.5. Comparison of 3b geometry with X-ray crystal structures.
angles a MH2 b MH1b MP2 /
6-31G(d,p)
lengths a MH2
b
MH1
b
MP2 /
6-31G(d,p)
N(2)-N(1)-C(6) 128.1 127.9 129.1
N(1)-N(2)-C(3) 115.0 115.0 115.3
N(1)-N(2) 1.363 1.364 1.354 N(2)-C(3)-O(3) 118.5 118.9 118.4
N(1)-C(6) 1.334 1.329 1.394 N(2)-C(3)-C(4) 123.6 124.0 124.6
N(2)-C(3) 1.298 1.304 1.313 O(3)-C(3)-C(4) 117.9 117.1 117.6
C(3)-O(3) 1.338 1.337 1.358 C(3)-C(4)-C(5) 119.0 117.7 118.5
C(3)-C(4) 1.415 1.422 1.426 C(4)-C(5)-C(6) 119.4 120.9 121.2
C(4)-C(5) 1.346 1.336 1.362 N(1)-C(6)-C(5) 114.9 114.5 112.1
C(5)-C(6) 1.435 1.437 1.456 N(1)-C(6)-O(6) 120.8 120.4 121.2
C(6)-O(6) 1.260 1.257 1.235 C(5)-C(6)-O(6) 124.3 125.1 126.7
N(1)-H(1) 0.82 0.90 1.011 N(2)-N(1)-H(1) 114 121 114.7
O(3)-H(3) 1.00 0.89 0.910 C(3)-O(3)-H(3) 109 116 106.5
Notes:
a Bond lengths in Å, bond angles in degrees.
b Two crystaline polymorphs of maleic hydrazide are described; triclinic MH1 from
P Cradwick [37] and monoclinic MH2 from A Katrusiak [38]
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Table 3.6. Free energies of aqueous solvation a
Structure Solvation method
IPCM-MP2 /
6-31G(d,p) 1SCFb,c
AM1-SM2
1SCFc
AM1-SM2
optd
PM3-SM3
1SCFc
PM3-SM3
optd
1-b -63.61 -70.42 -72.86 -72.42 -73.41
1-c -58.44 -68.78 -69.81 -68.66 -69.95 e
1-d -60.60 -72.33 -71.98 -71.84 -71.93
1b -13.95 -20.21 -20.63 e -21.34 -20.66
1c -15.59 -26.79 -28.68 e -25.71 -25.51
1e -13.83 -19.24 -21.25 e -21.99 -22.84
1f -9.81 -13.58 -14.68 e -17.11 -17.68
1g -10.22 -12.03 -13.14 -16.79 -16.69
1h -11.16 -13.20 -13.18 -13.75 -13.57
2-b -59.42 -68.96 -70.37 e -72.54 -73.29
2-c -59.30 -70.42 -70.54 -70.70 -70.90
2-d -58.60 -64.17 -63.67 e -64.91 -64.61
2b -13.99 -25.44 -26.73 e -25.65 -25.38 e
2f -15.68 -17.62 -18.77 e -21.40 -21.20
2g -8.68 -10.45 -11.43 -15.07 -15.16
2h -14.34 -14.43 -15.51 e -18.44 -18.95
2k -13.80 -14.60 -14.23 -15.36 -14.69
3-a -62.56 -71.68 -73.94 -72.63 -73.89
3-b -65.36 -73.54 -72.48 e -73.95 -72.93
3a -9.55 -15.28 -15.83 -18.16 -17.08
3b -9.87 -14.49 -15.24 e -17.80 -18.22
3h -11.70 -14.22 -14.39 -14.80 -14.94
4-a -68.96 -78.25 -80.30 e -80.14 -81.14 e
4-c -57.28 -69.61 -70.27 -69.38 -70.41 e
4c -13.34 -22.68 -25.07 -23.65 -24.35
4d -13.78 -20.01 -20.40 e -21.98 -21.11
4i -14.51 -13.78 -13.81 -14.60 -14.38
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Notes:
a Gsolv = Eaq - Egas
b Isodensity polarised continuum model single point calculations at MP2 / 6-
31G(d,p) geometries, using an isodensity value of 0.001 and a dielectric constant of
78.4.
c 1SCF: Single point energies using MP2 / 6-31G(d,p) optimised geometries.
d Opt: All energies obtained from structures optimised using AM1 and PM3, with
and without SM2 and SM3 solvation models respectively.
e Failure to fully optimise structure in aqueous phase: largest component of gradient
remains greater than 0.45, but energy stationary. Probably not significant.
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Table 3.7. Estimated tautomer ratios in gas phase and in aqueous
solutiona
Solvation methodStructure
None
(Gas
phase)
IPCM-MP2/
6-31G(d,p)
1SCF
AM1-SM2
1SCF
AM1-SM2
opt
PM3-SM3
1SCF
PM3-SM3
opt
1-b 73.44% 99.99% 96.69% 99.78% 99.92% 99.89%
1-c 26.52% 0.01% 2.19% 0.21% 0.06% 0.10%
1-d 0.03% 3E-06 1.11% 0.01% 0.02% 4E-05
1b 3E-05 2.89% 46.26% 9.73% 3.37% 0.42%
1c 3E-10 5E-06 30.25% 74.99% 0.05% 0.01%
1e 6E-10 5E-07 2E-06 6E-06 2E-06 3E-06
1f 100.00% 97.11% 23.49% 15.27% 96.57% 99.57%
1g 9E-13 2E-12 2E-14 1E-14 5E-13 2E-13
1h 6E-08 5E-07 7E-09 7E-10 2E-10 5E-11
2-b 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
2-c 1E-06 8E-07 1E-05 1E-06 4E-08 2E-08
2-d 2E-13 5E-14 6E-17 2E-18 5E-19 9E-20
2b 2E-08 1E-08 75.31% 81.67% 0.51% 0.14%
2f 1E-06 2E-05 0.01% 0.01% 0.02% 0.01%
2g 23.71% 2E-05 0.01% 0.01% 0.11% 0.05%
2h 74.46% 99.01% 23.90% 18.26% 99.34% 99.80%
2k 1.84% 0.99% 0.78% 0.05% 0.01% 2E-05
3-a 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
3-b 2E-07 2E-05 4E-06 1E-08 1E-06 3E-08
3a 4E-06 2E-06 2E-05 1E-05 7E-06 6E-07
3b 99.75% 94.87% 99.84% 99.94% 100.00% 100.00%
3h 0.24% 5.13% 0.15% 0.06% 2E-05 1E-05
4-a 1E-11 0.42% 3E-05 0.03% 0.09% 0.09%
4-c 100.00% 99.58% 100.00% 99.97% 99.91% 99.91%
4c 0.07% 0.03% 5.85% 64.39% 1.13% 13.98%
4d 99.93% 99.96% 94.15% 35.61% 98.87% 86.02%
4i 3E-05 0.01% 9E-10 2E-10 1E-10 3E-10
Notes:
a Calculated at 298.15 K, based on G298 in gas phase and solution.
HAi <=> HAj ; Kj,i = [HAj]/[HAi] = exp((Gi-Gj)/RT) ; [HA] = 1
Anions and neutral tautomers calculated and normalised separately.
Predominant tautomers shown in bold.
See Table 3.6 for explanation of solvation methods.
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Table 3.8. Equilibrium free energiesa and relative pKa estimates
b in
gas phase and in solution at 298.15K
Quantity,
system
Solvation method
None
(gas phase)
IPCM-MP2/
6-31G(d,p)
1SCF
AM1-SM2
1SCF
AM1-SM2
opt
PM3-SM3
1SCF
PM3-SM3
opt
3,4-dioxo-pyridazine
G298 (1-) -413.53141 -413.63304 -413.64377 -413.64777 -413.64706 -413.64865
G298 (1) -414.07013 -414.08567 -414.09214 -414.09461 -414.09728 -414.09829
pKa rel (1) 14.88 8.20 12.79 12.15 13.70 13.60
3,5-dioxo-pyridazine
G298 (2-) -413.53911 -413.53911 -413.63380 -413.64901 -413.65124 -413.65470
G298 (2) -414.05593 -414.07905 -414.08004 -414.08212 -414.08560 -414.08643
4.81 4.81 4.81 4.81 4.81 4.81pKa rel (2)
(lit. 4.81) 3,6-dioxo-pyridazine
G298 (3-) -413.52771 -413.62740 -413.64193 -413.64554 -413.64345 -413.64545
G298 (3) -414.06569 -414.08879 -414.08128 -414.08879 -414.08999 -414.09407
14.55 8.78 12.09 11.05 13.88 13.43pKa rel (3)
(lit. 5.67) 4,5-dioxo-pyridazine
G298 (4-) -413.52311 -413.61437 -413.63403 -413.63508 -413.63366 -413.63531
G298 (4) -414.05132 -414.08305 -414.07328 -414.08420 -414.08631 -414.08472
pKa rel (4) 10.05 11.09 13.08 13.20 14.81 13.50
pKa order 1 ~ 3 > 4 > 2 4 > 3 ~ 1 > 2 4 ~ 1 > 3 > 2 4 > 1 > 3 > 2 4 > 3 ~ 1 > 2 1 ~ 4 ~ 3 > 2
Notes:
a Weighted free energies over all anion and neutral tautomers respectively, based on
estimated tautomer ratios and G298 of individual components, in Hartree.
b pKa = (-log10(exp(- G298/RT))). Relative to system 2 = 4.81.
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Table 3.9. Literature pKas of related structures
Name Structure pKa Reference
2-hydroxy pyridine 5 11.6 [47]
3-hydroxy pyridine 6 8.7 [47]
4-hydroxy pyridine 7 11.1 [47]
2,3-dihydroxy pyridine 8 8.7 [49]
2,4-dihydroxy pyridine 9 6.5 [47]
2,5-dihydroxy pyridine 10 8.5 [48]
2,6-dihydroxy pyridine 11 4.5 [50]
3,4-dihydroxy pyridine 12 8.9 [49]
3-hydroxy pyridazine 13 10.5 [47]
4-hydroxy pyridazine 14 8.7 [47]
3-hydroxy pyridazine 1-oxide 15 4.1 [51]
4-hydroxy pyridazine 1-oxide 16 < 18 [33]
5-hydroxy pyridazine 1-oxide 17 < 16 [33]
6-hydroxy pyridazine 1-oxide 18 < 15 [33]
3,5-dihydroxy pyridazine 2 4.8 [16]
3,6-dihydroxy pyridazine 3 5.7 [47]
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Chart 3.1. 3,4-dioxo pyridazines
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Chart 3.2. 3,5-dioxo-pyridazines
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Chart 3.3. 3,6-dioxo-pyridazines
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Chart 3.4. 4,5-dioxo-pyridazines
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Chart 3.5. Other structures referred to in Chapter 3
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Chapter 3. Index of /pdb/
1a HF/6-31G(d) (34-12566.pdb)
1a MP2/6-31G(d,p) (34-1256m.pdb)
1b HF/6-31G(d) (34-13566.pdb)
1b MP2/6-31G(d,p) (34-1356m.pdb)
1b' HF/6-31G(d) (34-1356a.pdb)
1c HF/6-31G(d) (34-14566.pdb)
1c MP2/6-31G(d,p) (34-1456m.pdb)
1c' HF/6-31G(d) (34-1456a.pdb)
1d HF/6-31G(d) (34-15566.pdb)
1-a HF/6-31G(d) (34-156-6.pdb)
1-a MP2/6-31G(d,p) (34-156-m.pdb)
1e HF/6-31G(d) (34-23566.pdb)
1e MP2/6-31G(d,p) (34-2356m.pdb)
1e' HF/6-31G(d) (34-2356a.pdb)
1f HF/6-31G(d) (34-24566.pdb)
1f MP2/6-31G(d,p) (34-2456m.pdb)
1f' HF/6-31G(d) (34-2456a.pdb)
1g HF/6-31G(d) (34-25566.pdb)
1g MP2/6-31G(d,p) (34-2556m.pdb)
1-b HF/6-31G(d) (34-256-6.pdb)
1-b MP2/6-31G(d,p) (34-256-m.pdb)
1h HF/6-31G(d) (34-34566.pdb)
1h MP2/6-31G(d,p) (34-3456m.pdb)
1h' HF/6-31G(d) (34-3456a.pdb)
1h''' HF/6-31G(d) (34-3456c.pdb)
1i HF/6-31G(d) (34-35566.pdb)
1i MP2/6-31G(d,p) (34-3556m.pdb)
1i' HF/6-31G(d) (34-3556a.pdb)
1-c HF/6-31G(d) (34-356-6.pdb)
1-c MP2/6-31G(d,p) (34-356-m.pdb)
1-c' HF/6-31G(d) (34-356-a.pdb)
1j HF/6-31G(d) (34-45566.pdb)
1j' HF/6-31G(d) (34-4556a.pdb)
1-d HF/6-31G(d) (34-456-6.pdb)
1-d MP2/6-31G(d,p) (34-456-m.pdb)
1-d' HF/6-31G(d) (34-456-a.pdb)
1-e HF/6-31G(d) (34-556-6.pdb)
1-e MP2/6-31G(d,p) (34-556-m.pdb)
2a HF/6-31G(d) (35-12466.pdb)
2b HF/6-31G(d) (35-13466.pdb)
2b MP2/6-31G(d,p) (35-1346m.pdb)
2b' HF/6-31G(d) (35-1346a.pdb)
2c HF/6-31G(d) (35-14466.pdb)
2d HF/6-31G(d) (35-14566.pdb)
2d' HF/6-31G(d) (35-1456a.pdb)
2-a HF/6-31G(d) (35-146-6.pdb)
2e HF/6-31G(d) (35-14666.pdb)
2f HF/6-31G(d) (35-23466.pdb)
2f MP2/6-31G(d,p) (35-2346m.pdb)
2f' HF/6-31G(d) (35-2346a.pdb)
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2g HF/6-31G(d) (35-24466.pdb)
2g MP2/6-31G(d,p) (35-2446m.pdb)
2h HF/6-31G(d) (35-24566.pdb)
2h MP2/6-31G(d,p) (35-2456m.pdb)
2h' HF/6-31G(d) (35-2456a.pdb)
2-b HF/6-31G(d) (35-246-6.pdb)
2-b MP2/6-31G(d,p) (35-246-m.pdb)
2i HF/6-31G(d) (35-24666.pdb)
2j HF/6-31G(d) (35-34466.pdb)
2j MP2/6-31G(d,p) (35-3446m.pdb)
2j' HF/6-31G(d) (35-3446a.pdb)
2k HF/6-31G(d) (35-34566.pdb)
2k MP2/6-31G(d,p) (35-3456m.pdb)
2k' HF/6-31G(d) (35-3456a.pdb)
2k'' HF/6-31G(d) (35-3456b.pdb)
2k''' HF/6-31G(d) (35-3456c.pdb)
2-c HF/6-31G(d) (35-346-6.pdb)
2-c MP2/6-31G(d,p) (35-346-m.pdb)
2-c' HF/6-31G(d) (35-346-a.pdb)
2l HF/6-31G(d) (35-34666.pdb)
2l' HF/6-31G(d) (35-3466a.pdb)
2m HF/6-31G(d) (35-44566.pdb)
2m' HF/6-31G(d) (35-4456a.pdb)
2-d HF/6-31G(d) (35-446-6.pdb)
2-d MP2/6-31G(d,p) (35-446-m.pdb)
2n HF/6-31G(d) (35-44666.pdb)
2-e HF/6-31G(d) (35-456-6.pdb)
2-e' HF/6-31G(d) (35-456-a.pdb)
2o HF/6-31G(d) (35-45666.pdb)
2o' HF/6-31G(d) (35-4566a.pdb)
2-f HF/6-31G(d) (35-466-6.pdb)
2-f MP2/6-31G(d,p) (35-466-m.pdb)
3a HF/6-31G(d) (36-12456.pdb)
3a MP2/6-31G(d,p) (36-1245m.pdb)
3a MP2/6-311+G(2d,p) (36-1245m.pdb)
3b HF/6-31G(d) (36-13456.pdb)
3b MP2/6-31G(d,p) (36-1345m.pdb)
3b MP2/6-311+G(2d,p) (36-1345o.pdb)
3b' HF/6-31G(d) (36-1345a.pdb)
3-a HF/6-31G(d) (36-145-6.pdb)
3-a MP2/6-31G(d,p) (36-145-m.pdb)
3-a MP2/6-311+G(2d,p) (36-145-o.pdb)
3c HF/6-31G(d) (36-14456.pdb)
3d HF/6-31G(d) (36-14556.pdb)
3e HF/6-31G(d) (36-14566.pdb)
3e' HF/6-31G(d) (36-1456a.pdb)
3f HF/6-31G(d) (36-34456.pdb)
3f' HF/6-31G(d) (36-3445a.pdb)
3-b HF/6-31G(d) (36-345-6.pdb)
3-b MP2/6-31G(d,p) (36-345-m.pdb)
3g HF/6-31G(d) (36-34556.pdb)
3g' HF/6-31G(d) (36-3455a.pdb)
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3h HF/6-31G(d) (36-34566.pdb)
3h MP2/6-31G(d,p) (36-3456m.pdb)
3h MP2/6-311+G(2d,p) (36-3456o.pdb)
3h' HF/6-31G(d) (36-3456a.pdb)
3h'' HF/6-31G(d) (36-3456b.pdb)
3-c HF/6-31G(d) (36-445-6.pdb)
3i HF/6-31G(d) (36-44556.pdb)
4a HF/6-31G(d) (45-12366.pdb)
4b HF/6-31G(d) (45-13366.pdb)
4c HF/6-31G(d) (45-13466.pdb)
4c MP2/6-31G(d,p) (45-1346m.pdb)
4c' HF/6-31G(d) (45-1346a.pdb)
4d HF/6-31G(d) (45-13566.pdb)
4d MP2/6-31G(d,p) (45-1356m.pdb)
4d' HF/6-31G(d) (45-1356a.pdb)
4-a HF/6-31G(d) (45-136-6.pdb)
4-a MP2/6-31G(d,p) (45-136-m.pdb)
4e HF/6-31G(d) (45-13666.pdb)
4e MP2/6-31G(d,p) (45-1366m.pdb)
4f HF/6-31G(d) (45-33466.pdb)
4f' HF/6-31G(d) (45-3346a.pdb)
4g HF/6-31G(d) (45-33566.pdb)
4g' HF/6-31G(d) (45-3356a.pdb)
4-b HF/6-31G(d) (45-336-6.pdb)
4-b MP2/6-31G(d,p) (45-336-m.pdb)
4h HF/6-31G(d) (45-33666.pdb)
4h MP2/6-31G(d,p) (45-3366m.pdb)
4i HF/6-31G(d) (45-34566.pdb)
4i'' HF/6-31G(d) (45-3456b.pdb)
4i MP2/6-31G(d,p) (45-3456m.pdb)
4-c HF/6-31G(d) (45-346-6.pdb)
4-c MP2/6-31G(d,p) (45-346-m.pdb)
4-c' HF/6-31G(d) (45-346-a.pdb)
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4. Pyridazinediones as candidates for neuroactive
amino acid analogues
Abstract
The primary inhibitory amino acid neurotransmitter GABA and the primary excitatory amino
acid neurotransmitter glutamate are introduced, with emphasis on GABAA and AMPA receptors
respectively. Medicinal chemistry, pharmacology, therapeutics, and molecular biology are
discussed briefly. The role 3-isoxazolols have played historically in developing our
understanding of these receptors is emphasised. A rationale for investigating the replacement of
the ring oxygen of 3-isoxazolols by an amide to form a pyridazinediones is offered, and
illustrated with molecular modelling. The significance of pyridazinedione tautomerism and the
rationale for investigating non-tautomeric N-methyl derivatives is discussed. Analogues of some
of the more significant 3-isoxazolol GABA and EAA analogues are earmarked for synthesis, a
total of 12 target compounds being selected.
Index
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4.2. Brief introduction to Excitatory Amino Acid (EAA) receptors
4.3. Pyridazinediones as amino acid analogues
4.3.1. The resemblance of pyridazinediones to 3-isoxazolols
4.3.2. Choosing to investigate maleic hydrazide derivatives
4.3.3. The role of tautomerism
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4.4. References
A number of excellent and recent reviews of GABA and EAA receptor
pharmacology and medicinal chemistry are available [1,2]. It is not within the scope
of this chapter to cover these subjects in any detail, rather to provide an overview of
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the context in which the theoretical and synthetic studies described in the other
chapters took place.
4.1. Brief introduction to GABA receptors
The ubiquitous amino acid -aminobutyric acid (GABA, 1) has long been regarded
as the most important and prevalent inhibitory neurotransmitter in the mammalian
brain (Central Nervous System, CNS) [3,4]. To indicate its therapeutic importance,
one need only consider the range of therapeutically useful compounds which owe
at least some of their activity to the GABA system: sedatives such as barbiturates
and benzodiazepines (see scheme 4.1), and steroid anaesthetics modulate the
activation of various populations of GABA receptors, and the action of volatile
anaesthetics and alcohol is also believed to be mediated at least in part by the
GABA system [5]. GABA receptors are implicated in a wide range of neurological
phenomena such as anxiety, analgesia, convulsions, coma, dementia, epilepsy,
hypertension and schizophrenia [6].
GABA (1)
diazepam
(a benzodiazepine)
pentobarbitone
(a barbiturate)
(+)-bicuculline (2)
Scheme 4.1 Some compounds acting at the GABA receptor
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As a very simple, flexible amino acid, it comes as no surprise that it has been found
to activate a highly heterogeneous population of receptors. On the basis of
medicinal chemistry, i.e. the synthesis or extraction from natural sources of GABA
analogues, and the testing of these on various preparations, and to a lesser extent on
the basis of molecular genetics, GABA receptors have been classified into three
classes: GABAA, GABAB, and GABAC [1].
GABAA receptors, the longest classified and best understood, as well as the most
prevalent, and with which this study is primarily concerned, are ligand-gated
chloride ion channels. They are blocked by the potent competitive antagonist (+)-
bicuculline (2), a phthalideisoquinoline alkaloid isolated from Dicentra cucullaria [7].
A major leap forward in the study of GABA receptors was made when  it was
found that a muscimol (5-aminomethyl-3-isoxazolol, 3) is a potent agonist of GABA
receptors, whose action is mostly blocked by bicuculline (2) [8]. Thus it is a potent
GABAA agonist, but more recent work shows that it has some affinity for GABAB
receptors, and is now known to be a partial agonist at GABAC [1,4]. Muscimol is the
main psychoactive component of Amanita muscaria (the red-and-white toadstool of
fairytale fame) known since antiquity to cause sedation and a kind of toxic delirium
when ingested [9].
A large number of muscimol (3) analogues were synthesised in the effort to gain
further insight into the nature of the GABAA receptor [10]. Mostly, activity was
poorer, although dihydromuscimol and homomuscimol (5-aminoethyl-3-isoxazolol)
are worthy of some note. The methylated positional isomer of muscimol, 4-
aminomethyl-5-methyl-3-isoxazolol (4), a compound of minor significance in this
study, was found to be without activity [10].
The discovery that a cyclised form of muscimol, THIP (5), also activated the GABAA
receptors, although with somewhat less efficacy than muscimol, was another leap
forward [11]. It was noted that the action of THIP, for example with respect to
benzodiazepine binding, showed differences from GABA and muscimol [12]. Later,
it was found that unlike muscimol which is a GABAC agonist, THIP is a GABAC
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antagonist [1]. The differences in action of compounds such as THIP and muscimol
were instrumental in indicating the heterogeneity of the GABAA receptor, now
confirmed from molecular biology by the "mix-and-match" of various cloned
subunits which can be assembled in a multitude of ways to form the pentameric
receptor [1]. THIP is also noteworthy for its potent analgesic effects, and for having
proceeded to clinical trials in this regard. The isomer of THIP, 4,5,6,7-
tetrahydroisoxazole[4,5-c]pyridin-3-ol (THPO, 6) was found to be not an agonist,
but a GABA uptake inhibitor [13,14], whose minor significance to this study will
also become apparent.
muscimol (3) 4-aminomethyl-5-methyl-
3-isoxazolol (4)
THIP (5) THPO (6)
Scheme 4.2 3-isoxazolols with varying activity at GABA receptors
The search for new kinds of substances active at GABAA receptors goes on, both
because of the therapeutic potential of potent and specific compounds, and because
the more the (currently small) catalogue of compounds known to be active is
expanded, the better understanding we gain of this vital neurochemical system.
As was alluded to in the previous chapters, much of this thesis is concerned with
carboxylate bioisosteres. Very few classes of structures containing a replacement for
carboxylate are currently known to produce agonists at GABAA. By far the best
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studied are the 3-isoxazolols. Subsequently, their sulfur analogues, the 3-
isothiazolols have been shown to be active [15]. However, 5-isoxazolols and 3-
diazolols have been shown to be inactive, underscoring strict requirements for
activity [1]. Sketchy reports indicate possible activity for two additional classes,
quisqualamine - an oxadiazoledione derivative, and kojic amine, a 3-hydroxypyran-
4-one. See section 7.1.2 for a discussion of these two compounds. Other structures
known to produce analogues with agonist or partial agonist properties contain a
naked carboxylate, or in a very few instances, sulfonate moiety [1].
This begs the question: are there other as yet untested acidic hydroxy heterocycles
which can act as carboxylate bioisosteres at the GABAA receptor?
One of the main reasons to examine heterocyclic carboxylate bioisosteres rather
than analogues featuring a naked carboxylate, is because incorporation of the acidic
function within a ring greatly increases the lipophilicity of the compound, and thus
its ability to permeate the blood brain barrier (BBB), vital to the development of
systemically administerable therapeutics.
4.2. Brief introduction to Excitatory Amino Acid (EAA) receptors
It has long been known that the CNS contains high concentrations of glutamate (7),
and that glutamate and aspartate (8) cause near universal neuronal excitation.
Glutamate is now accepted as the major excitatory neurotransmitter in the CNS,
while the role of aspartate is less well defined [5]. The receptors for such substances
are known as Excitatory Amino Acid (EAA) receptors [16].
L-glutamate (7) L-aspartate (8)
Scheme 4.3 Two endogenous excitatory amino acids
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As might be expected from their ubiquitous occurrence, EAA receptors are
suggested to play a role in a wide variety of brain functions and abnormalities. To
name a few, EAA receptors are implicated in such disorders as epilepsy [16],
Huntington's chorea [17], Alzheimer dementias [18], AIDS-related dementia,
schizophrenia and Parkinsonism [19]. One of the most significant potential
applications of EAA-related compounds concerns neuroprotection under conditions
of ischæmia such as stroke. It is known that high levels of glutamate are excitotoxic
to neurones, and are released under ischæmic conditions. It is reasoned therefore
that glutamate blockers (particularly of the AMPA subclass) are potentially able to
protect the brain from damage immediately following a stroke. Drugs based on this
principle have been trialled clinically, and new agents are greatly sought after [20].
Glutamate receptors, implicated in learning and memory, are important in
mediating the phenomenon of Long Term Potentiation (LTP) which has been the
subject of intense discussion and research since the 1980s, as a postulated cellular
mechanism of memory [21,22].
The very importance of EAA receptors is actually an impediment to furthering their
understanding: the development of therapeutic agents acting at various EAA
receptors is hampered by the very widespread distribution and function of the
receptors. This serves as an impetus for research into more specific and localised
targets.
In recent years, molecular biology and extensive medicinal chemistry have seen the
classification of EAA receptors into a number of classes [5]. The primary division is
between the metabotropic and ionotropic classes of receptors. On the basis of
sequence homology and agonist/antagonist pharmacology, three classes of
metabotropic (G-protein-coupled) receptors are now recognised [23]. Better
understood are the ionotropic receptors (permeable to Na+ and in some cases to
Ca2+) with which this thesis is chiefly concerned.
The ionotropic receptors are also currently divided into three classes, on the basis of
medicinal chemistry and molecular biology [2]. A number of different subunits
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which comprise these receptors have been cloned, and homo- and hetero-oligomers
exist for all three classes. The first class to be identified was the NMDA receptor,
after the potent and specific agonist N-methyl-D-aspartate (9), and it remains the
best understood [24]. As with the other classes of EAA receptors, specific
antagonists have been found to aid characterisation.
Non-NMDA ionotropic EAA receptors, originally named quisqualate (QUIS)
receptors, after the potent naturally occurring excitotoxin quisqualic acid (10), (S)-
-amino-3,5-dioxo-1,2,4-oxadiazolidine-2-propanoic acid (from Quisqualis sp.), have
been shown to belong to two classes named AMPA receptors and kainate (KAIN)
receptors, after the potent and selective agonist AMPA (2-amino-3-(3-hydroxy-5-
methylisoxazol-4-yl)propanoic acid, 11) and the potent, but somewhat less selective
agonist kainic acid (12) [16].
NMDA (9) quisqualate (10) AMPA (11) kainate (12)
Scheme 4.4 Agonists which have been used to characterise ionotropic EAA receptor subtypes
Just as the identification of muscimol as a GABA agonist was a watershed, likewise,
another component of Amanita muscaria, the -carboxylate derivative of muscimol,
known as ibotenic acid (13), proved to be a crucial lead in the development of
understanding of ionotropic glutamate receptors. The similarity {muscimol is to
GABA, as ibotenic acid is to glutamate} is immediately apparent. However, no such
general homology exists across the range of known active compounds at amino acid
receptors. Ibotenic acid proved to be a non-specific agonist, activating both NMDA
and non-NMDA ionotropic receptors, and also possessing metabotropic activity
[25].
Its positional methylated isomer AMAA (R,S)-2-amino-2-(3-hydroxy-5-
methylisoxazol-4-yl)acetic acid (14) was found to be a potent specific agonist of
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NMDA receptors [26]. 3-Isoxazolols unsubstituted at position 5-, though not
unknown, appear to be particularly difficult to synthesise. Interestingly, whereas
the (S) isomer of ibotenic acid and also of most AMPA-specific agonists is the more
potent, the (R) isomer of AMAA has recently been found to be the more potent [27].
This thesis considers for the most part racæmic mixtures, being much easier to
produce and screen initially.
Homologisation of ibotenic acid by adding an extra methylene to the -amino acid
moiety, substantially increased the specificity with respect to non-NMDA receptors.
It was found that homoibotenic acid (HIBO, 15) is a specific AMPA agonist, and
that while fairly weak, certain 4-substituted derivatives are potent agonists [28] (see
chapter 8, table 8.1 for a full list).
The methylated positional isomer of HIBO (15), which is also the homologue of
AMAA (14), is 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid (AMPA,
11) [29]. The discovery of AMPA was of great importance in differentiating non-
NMDA receptors, which were subsequently known as AMPA and Kainate after
their respective potent agonists.
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ibotenic acid (13) AMAA (14)
HIBO (15) willardiine (16)
Scheme 4.5 isoxazole -amino acids with varying activity at EAA receptors, and the amino acid
willardiine
The extensive range of hydroxy heterocycles which are now known to be capable of
incorporation as -carboxylate bioisosteres in potent AMPA analogues is reviewed
in detail in chapter 8, but when the current investigation was commenced, only a
small handful were known, the six-membered uracil derivative willardiine (16) [30]
being the most important example, other than the 3-isoxazolols. The question was
asked: are there other as yet untested acidic hydroxy heterocycles which can act as
carboxylate bioisosteres at the AMPA receptor?
4.3. Pyridazinediones as amino acid analogues
Having introduced the two most important types of amino acid neuroreceptors, we
now turn our attention to the pyridazinediones, and the ways in which they might
be used to advance our understanding of these receptors.
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Firstly, a note regarding nomenclature: tautomerism of maleic hydrazides makes
precise naming difficult. In the case of the non- N-methylated compounds, a
mixture of two tautomers is expected for all structures, or at any rate, the precise
structure cannot be determined. The literature has called such compounds both 3,6-
dihydroxypyridazines, 3,6-pyridazinediols, and more often, 3,6-pyridazinediones,
pyridazine-3,6-diones, and so on. In general, the convention of calling maleic
hydrazide derivatives pyridazine-3,6(1,2H)-diones has been used in this text, even
though we know that the actual structures are a mixture of tautomeric
hydroxypyridazinones. In the case of the N-methyl derivatives, naming has
followed the correct structure, e.g. 2-methyl-6-hydroxypyridazin-3(2H)-one, even
though this might be referred to as a pyridazinedione in the literature.
"Dioxopyridazines" and "pyridazinediones" have also been used as a colloquialisms
for the whole class of structures.
4.3.1 The resemblance of pyridazinediones to 3-isoxazolols
The heterocycle which has proved the most fertile source of GABAA and AMPA
analogues is 3-isoxazolol. The conjugate base of this acidic heterocycle contains an
O-C-N portion which closely resembles the O-C-O of carboxylate; 3-isoxazolol is
considered to be a carboxylate bioisostere. However, there is a greater degree of
charge delocalisation associated with the heteroaromatic ring than is the case for
carboxylate, and depending on the receptor environment, this may promote
binding.
When considering which pyridazinediones might be employed as novel amino acid
analogues, a first step was to examine the similarities and differences between
various pyridazinediones and 3-isoxazolol.
Chapters 2 and 3 examined in some detail the structures, charge distributions, and
tautomeric preferences of all dioxo substituted pyridazines. All four of the acidic
hydroxy pyridazine 1-oxides and four pyridazinediones might be considered as
potential carboxylate bioisosteres. However, examining the structures and
tautomeric preferences of the conjugate bases, it is apparent that 4,5-
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dioxopyridazine is not capable of forming an O-X-N anionic structure, and that 3,4-
dioxopyridazine and 3,5-dioxopyridazine do not show a tautomeric preference for
an O-X-N anionic system such as is found in the base of 3-isoxazolol. Furthermore,
of the remaining structures, only two possess the negatively charged structure O-C-
N which most closely resembles the base of 3-isoxazolol. Examining the point
charges calculated from electrostatic potentials, these same two structures, namely
pyridazine-3,6-dione (maleic hydrazide) and 3-hydroxy pyridazine 1-oxide, also
show the largest negative charge distributions on the O-X-N structure. Thus, these
two were the acidic pyridazinones considered most worthy of investigation as
novel ring structures around which to design amino acid analogues.
Figure 4.1 base of maleic hydrazide
(linked to full size image)
Figure 4.2 base of 3-hydroxypyridazine 1-oxide
(linked to full size image)
Figure 4.3 base of 4,5-dimethyl-3-isoxazolol
(linked to full size image)
Figures 4.1, 4.2, and 4.3 depict anionic base structures optimised at the MP2 / 6-
31G(d,p) level of ab initio theory. Point charges and dipoles were calculated using
the Merz-Kollman-Singh method [34] and are depicted in yellow. All three
structures show similar geometry and charge distribution in the O-C-N region. The
pyridazines however have a second region of negative charge associated with the
second oxygen substituent.
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4.3.2 Choosing to investigate maleic hydrazide derivatives
Of all the pyridazinones, the most accessible in terms of ease of synthesis and large
synthetic knowledge base, is maleic hydrazide and its derivatives. In fact, maleic
hydrazide itself is employed commercially as a plant growth inhibitor under trade
names such as Fazor, Malazide and Regulox [35]. Though less well understood, 3-
hydroxypyridazine 1-oxide chemistry is also fairly well documented by comparison
with other pyridazinediones [31].
Pyridazine-3,6-diones are attractive as potential carboxylate bioisosteres for a
number of reasons. As discussed in chapter 3, though slightly less acidic, they are of
comparable acidity to carboxylic acids, within a couple of pH units of the -
carboxylate of glutamate for example. Both are almost entirely deprotonated at
physiological pH
The pyridazine ring, having two adjacent nitrogen atoms, possesses a large dipole;
larger than other diazoles or pyridine [31]. It is hypothesised that the local binding
region of the AMPA receptor in particular is strongly polarised, and that employing
a highly polar heteroaromatic group could increase activity. Pyridazines have been
highly favoured in certain areas of medicinal chemistry as aromatic bioisosteres on
account of their large dipoles [32,33]
The structural difference between pyridazine-3,6-dione and 3-isoxazolol, lies in the
replacement of the ring oxygen of isoxazole with an amide linkage. Whether amino
acid analogues based on pyridazine-3,6-dione are active or not should depend
heavily on whether this larger more negatively charged amide region can be
accommodated by the various receptors.
A potential advantage of pyridazinediones over 3-isoxazolols, whose behaviour as
GABA and EAA analogues has now been explored fairly exhaustively, is that being
six-membered rather than five-membered rings, should a potent lead compound be
found, there is a greater opportunity for a more diverse range of derivatives with
specifically located substituents. In particular, having the extra position for
substitution was considered an advantage for the potential for design of
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antagonists. In the early 1990s when pyridazinediones were first postulated as
potential amino acid neurotransmitter analogues, only one active compound
containing a six-membered ring had achieved prominence: the naturally occurring
(Family Leguminosae) amino acid willardiine (16), a uracil-derived AMPA analogue
[30]. In chapter 8, the larger range of AMPA analogues based on six-membered
heterocyclic carboxylate bioisosteres now known is reviewed. Willardiines and
other six-membered heterocycles remain a fertile area of amino acid
neurotransmitter analogue research.
While 3-isoxazolols possess only one ring oxygen substituent, quisqualate (10) and
willardiine (16), like pyridazindiones, have two. While both 4- and 5- alanino
substituted isoxazolols, e.g. AMPA (11) and HIBO (15), and 4- and 5- glycino
substituted isoxazolols, e.g. AMAA (13) and ibotenic acid (14) were known to
produce analogues active at EAA receptors of varying potency, little had been
determined about the dependence of activity on the relative positions of oxygen
substituents, particularly when the heterocycle is six-membered and contains more
than one potential acidic group. Even less was known about the possibilities of six-
membered heterocycles as scaffolds for GABA analogues. Studying a variety of
substituted pyridazinediones was therefore an attractive means for probing the
relationship between oxygen substitution and amino acid analogue activity.
4.3.3 The role of tautomerism
As discussed in chapter 3, maleic hydrazide strongly prefers a lactam-lactim
structure. The structure of the preferred anion of maleic hydrazide is N-protonated.
But in the case of derivatisation at position 4 to produce an amino acid analogue,
symmetry is broken and the two N-protonated tautomers are no longer identical.
Very little energy separates the structures bearing the two possible sites of N-
protonation, and the solution structure is likely to be a dynamic equilibrium
mixture of both. That means that the maleic hydrazide derivatives may be present
as analogues of either, or more likely both, of the isomeric 4- and 5- substituted 3-
isoxazolols.
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Therefore, maleic hydrazides are uniquely placed to serve simultaneously as
analogues of both 4- and 5- substituted 3-isoxazolols. However, should maleic
hydrazide be N-substituted with a group other than a labile proton, the tautomeric
ambiguity is at once removed. The simplest such substituent to introduce would be
a methyl group. Whereas a proton is labile in aqueous solution, an N-methyl group
is not.
Thus in addition to attempting the synthesis of ambiguous maleic hydrazides
derivatised at the 4-position, it was also considered desirable to attempt to make the
derivatives which had the carboxylate-like region "locked" in either form. So, 4-
substituted and 5-substituted 2-methyl-6-hydroxypyridazin-3(2H)-ones would
putatively be able to provide information about the dependence of activity on the
relative position of the side chain and the negatively charged ring oxygen. It was
hoped that the N-methylated versions would assist in differentiating how any
activity found in the unmethylated maleic hydrazide derivatives was dependent on
tautomeric structure.
4.3.4 The target series
The central question to be determined is posed thus: can the ring oxygen of an
archetypal isoxazolol which is active at EAA or GABAA receptors be replaced by an
amide linkage, to form a pyridazinedione, and retain activity? And since this
creates a mixture of tautomers, each of which may be considered analogues of two
isoxazolols, what is the result of fixing the relative positions of the side-chain and
acidic bioisostere by N-methylation?
To answer these questions, a set of test compounds to be synthesised and evaluated
for activity was proposed, based on analogy with the most significant 3-isoxazolols
known to possess GABA and EAA agonist activity, discussed above. Four basic
kinds of derivatisation were found to account broadly for the range of 3-isoxazolols
with agonist activity: substitution by an aminomethyl group or fusion with a
tetrahydropyridine ring to produce GABAA agonists, and substitution by a glycine
group or alanine group to produce EAA agonists.
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This suggested the following target series: maleic hydrazide analogues of muscimol
(3) and its inactive analogue 4-aminomethyl-5-methyl-3-isoxazolol (4); analogues of
THIP (5) and THPO (6); analogues of ibotenic acid (13) and AMAA (14); and
analogues of HIBO (15) and AMPA (11). The inclusion of the two N-methyl
derivatives of each of these four paired systems, removing tautomeric ambiguity,
gives a total target series of twelve compounds by which to thoroughly investigate
the potential of pyridazine-3,6-diones as amino acid analogues. These structures (17
to 28) are presented in table 4.1.
Table 4.1 Target series: structures of known amino acid analogues
and their pyridazinedione counterparts
3-isoxazolol pyridazinedione (R=H, CH3)
name structure
(linked to .pdb geometry)
activity numbers structure
(linked to .pdb geometry)
figures
(overlays)
muscimol (3)
potent
non-
specific
GABA
agonist
17a (R=H)
21 (R=CH3)
Figure 4.4
4-
aminomethyl
-5-methyl-
3-isoxazolol
(4)
no GABA
binding
inhibition
no in vivo
activity at
spinal
neurones
17b (R=H)
22 (R=CH3)
Figure 4.5
THIP (5)
potent
GABAA
partial
agonist,
GABAC
antagonist
18a (R=H)
23 (R=CH3)
Figure 4.6
THPO (6)
potent
GABA
reuptake
inhibitor
18b (R=H)
24 (R=CH3)
Figure 4.7
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ibotenic
acid (13)
potent
non-
specific
NMDA/
AMPA
agonist
19a (R=H)
25 (R=CH3)
Figure 4.8
AMAA
(14)
specific
NMDA
agonist
19b (R=H)
26 (R=CH3)
Figure 4.9
homoibo
tenic
acid (15)
weak
specific
AMPA
agonist
20a (R=H)
27 (R=CH3)
Figure 4.10
AMPA
(11)
potent
specific
AMPA
agonist
20b (R=H)
28 (R=CH3)
Figure 4.11
The structures in table 4.1 were optimised using AM1-SM2 aqueous semi-empirical theory in low
energy conformations. Electrostatic isopotentials in the plane of the aromatic ring were
determined from the wavefunction using Spartan 5.0 [36]. Compounds were overlayed with
matching ionic groups and carbon backbone, and are depicted in figures 4.3 to 4.10
The next chapters describe the pursuit of the pyridazine-3,6-diones proposed here
as neuroactive amino acid analogues. As suggested above, 3-hydroxy pyridazine 1-
oxides were also considered worthwhile candidates for synthesis and testing. While
these compounds do not possess the kind of interesting tautomeric properties of the
pyridazine-3,6-diones, and were thought to be somewhat more challenging to
produce synthetically, they do have a larger dipole, and more closely resemble the
known AMPA agonist willardiine (16). Co-workers [37] were therefore
investigating the 3-hydroxypyridazine 1-oxides, among other structures, at the
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same time as this work on pyridazine-3,6-diones was undertaken. As it turned out,
it was the 3-hydroxypyridazine 1-oxides which proved the richer source of active
AMPA analogues, and these results are described in the review of heterocycles
active at AMPA receptors in chapter 8. To date, their synthesis and activity as
GABA analogues remains unexplored.
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Chapter 4: Index of optimised geometries
3-isoxazolols pyridazinones
muscimol (3) 4-aminomethyl-5-methyl-6-hydroxypyridazin-3(2H)-one (17a)
4-aminomethyl-5-methyl-
3-isoxazolol (4) 4-methyl-5-aminomethyl-6-hydroxypyridazin-3(2H)-one (17b)
THIP (5) 1-hydroxy-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4(3H)-one (18a)
THPO (6) 4-hydroxy-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1(2H)-one (18b)
ibotenic acid (13) 2-Amino-2-(6-hydroxypyridazin-3(2H)-on-4-yl)ethanoic acid (19a)
AMAA (14) 2-Amino-2-(6-hydroxypyridazin-3(2H)-on-5-yl)ethanoic acid (19b)
HIBO (15) 2-Amino-3-(6-hydroxypyridazin-3(2H)-on-4-yl)propanoic acid (20a)
AMPA (11) 2-Amino-3-(6-hydroxypyridazin-3(2H)-on-5-yl)propanoic acid (20b)
Amanita muscaria
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5. Synthesis of pyridazine amino acids
Abstract
The attempted synthesis of the twelve target compounds proposed in chapter 4 is described.
Three aminomethyl pyridazines and three alanino pyridazines (muscimol and AMPA
analogues) were readily produced via free-radical bromination of parent protected methyl
pyridazines, followed by derivatisation to an amine or -amino acid, and deprotection. An
unusual N-methyl bromination product prompted the synthesis of another, N-substituted,
alanino pyridazine. Three tetrahydro pyridopyridazinediones (THIP analogues) were readily
produced by reduction of the hydazides of pyridine-3,4-dicarboxylate. Three methods for
producing pyridazinyl glycines (AMAA and HIBO analogues) were trialed: ring nucleophilic
substitution, various aldehyde syntheses, and synthesis via an ethyl pyridazinyl acetate. The
final method came within a step of completion, but -amino acid decarboxylation during
deprotection prevented the synthesis of the pyridazinedionyl glycine. In total, ten GABA and
glutamate analogues were synthesised for pharmacological screening, described in chapter 7.
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5.1 Analogues of muscimol (5-aminomethyl-3-isoxazolol)
5.1.1 4-Aminomethylpyridazine-3,6(1,2H)-dione
Scheme 5.1 Synthesis of 4-aminomethylpyridazine-3,6(1,2H)-dione 7, linked to experimental
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A 3,6-diprotected 4-methyl pyridazine-3,6-dione was sought as a precursor to
pyridazinedione muscimol analogues. An attempt at using a labile trimethylsilyl
protecting group for the oxygens of citraconic hydrazide 2 was unsuccessful
because of instability in the presence of even traces of moisture, hence the more
robust dimethoxy derivative 4 was synthesised.
3,6-Dichloro-4-methyl-pyridazine 3 had been prepared by standard techniques from
citraconic anhydride 1 via citraconic hydrazide 2 [1]. The dimethoxy derivative 4, a
known compound [2,3], was prepared by refluxing 3 with sodium methoxide in
xylene. Bromination by N-bromosuccinimide (NBS) in CCl4 afforded 36% of the
bromomethyl derivative 5, along with the dibromomethyl derivative. NBS had
previously been used in the synthesis of AMPA and 4-methyl HIBO from 3-
methoxy-4,5-dimethyl isoxazole [4], but its action on methoxy methyl pyridazines
had not been reported. One account describes the success of the reaction on 2,4-
dimethyl-6-phenylpyridazin-3(2H)-one [5].
Simple nucleophilic substitution of the activated bromide with ammonia in
methanol at 0ºC gave the protected amino acid 6, which was demethylated to the
muscimol analogue 4-aminomethyl pyridazin-3,6(1,2H)-dione 7 by reflux in
concentrated HBr, conditions which have also been used to demethylate methoxy
isoxazoles [4]. While the final product 7 resisted all attempts to obtain a crystalline
material, it was purified by chromatography on ion exchange resin, followed by
precipitation from a hot aqueous solution with ethanol. This compounds is
probably present in aqueous solution as a mixture of zwitterionic tautomers, and
this may complicate the crystallisation procedure. TLC and n.m.r. evidence
indicated greater than 95% purity.
Attempts at further purification via the t-Boc derivative of 7 gave poor yields for
insubstantial gain in purity.
An attempt at partial deprotection of the t-butyloxycarbonyl (t-Boc) derivative
under gentler conditions (6M HCl) to produce 4-aminomethyl-6-methoxypyridazin-
3(2H)-one and/or 5-aminomethyl-6-methoxypyridazin-3(2H)-one produced a
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mixture of unclear composition, with at least three major components by TLC and
n.m.r., showing little promise. This reaction also served to show that hydrolysis
under harsher conditions with HBr is necessary for full deprotection of 3,6-
dimethoxy pyridazines.
Attempts to produce the homologue of 7, i.e. the aminoethyl derivative, via
nucleophilic substitution of 5 with cyanide, followed by reduction, were
unsuccessful. The cyano group strongly activates the methylene, leading to further
substitution and mixtures of dimeric products under gentle conditions in DMSO or
acetonitrile/water solvents. Further attempts to synthesise analogues of
homomuscimol (5-aminoethyl-3-isoxazolol) were abandoned when it later became
apparent that pyridazine-3,6-diones held no promise as GABAergic agents (see
chapter 7).
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5.1.2 2-Methyl-4-aminomethyl-6-hydroxypyridazin-3(2H)-one
Scheme 5.2 Synthesis of 2-methyl-4-aminomethyl-6-hydroxypyridazin-3(2H)-one 15, linked to
experiments
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Several methods were tried to produce a 4-methyl-6-alkoxypyridazin-3(2H)-one, as
a protected precursor for N-methyl derivatives. The action of dimethyl sulfate on
citraconic hydrazide 2 produced complex mixtures with poor conversion, as did
methyl iodide. However detailed chromatography and analysis of the products
greatly assisted subsequent identification. Katrusiak and Baloniak subsequently
described in detail the mixtures produced by the action of these methylating agents
on the simpler maleic hydrazide system [6], testimony to the difficulty of this route.
An attempt to isomerise 4 to give methyl ethers of 8 or 9 using p-toluenesulfonic
acid at 170ºC also failed, starting material and a complex mixture including
degradation products resulting.
Condensation of citraconic anhydride 1 with N-methyl hydrazine producing the N-
methyl derivatives of 2, i.e. "citraconic methyl hydrazides", was successful
following a method previously used for N-phenyl derivatives [7]. Separation of the
two isomers 8 and 9, produced in near equal amounts, was achieved by careful
successive fractional crystallisation.
The isomer of higher Rf, lower melting point, and higher water solubility was
identified by the following procedure: chlorination of the isomer using excess POCl3
using a typical method for converting hydroxy pyridazines to their chlorides [8]
produced only one compound of above baseline Rf, and despite a very poor yield
from a difficult workup, in sufficient quantity after column chromatography for
identification as the 6-chloro derivative, subsequently shown to be 10.
Dehalogenation with hydrogen at 1 atm and palladium on carbon catalyst by a
typical method [9] gave a product with a coupling consistant with an ortho-
arrangement of aromatic protons (J 4.1 Hz), but not ruling out a meta- arrangement.
However only one of these protons was coupled with the methyl group (J 1.2 Hz).
The Overhauser effect (n.O.e.) n.m.r. spectrum clearly showed one aromatic
hydrogen rather than two proximal to the 4-methyl group, when this group was
irradiated. This strongly indicated that the compound was 2,4-dimethylpyridazin-
3(2H)-one 11. Thus the hydrazide isomer of higher Rf was shown to be 2,4-
dimethyl-6-hydroxypyridazin-3(2H)-one 8. These two simple pyridazines 10 and 11
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are apparently previously unreported, perhaps because of the difficulties of
separation and the chlorination reaction.
Prior to this synthesis, and n.O.e. experiments, the identities of the two isomers 8
and 9 had also been correctly predicted on the basis of theoretical calculations on
their derivatives, as described in Chapter 6.
After trying several methods of protecting the hydroxyl groups of 8 and 9, as
described in Section 5.1.3, ethoxylation using ethyl iodide in ethanol / KOH was
found to be the most convenient means of protection. It was applied to 8, producing
a good yield of 2,4-dimethyl-6-ethoxypyridazin-3(2H)-one 12, which was easily
recrystallised from petroleum ether or cyclohexane despite its low melting point.
The bromination of 12 using NBS was more difficult than that of 4, there being a
greater range of products, including the N-bromomethyl derivative as described in
Chapter 6. Nevertheless, the major product, recovered in acceptable yield, was 2-
methyl-4-bromomethyl-6-ethoxypyridazin-3(2H)-one 13.
Nucleophilic substitution with ammonia in methanol to produce 2-methyl-4-
aminomethyl-6-ethoxypyridazin-3(2H)-one 14 was near quantitative, and
deprotection by hydrolysis with concentrated HBr followed by ion exchange
chromatography afforded 2-methyl-4-aminomethyl-6-hydroxypyridazin-3(2H)-one
15, which resisted all attempts to recrystallise, but was of fair purity by n.m.r. and
TLC, contaminated by about 2% starting material.
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5.1.3 2-Methyl-5-aminomethyl-6-hydroxypyridazin-3(2H)-one
Scheme 5.3 Synthesis of 2-methyl-5-aminomethyl-6-hydroxy-pyridazin-3(2H)-one 20, linked to
experimental
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Of the two citraconic hydrazides 8, 9 whose preparation was described in Section
5.2.1, the isomer of lower Rf, higher melting point, and lower water solubility was
identified by the following procedure: chlorination of the isomer using excess POCl3
produced only one compound of above baseline Rf, and despite a poor yield, in
sufficient quantity after column chromatography for identification as the 6-chloro
derivative 16. Straightforward dehalogenation with hydrogen at 1 atm and
palladium on carbon catalyst gave a product, whose n.O.e. spectrum clearly
showed two equidistant aromatic protons on irradiation of the 5-methyl group, i.e.
2,5-dimethylpyridazin-3(2H)-one 17. Thus the isomer of lower Rf was shown to be
2,5-dimethyl-6-hydroxypyridazin-3(2H)-one 9. Again, these simple pyridazinone
derivatives 16 and 17 are apparently previously unreported.
In order to derivatise the 5-methyl position, it was necessary to protect the 6-
hydroxy group. 6-Alkoxy pyridazines are intermediate in nature between an ester
and an aromatic ether because of the lactim structure and the strongly acidic
hydroxyl of the parent compound, and are thus easier to cleave than other aromatic
ethers. A number of methods of achieving alkylation were tried. A t-butoxy
derivative was attractive as being an easily removable group, in preference to an
isopropoxy, in preference to a primary alkoxy derivative. Attempted t-butylation
using isobutene / sulfuric acid in ether, returned starting material. Production of
the 6-methoxy derivative using dimethyl sulfate as the alkylating agent, in
methanol / potassium hydroxide, after the method of Druey et al. [10] which had
been successfully applied to methylate the simpler 2-methyl-6-hydroxypyridazin-
3(2H)-one, produced poor yields. The application of diethyl sulfate in ethanol /
sodium ethoxide to make the ethoxy pyridazine fared somewhat better, producing
the ethoxy derivative cleanly, but still with insufficient yield (36%). Turning to alkyl
bromides, also previously used to alkylate pyridazinones [11, 12]: an attempt at
alkylation by isopropyl bromide in a two phase system (aqueous sodium hydroxide
/ dichloromethane) with the phase transfer catalyst tetra-n-butylammonium
hydrogen sulfate, produced no organic soluble products. Alkylation with isopropyl
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bromide in dry DMF with potassium carbonate as the base produced a very low
yield of the desired isopropoxy pyridazine. Using the more aggressive sodium
isopropoxide base with isopropyl bromide in isopropanol also failed to produce the
desired product, and there was indication from n.m.r. of rearrangement of the
starting material, as evidenced by a significant movement of the Ar-H proton shift
in the n.m.r.n.m.r. of the residues (7.04). Isopropylation in ethanol / potassium
hydroxide [13] also failed, perhaps due to the volatility of isopropyl bromide vs.
speed of reaction. Performing the same reaction in a bomb at higher temperature
produced a low yield of the isopropoxy pyridazine. Several attempts to improve the
yield gave mixed results. It was reasoned that the yield could be improved by
employing a less hindered primary alkyl halide, a less volatile agent, and an iodide
as a better leaving group. Butyl iodide in ethanol / potassium hydroxide produced
a fair yield, but the product was of low melting point, hindering recrystallisation.
Ethyl iodide in potassium hydroxide gave good yields (around 60%) of the ethoxy
pyridazine 18 with facile recrystallisation. Ethyl iodide was used exclusively for
preparations thereafter. The methoxy derivative 18a was also synthesised using
methyl iodide, for the purposes of the comparisons with theoretical calculations
described in Chapter 6.
The free radical bromination 18 proved particularly problematic. When the crude
product of this reaction was reacted with ammonia in methanol, the major product
was the 2-(methoxymethyl) derivative, the N-methyl bromide being particularly
labile in the presence of methanol or moisture. This indicated a strong preference
for the unexpected bromination at the 2-position over the 5-position. A close re-
examination of the bromination of 12 also indicated the occurrence of 2-methyl
bromination, but in this case, 4-methyl bromination was favoured. These results
along with the results of a number of other methylpyridazine brominations which
were being performed by co-workers, including the bromination of 2,4,5-trimethyl-
6-methoxypyridazin-3(2H)-one, prompted the investigation which is presented in
Chapter 6. The side reaction of N-methyl bromination was later used to synthesise
an N-alanino pyridazine, as described in Section 5.3.4. No significant quantity of
any aminomethyl derivatives could be separated after workup of the ammonia /
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methanol treatment of the crude bromides of 18; a new N-aminomethyl GABA
analogue was therefore not available.
Despite the very poor yields of the 5-bromomethyl compound 19 within the
bromination mixture, the product was preferentially stable and separable under
column chromatography, and a sufficient quantity could be synthesised to allow
the production of the desired analogues in sufficient quantity for pharmacological
screening, this being the main objective.
Thus, the purified 5-bromomethyl compound 19 was aminated in ammonia /
methanol to produce the protected amino acid 20 in high yield. Furthermore, the
deprotection of the hydroxyl using concentrated hydrobromic acid was also
straightforward, and the conversion high, although recrystallisation could not be
achieved. The product 21 was sufficiently pure after chromatography on ion
exchange resin for screening for GABAergic activity.
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5.2 Analogues of THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-3-
ol)
5.2.1 5,6,7,8-Tetrahydropyrido[3,4-d]pyridazine-1,4(2,3H)-dione
Scheme 5.4 Synthesis of 5,6,7,8-Tetrahydropyrido[3,4-d]pyridazine-1,4(2,3H)-dione 25, linked to
experimental
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Following the method of Silhankova et al. [14], the dimethyl
pyridazinedicarboxylate 23 was prepared by refluxing the dicarboxylic acid 22 in
sulfuric acid / methanol.
Condensation with hydrazine (after Jones [15]) gave the pyridopyridazinedione 24.
The tautomeric preference for this compound is not known but a mixture is likely.
The two tautomers depicted differ by less than half a Kcal according to semi-
empirical theories, the 1-hydroxy form being slightly favoured (depicted right).
Selective reduction of the pyridine ring of 24 with hydrogen and palladium on
carbon catalyst (cf Kakimoto [16]) gave the tetrahydropyridazinedione THIP
analogue 25.
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5.2.2 1-Hydroxy-3-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4(3H)-one
Scheme 5.5. Synthesis of 1-hydroxy-3-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4(3H)-one
30, and 2-methyl-4-hydroxy-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1(2H)-one 31, linked to
experimental
The dimethyl pyridinedicarboxylate 23 whose synthesis was described in section
5.2.1 was condensed with methyl hydrazine, in analogous fashion with the
synthesis of 8 and 9 (section 5.1.2), but under more gentle conditions [15]
Highly insoluble, the resulting mixture was carefully fractionally crystallised from a
large volume of water, giving a nearly 50% yield of a highly pure isomer which
later proved to be 26.
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In order to determine the identity of the products of this condensation, the
following series of reactions was performed on the major, less soluble product:
chlorination of the isomer with phosphorus oxychloride according to a method
used on a pyrido[2,3-d]pyridazinedione [17] produced the
chloropyridopyridazinone 28, and dehalogenation / ring reduction with hydrogen
and palladium on carbon catalyst gave the tetrahydropyridopyridazinone 29. A
Nuclear Overhauser Effect (n.O.e.) 1H n.m.r. experiment on this compound,
irradiating the aromatic 1-H, produced only a single low field enhancement,
corresponding to the chemical shift of an allylic methylene, as opposed to an
aminomethylene. This indicates the peri- interaction between the aromatic proton
and the aliphatic methylene, thus proving the identity of 29, and hence 26 and 27.
The N-methyl hydroxypyridopyridazinone 26 was then easily reduced under the
same conditions as the unmethylated 24, to produce the final desired
tetrahydropyridazinone product 30, which was successfully purified by
recrystallisation.
5.2.3 2-Methyl-4-hydroxy-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1(2H)-one
See scheme 5.5 for synthesis.
Whereas the pure the methyl hydrazide isomer 26, being of lower Rf and higher
melting point, and the major product of condensation by a factor of two, proved
easy to crystallise from the reaction of 23 with methyl hydrazine, the minor isomer
27 proved difficult to isolate. Fractional crystallisations of the remaining liquor
could not improve on 85 : 15 co-crystallisation of 27 : 26. Fortunately,
straightforward hydrogenation of this mixture produced a product containing
mostly the desired tetrahydropyridazinone which was easily recrystallised to give
the the isomer 31 only.
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5.3 AMPA / HIBO analogues
5.3.1 2-Amino-3-(pyridazine-3,6(1,2H)-dion-4-yl)propanoic acid
Scheme 5.6 Synthesis of 2-Amino-3-(pyridazine-3,6(1,2H)-dion-4-yl)propanoic acid 33 linked to
experimental
The bromide 5, whose synthesis was described in section 5.1.1, was the starting
material for the synthesis of this alanino pyridazinone. The salts of dialkyl
acetamidomalonates have long been used as convenient nucleophiles for amino
acid synthesis [18], a method known as the Modified Sörensen Reaction. In this case
the base of dimethyl acetamidomalonate (DMAM), rather than the more common
diethyl derivative, was formed from sodium methoxide in methanol, to prevent
transesterification and thus aid the purification of the intermediate 32. The reaction
proceeded rapidly n.m.r. at room temperature, but two side products were isolated.
The first, a methoxymethyl pyridazine, is the result of the competitive nucleophilic
substitution by methoxide. It may be possible to reduce its presence by careful
stoichiometric control and by the pre-formation of the DMAM anion prior to
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addition of the bromide. The other byproduct was probably the result of small
amounts of moisture in the reaction mixture. Partial hydrolysis of one of the methyl
esters, followed by rapid decarboxylation, produces a partially decarboxylated
compound which is in fact an intermediate between 32 and 33, and therefore
useable. This compound was detected by TLC, isolated by column chromatography,
and characterised by n.m.r. spectroscopy.
The full deprotection of 32, including decarboxylation, to produce the desired
amino acid 33 was accomplished in a straightforward manner with concentrated
HBr, as per the deprotection of the aminomethyl analogue 6. Purification was
readily accomplished using acidic ion exchange resin.
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5.3.2 2-Amino-3-(2-methyl-6-hydroxypyridazin-3(2H)-on-4-yl)propanoic acid
Scheme 5.7 Synthesis of 2-amino-3-(2-methyl-6-hydroxypyridazin-3(2H)-on-4-yl)propanoic acid 35
linked to experimental
The bromide 13, whose synthesis was described in section 5.1.2, was reacted with
the base of a dialkyl acetamidomalonate to produce the protected amino acid 34. In
order to avoid transesterification and subsequent difficulty of purification, sodium
ethoxide in ethanol was used to produce the diethyl acetamidomalonate (DEAM)
base. The reaction was clean and high yielding so long as it was scrupulously dry;
small amounts of moisture producing traces of the partially hydrolysed,
decarboxylated 2-acetamidoethyl propanoate derivative. The intermediate (34) was
easily isolated and recrystallised. Hydrolysis by reflux with concentrated hydrogen
bromide, followed by acid ion exchange resin chromatography gave the alanino
pyridazinone 35 in good yield and purity by n.m.r. spectroscopy.
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5.3.3 2-Amino-3-(2-methyl-6-hydroxypyridazin-3(2H)-on-5-yl)propanoic acid
Scheme 5.8 Synthesis of 2-amino-3-(2-methyl-6-hydroxypyridazin-3(2H)-on-5-yl)propanoic acid 37
linked to experimental
Synthesis of the AMPA analogue 37 proceeded from the bromide 19 whose
synthesis and difficult isolation was described in section 5.1.3. Though somewhat
poorer yields were obtained from the nucleophilic substitution of 19 with DEAM
anion compared with 13, the protected amino acid 36 was easily isolated in high
purity and recrystallised. The hydrolysis of 36 by concentrated HBr was
substantially more difficult than that of 34, presumably because of the steric
hindrance of the proximal methylene. It was apparent that degradation was
occurring after 12 hours of slow hydrolysis in three stages with purification and
fresh HBr in between. The product resisted attempts to recrystallise from
alcohol/water mixtures. The roughly 90% pure product was used for
pharmacological screening, and when found to lack activity, no further attempt at
purification was made.
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5.3.4 2-Amino-3-(6-hydroxypyridazin-3(2H)-on-2-yl)propanoic acid
Scheme 5.9 Synthesis of 2-amino-3-(6-hydroxypyridazin-3(2H)-on-2-yl)propanoic acid 43 linked to
experimental
Since it had been discovered in the course of the synthesis of the bromomethyl
pyridazinone 19 that N-methyl bromination was a major side product of this free
radical bromination, this opened up the possibility of the synthesis of N-alanino
derivatives. While not strictly an AMPA analogue in the way that 37 is, the
synthesis of 43 was attempted in order to learn more about the functionalisation of
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N-methyl pyridazinones as well as provide a fourth kind of alanino pyridazindione
for AMPA receptor screening. Most importantly, 43 is an isomer of the important
natural AMPA agonist willardiine, which is also an N-alanino heteroaromatic
dione, specifically the pyrimidine, 1-alanino uracil. Chapter 8 covers in more depth
the activities of the willardiines and azawillardiines. The ability to synthesise N-
alanino heterocycles from readily accessible N-methyl compounds is therefore of
potential importance.
The mono-methylated starting material 39 was chosen rather than attempt to
functionalise the dimethyl pyridazinediones previously synthesised, in order to
simplify the synthesis and the product. A long known compound [19], it was made
by standard condensation of maleic anhydride 38 with methyl hydrazine. Its ethoxy
derivative 40 which is also known [19] was readily produced by the same method
using ethyl iodide which was successful for its 4- and 5- methyl derivatives 12 and
18.
As expected, the bromination reaction was successful, giving a fair yield of the N-
bromomethyl compound 41 which could be isolated, and stored for long periods if
kept cold and dry, although it readily decomposed in moist air at room
temperature. The substitution with the base of DEAM in ethanol to give the
protected amino acid 42 was straightforward and high yielding.
Deprotecting 42 proved highly problematical however. It soon became apparent
that no amount of refluxing with concentrated hydrobromic acid could hydrolyse
the ethoxy group, even though the amino acid function was readily deprotected.
While HBr has been the reagent of choice for this kind of deprotection of
heterocyclic phenols, it was found that refluxing with the stronger 57% hydriodic
acid for 15 hours gave small amounts of the desired deprotected product 43, along
with the partially deprotected ethoxy compound and some degradation. It being
reasoned that the products of deprotection were diluting or altering the hydriodic
acid, and possibly lowering the reflux temperature, the intermediate mixture was
isolated on ion exchange resin with copious washings to remove traces of free
iodine, and then re-refluxed with fresh acid for a further 9 hours whereupon the
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reaction was complete. Remarkably, under such harsh conditions the compound
was fairly stable, and a respectable yield was obtained. By contrast with the other
amino acids synthesised, this compound was also readily purified by
recrystallisation from ethanol/water.
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5.4 AMAA / ibotenic acid analogues
To complete the synthesis of the series of pyridazinones corresponding to the major
types of isoxazolols active at amino acid receptors, it was desired to produce
glycino-pyridazinones. Three possible routes were considered
5.4.1 Pyridazine glycines via ring nucleophilic substitution
Pyridazines, like other diazines, are electron deficient and susceptible to
nucleophilic substitution [20]. In particular, 4- or 5- halopyridazines are strongly
activated, relative to 3- or 6- halo substituents. The presence of a keto- or methoxy-
is a deactivating influence. It was therefore considered worthwhile to test whether
the Sörensen Reaction could be used to prepare pyridazine glycino pyridazinones
as it was to prepare alanino pyridazinones.
A starting material for the attempted synthesis of the glycino pyridazine-3,6-diones
was 3,6-dimethoxy-4-chloropyridazine 44. This compound was prepared by
chlorinating maleic hydrazide with phosphorous oxychloride, reacting with sodium
methoxide to produce 3,6-dimethoxypyridazine, which is then converted to the N-
oxide by hydrogen peroxide [21]. The N-oxide is converted to the 4-chloride by
again chlorinating with phosphorous oxychloride [22].
Starting materials for the attempted synthesis of the two N-methyl glycino-
pyridazine-3,6-diones were 4,6- and 5,6-dichloro-2-methylpyridazin-3(2H)-one 45
and 46. Chloromaleic anhydride is prepared from maleic anhydride by direct
chlorination-dehydrochlorination [23]. Condensation with methylhydrazine gives
the two chloro-2-methylpyridazinedione isomers. Chlorination with phosphorous
oxychloride then gives the desired 4,6- and 5,6- dichloro compounds [24].
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Scheme 5.10. Chloropyridazines synthesised as starting materials for ring nucleophilic
substitution
The reaction of 2-methyl-5,6-dichloropyridazin-3(2H)-one 46 with sodium DMAM
in methanol produced quantitatively 2-methyl-5-methoxy-6-chloropyridazin-3(2H)-
one 48, rather than the protected amino acid 47, showing the preference for
substitution with a less hindered base. Producing the DMAM anion using sodium
hydride in THF to prevent the presence of a competing nucleophile, slowly
produced a small amount of the same product, along with degradation, presumably
by slow degradation of DMAM to produce methoxide. Using DMF as a solvent
fared no better, no product being formed at room temperature, and a complex
mixture at reflux.
It was clear that ring substitution with such a hindered base was unfavourable, and
this line was pursued no further.
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Scheme 5.11 Failure of Modified Sörensen Reaction on ring halogen
142
5.4.2 Pyridazine glycines via pyridazine aldehydes
Scheme 5.12 Synthesis of a pyridazinyl aldehyde 49 but failure of -amino acid syntheses.
Synthesis of aryl glycines has often been accomplished via the aryl aldehyde, for
example methods such as the Bücherer-Bergs [25, 26] and Strecker [26] syntheses.
3.6-Dimethoxypyridazine-4-carboxaldehyde 49 would therefore be a desirable
starting material for the synthesis of the glycino pyridazinedione. This compound
proved remarkably difficult to synthesise, and once made, of poor stability. Simple
underivatised pyridazine aldehydes are particularly rare in the literature [20].
Preparation of the pyridazine aldehyde directly, or the pyridazine carboxylic acid
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by oxidation of the 4-methyl group in the hope of reduction to the aldehyde showed
no promise. The adduct of hexamine with the bromomethyl derivative 5 (Sommelet
reaction [27], a known aldehyde synthesis) was hydrolysed to form the
aminomethyl pyridazine 6, but the aldehyde was not formed.
A reasonable method of production of a methoxy heteroaromatic aldehyde is the
aqueous hydrolysis of the dibromomethyl compound [28]. While 3,6-dimethoxy-4-
(dibromomethyl)pyridazine 48 had already been synthesised as a byproduct in the
preparation of (5), the material proved highly refractory to aqueous hydrolysis.
Several conditions were tried; refluxing with sulfuric acid caused degradation.
Calcium carbonate was tried as a base, as was dimethylaniline, and various
dioxane/water and THF/water mixtures tried as solvent. Attempts to make a
dimethyl acetal from the dibromide with sodium methoxide were unsuccessful.
Eventually, application of the method of Eliel et al. [29], employing a long reflux in
ethanol/water with sodium acetate, followed by the mild acid hydrolysis of the
diethoxy acetal 50 proved successful, although the yield was poor, and the product
slightly contaminated by the acetal.
The feasibility of producing the 2-methyl-6-ethoxypyridazin-3(2H)-one-4-
carboxaldehyde from a dibromide was tested, and found to be possible, although
again, the yields were poor.
Unfortunately, all attempts to progress the small amounts of aldehyde to an amino
acid or protected amino acid proved futile. Both Bücherer-Bergs (51) and Strecker
(52) syntheses produced similar tars, apparently cyanides being incompatible with
this substance. Aldehydes as a route to pyridazinonyl glycines were abandoned at
this point.
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5.4.3 Glycino pyridazinones via 2-(pyridazinyl)ethyl acetates
Scheme 5.13 Synthesis of an ethyl 2-(dimethoxypyridazinyl)acetate 53, and its oxime and
bromide, but failure of synthesis of glycino pyridazinone 58.
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In a fairly recent paper, Sitazmzé et al. [30], showed that certain 4-methyl
pyridazines, including some 3-methoxy-4-methylpyridazines, could be metalated at
the 4-position with lithium diisopropylamide (LDA), and subsequently alkylated
with a variety of halides. It was reasoned that, could ethyl 2-(pyridazinonyl)acetates
be made by this procedure, the activated aromatic methylene would be highly
susceptible to further manipulation and hence provide a potential route to glycino
pyridazinones. Lithiated methyl isoxazoles have previously been used in the
synthesis of ibotenic acid analogues [31].
As shown in scheme 5.13, the metalation of 3,6-dimethoxy-4-methylpyridazine 4
with LDA and subsequent alkylation with ethyl chloroacetate gave a good yield of
the ethyl 2-(3,6-dimethoxypyridazin-4-yl)acetate 53. From this compound, two main
routes were investigated on a test scale for feasibility.
Bromination of 53 with N-bromosuccinimide proceeded remarkably cleanly to give
ethyl 2-bromo-2-(3,6-dimethoxy-pyridazin-4-yl)acetate 54. However, the action of
ammonia on this compound did not produce ethyl 2-amino-2-(3,6-
dimethoxypyridazin-4-yl)acetate 55 cleanly. There was some n.m.r. evidence of
dimerisation to a diketopiperazine byproduct.
Reduction of hydroximino esters has been recorded as an alternative route to -
amino acids [32]. The action of nitrous acid on 53 produced the oxime 56 in high
yield, with some evidence of a cis-trans mixture by n.m.r. spectroscopy. Reduction
to the amine 55 was promising, as was reduction/acetylation to a fully protected
amino acid 57, a preferred intermediate.
Hydrolysis under reasonably mild conditions (6M HCl) of the aminated products
followed by ion exchange chromatography appeared to afford small amounts of 7,
along with methoxy derivatives. There was no evidence for the presence of 58 from
TLC or n.m.r. This suggested that the decarboxylation of the -amino acid was
occurring more readily than the hydrolysis of the ring methoxy groups. At this
point, the attempt to make a pyridazinyl glycine by this route was abandoned.
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Although unsuccessful to date, the route described here offers the most promise of
application to the synthesis of other glycino pyridazinones. The key factor is the
potential for decarboxylation. If an appropriate leaving group could be found for
ring-hydroxyl protection, hydrolysis could possibly be accomplished without
decarboxylation. On the other hand, it may be that some or all pyridazine glycines
are simply unstable under typical synthetic conditions; Goddfried Heinisch, a
specialist in pyridazine medicinal chemistry, considered this a strong possibility
[33]. It is worth noting in passing the care with which the deprotections of AMAA
and ibotenic acid derivatives have been performed to avoid decarboxylation [31, 34]
and that ibotenic acid apparently owes at least some of its in vivo activity to
decarboxylation to muscimol [35].
5.5 Conclusion
This chapter has described the methods whereby a range of hydroxypyridazinone
derivatives were synthesised. The central question being sought to be answered
was: "How does replacement of a ring oxygen in a range of 3-isoxazolols, known to
be archetypal agonists at GABA or EAA receptors, by either a ring amide or an N-
methyl amide, to form a 6-hydroxypyridazin-3(2H)-one, affect potency at these
receptors?". Synthesis was primarily a means to this end, all but three final
products, the glycino pyridazines, being sucessfully made. As will become clear in
chapter 7, the results of activity screening were disappointing, and this line of
investigation was abandoned. Hence, the experimental work was not taken up to
the stage of full characterisation of purified compounds. The chemistry was
challenging and the products were often very difficult to purify. n.m.r. spectroscopy
and TLC behaviour gave good indications of the identities of the compounds and,
considering the poor or nil activity of these various series of pyridazinones, it was
considered that the large effort required for full characterisation would be better
invested in the other areas. The most important advances of this work were
increased understanding of synthetic methods pertaining to hydroxypyridazines,
some of which were subsequently applied by co-workers in the synthesis of more
potent glutamate analogues. Highlights of the synthetic program included the
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convenient synthesis of an N-alanino pyridazine, the syntheses and realisation of
the instability of pyridazine 4-carboxaldehydes, and the extension of the scope of
the methylpyridazine metalation / alkylation reaction to include the formation of
an ethyl pyridazinylacetate.
Chapter 2 considered in detail the structure, tautomerism and pKa of the
hydroxypyridazine N-oxides. Some N-oxide derivatives which were synthesised by
similar methods described here, were soon found to produce potent AMPA
analogues. Chapter 8 summarises their activity as well as the AMPA analogues
synthesised in this chapter, along with other ring structures known to have been
trialled in this capacity.
5.6 Experimental
5.6.6. 4-Aminomethyl-3,6-dimethoxypyridazine
Impure 4-bromomethyl-3,6-dimethoxypyridazine (1.144 g, 4.9 mmol, 5) was
dissolved in methanol (100 mL) saturated with gaseous ammonia at 0ºC for 30
minutes. The mixture was allowed to stand loosely stoppered overnight at room
temperature, then evaporated to give a pale yellow solid (1.228 g). The product was
dissolved in 0.3M HCl (30 mL), washed twice with equal volumes CH2Cl2, made
basic with excess 25% NH3, and extracted four times with 30 mL CH2Cl2. The
solvent was removed from the pooled extracts to leave 4-aminomethyl-3,6-
dimethoxypyridazine (0.639 g, 3.8 mmol, 77%, 6) as a waxy yellow solid. 1H n.m.r. 
(CDCl3) 3.78, d, J 1.1 Hz, 2 H, 4-CH2NH2; 4.04, s, 3 H, OCH3; 4.07, s, 3 H, OCH3; 6.95,
t, J 1.1 Hz, 1 H, 5-H. 13C n.m.r. (CDCl3=77.0) 40.5, 4-CH2NH2; 54.4, OCH3; 54.5,
OCH3; 117.3, C(5)H; 136.5, C(4)CH2; 160.4, COMe; 162.6, COMe. m.p. 89-91ºC. Mass
spectrum: m/z 170 (M+1, 100%), 153 (7%), 135 (6%).
5.6.7. 4-Aminomethylpyridazine-3,6(1,2H)-dione
4-Aminomethyl-3,6-dimethoxypyridazine (0.601 g, 3.55 mmol, 6) was dissolved in
48% HBr (10 mL), and heated to reflux for 90 minutes. Removal of excess HBr under
vacuum gave 1.192 g of an orange solid. TLC showed several spots, only one of
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which (Rf 0.32, butanol/acetic acid/water 4:1:1) was ninhydrin positive. The impure
product was absorbed onto Dowex 50W (H+) ion-exchange resin, washed with
several volumes of water, then eluted with 1M pyridine. The pyridine fractions
were evaporated to leave 4-aminomethylpyridzine-3,6(1,2H)-dione (0.445 g, 3.15
mmol, 89%, 7) as an orange gel. This could be converted to a yellow powder either
by forming the hydrochloride or hydrobromide salt, or by precipitation from
absolute ethanol. Recrystallisation from water and ethanol proved unsatisfactory.
1H n.m.r. (D2O, DOH=4.81) 4.05, d, J 1.1 Hz, 2 H, N-CH2-; 6.98, t, J 1.1 Hz, 1 H, 5-H.
13C n.m.r. (D2O, dioxane=67.4) 39.2 (CH2), 129.3 (CH), 137.0 (C), 157.3 (CO), 159.0
(CO). m.p. 244ºC with gas evolution. Mass spectrum: m/z 142 (M+1, 100%), 125
(14%).
5.6.8. 2,4-dimethyl-6-hydroxypyridazin-3(2H)-one
5.6.9. 2,5-dimethyl-6-hydroxypyridazin-3(2H)-one
Hydrochloric acid (112 g, 32%, 1.0 mol), methyl hydrazine (41.5g, 0.9 mol) and
water (200 mL) were heated to boiling in a 1 litre flask. Citraconic anhydride (100.9
g, 0.9 mol, 1) was added. A white solid formed rapidly, which redissolved on
further boiling. The mixture was held at reflux for four hours, cooled to a white
solid gel, and then evaporated to a white paste. TLC showed 100% conversion to
roughly equal amounts of the two isomers (Rf 0.33, 0.22, ethyl acetate). A first
crystallisation from boiling water gave the lower isomer, later identified as 2,5-
dimethyl-6-hydroxypyridzine-3(2H)-one (59.08 g, 0.42 mol, 42%, 9). A second
crystallisation gave the more soluble upper isomer, later identified as 2,4-dimethyl-
6-hydroxypyridzine-3(2H)-one (20.67 g, 0.15 mol, 15%, 8), only slightly
contaminated by the lower isomer. The remaining liquor, containing mostly the
upper isomer, with a proportion of the lower isomer, was retained for further
fractional crystallisation. Attempted recrystallisations from various alcohols gave
poorer separations than from water. Lower isomer: 1H n.m.r. (D2O, DOH=4.81)
2.13, d, J 1.1 Hz, 3 H, 5-CH3; 3.56, s, 3 H, N-CH3; 6.85 q, J 1.1 Hz, 1 H, 4-H. m.p. subl.
268ºC. Mass spectrum: m/z 141 (M+1, 100%). Upper isomer: 1H n.m.r. (D2O,
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DOH=4.81) 2.11, d, J 1.1 Hz, 3 H, 4-CH3; 3.58, s, 3 H, N-CH3; 7.04 q, J 1.1 Hz, 1 H, 5-
H. m.p. 178-9ºC. Mass spectrum: m/z 141 (M+1, 100%).
5.6.10. 2,4-Dimethyl-6-chloropyridazin-3(2H)-one
2,4-dimethyl-6-hydroxypyridazin-3(1H)-one (2.0 g, 14.3 mmol, 8) was dissolved in
phosphorus oxychloride (30 mL), and heated with stirring at 80ºC for 1 hour,
producing a brown tar. Excess POCl3 was distilled off under vacuum, and the
resultant tar was allowed to cool, dissolved in dichloromethane (ca. 30 mL), and
poured onto 100 mL of an ice/acetone mixture with stirring, and external cooling
with an ice/salt/acetone bath. The mixture was allowed to assume room
temperature, the organic layer separated, and evaporated, to leave 733 mg of brown
tar. TLC on silica with ethyl acetate:toluene 1:4 showed the presence of the desired
product, Rf 0.35. The tar was chromatographed on a silica column, eluting with the
same solvent mixture, and evaporation of the desired fraction afforded 2,4-
dimethyl-6-chloropyridazin-3(2H)-one (25 mg, 0.16 mmol, 1%, 10), as a crystalline
solid, around 95% pure by n.m.r. 1H n.m.r. (CDCl3) 2.22, d, J 1.3 Hz, 3 H, 5-CH3;
3.75, s, 3 H, N-CH3; 7.08, q, J 1.3 Hz, 1 H, 4-H.
5.6.11. 2,4-Dimethylpyridazin-3(2H)-one
2,4-Dimethyl-6-chloropyridazin-3(2H)-one (30 mg, 0.19 mmol, 10) was dissolved in
methanol (5ml), two drops conc. ammonia, and ca. 10 mg palladium on carbon
catalyst addded. The mixture was hydrogenated overnight at 1 atm, filtered, and
evaporated. Column chromatography on silica, eluting with toluene : ethyl acetate
1:1, afforded 2,4-dimethylpyridazin-3(2H)-one (8 mg, 0.06 mmol, 34%, 11).
Irradiation of 4-methyl peak in n.O.e. experiment gave a large enhancement of one
of the two ring protons (d=7.04), but negligible enhancement of the other (d=7.63),
confirming 2,4-dimethyl substitution. Enhancement height ratio of 8:1 corresponds
to a distance ratio of 1:2 by square root of 6th power law, which is approximately
correct for methyl to protons on 5 vs 6. 1H n.m.r. (CDCl3) 2.22, d, J 1.2 Hz, 3 H, 5-
CH3; 3.80, s, 3 H, N-CH3; 7.04, dq, 1 H, 4-H; 7.63, d, J 4.1 Hz, 1 H, 3-H. n.O.e.
irradiation at 2.22 ppm; enhancement at 7.04.
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5.6.12. 2,4-Dimethyl-6-ethoxypyridazin-3(2H)-one
Potassium hydroxide (2.24 g, 40 mmol) was dissolved in absolute ethanol (30 g).
2,4-Dimethyl-6-hydroxypyridazin-3(2H)-one (2.80 g, 20 mmol 8) was added with
stirring. To this slurry was added ethyl iodide (6.24 g, 40 mmol), and the mixture
heated at reflux with stirring overnight. The mixture was concentrated to a third its
volume in vacuum, and water (20 mL) added. This procedure was repeated a
further two times, followed by extraction three times with ethyl acetate (20 mL).
The combined extracts were washed twice with brine, and twice with water, then
evaporated to leave relatively pure 2,4-dimethyl-6-ethoxy-pyridazin-3(2H)-one (2.55
g, 15 mmol, 76%, 12). Recrystallisation from petroleum ether gave 1.60 g product as
large pale yellow crystals. 1H n.m.r. (CDCl3) 1.34, t, J 7.0 Hz, 3 H, -CH2-CH3; 2.18,
d, J 1.1 Hz, 3 H, 4-CH3; 3.65, s, 3 H, N-CH3; 4.14, q, J 7.0 Hz, 2 H, -CH2-CH3; 6.76, q, J
1.1 Hz, 1 H, 5-H. 13C n.m.r. (CDCl3=77.0) 14.3, CH2CH3; 17.0, 4-CH3; 39.5, N-CH3;
62.4, CH2; 123.3, CH; 142.5, C-CH3; 152.2, C-OEt; 160.2, C=O. m.p. 43-5ºC. Mass
spectrum: m/z 169 (M+1, 100%), 141 (44%).
5.6.13. 2-Methyl-4-bromomethyl-6-ethoxypyridazin-3(2H)-one
2,4-Dimethyl-6-ethoxypyridazin-3(2H)-one (1.37 g, 8.2 mmol, 12), N-bromo
succinimide (1.52 g, 8.5 mmol), and CCl4 (25 mL) were stirred together in a 50 mL
flask fitted with a reflux condenser and irradiated for 25 minutes with an 800W
"Lowel-Tota" high intensity lamp at a distance of 10 cm, by which time a surface
layer of insoluble succinimide had formed. The mixture was allowed to cool,
washed twice with equal volumes of water, dried over Na2SO4, and evaporated to
2.0g of yellow oil. This crude bromide could be used for further reaction without
purification or purified by column chromatography on silica gel, eluting first with
toluene/ethyl acetate 4:1 followed by pure ethyl acetate. Several fractions were
recovered, including starting material, N-bromomethyl, and dibrominated
compounds. The major fraction (Rf 0.56, toluene/ethyl acetate 1:1) was identified as
the desired product, 2-methyl-4-bromomethyl-6-ethoxypyridazin-3(2H)-one (0.59 g,
2.4 mmol, 29%). This compound was easily recrystalised from petroleum ether. 1H
n.m.r. (CDCl3) 1.37, t, J, 7.0 Hz, 3 H, -CH2-CH3; 3.68, s, 3 H, N-CH3; 4.18, q, J 7.0 Hz,
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2 H, -CH2-CH3; 4.38, d, J 0.9 Hz, 2 H, 4-CH2Br; 7.08, t, J 0.9 Hz, 1 H, 5-H. m.p. 93-
95ºC. Mass spectrum: m/z 249 (M+1, 81%), 247 (M+1, 100%), 169 (M+2-Br, 65%), 167
(M-Br, 59%).
5.6.14. 2-Methyl-4-aminomethyl-6-ethoxypyridazin-3(2H)-one
2-Methyl-4-bromomethyl-6-ethoxypyridazin-3(2H)-one (500 mg, 2.03 mmol, 13) was
dissolved in methanol (20 mL), saturated with ammonia at 0ºC, and allowed to
stand loosely stoppered at room temperature for 24 hours. The solvent was
removed, leaving 543 mg of orange powder. This was dissolved in dilute
hydrochloric acid (20 mL, 0.25M), and washed twice with equal portions of
dichloromethane, removing the orange colouring. The aqueous layer was basified
with ammonia solution (2 mL, 25%), and extracted four times with 20 mL portions
of dichloromethane. Evaporation gave 2-methyl-4-aminomethyl-6-ethoxypyridazin-
3(2H)-one (333 mg, 1.81 mmol, 90%, 14) as a white crystalline solid. 1H n.m.r. 
(CDCl3) 1.36, t, J 7.1 Hz, 3 H, -CH2CH3; 3.65, s, 3 H, N-CH3; 3.77, d, J 1.3 Hz, 2 H, -
CH2NH2; 4.17, q, J 7.1 Hz, 2 H, -CH2-CH3; 6.92, t, J 1.3 Hz, 1 H, 5-H. m.p. 72-4ºC.
Mass spectrum: m/z 184 (M+1, 100%), 167 (8%).
5.6.15. 2-Methyl-4-aminomethyl-6-hydroxypyridazin-3(2H)-one
2-Methyl-4-aminomethyl-6-ethoxypyridazin-3(2H)-one (304 mg, 1.66 mmol, 14) was
dissolved in 48% hydrobromic acid (10 mL), and heated to reflux for 90 minutes.
The mixture was evaporated, leaving 511 mg of pale orange powder. This was
dissolved in 10 mL water, absorbed onto a Dowex 50W H+ ion exchange resin
column, eluted with 125 mL water, followed by 50 mL 1M pyridine. The pyridine
fraction was evaporated to leave 295 mg pale orange residue, partly amorphous,
partly crystallised, Rf 0.47 (butanol, acetic acid, water 4:1:1). The residue was
suspended in 10 mL absolute ethanol, and evaporated to dryness to leave 2-methyl-
4-aminomethyl-6-hydroxypyridazin-3(2H)-one (270 mg, 1.74 mmol, 105%, 15) as a
pale orange powder. Recrystallisation from water/ethanol was unsuccessful. The
product was contaminated with a small amount (ca. 2%) of starting material. 1H
n.m.r. (D2O, DOH=4.81) 3.56, s, 3 H, N-CH3; 4.06, d, J 0.9 Hz, 2 H, -CH2NH2; 6.98, t,
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J 0.9 Hz, 1 H, 5-H. 13C n.m.r. (D2O, dioxane=67.4) 39.7 (CH2), 39.7 (N-CH3), 131.5
(CH), 135.3 (C), 158.7 (CO), 161.8 (CO). m.p. 191ºC, with gas evolution. Mass
spectrum: m/z 156 (M+1, 100%), 139 (20%), 135 (11%), 127 (7%), 105 (5%).
5.6.16. 2,5-Dimethyl-6-chloropyridazin-3(2H)-one
2,5-Dimethyl-6-hydroxypyridazin-3(2H)-one (10.0 g, 71.4 mmol, 9) was added to
phosphorus oxychloride (60 mL), stirred and heated to 110ºC for 40 minutes, by
which time the starting material had fully dissolved, leaving a dark amber solution.
The mixture was cooled, and the excess POCl3 distilled off under vacuum. The
remaining thick brown tar was poured onto a 200 mL mixture of conc. ammonia
and ice with vigorous stirring. The mixture was filtered, the filtrate extracted with
ether, and the residue triturated with CH2Cl2. Both solvents were removed under
vacuum, leaving 1.22 g and 2.63 g of residue respectively, which appeared to be of
similar composition by TLC. The ether residue was chromatographed on silica,
eluted with 4:1 toluene: ethyl acetate, and 0.646 g product recovered. The CH2Cl2
residue was treated the same way, with a recovery of 0.360 g. The product was 2,5-
dimethyl-6-chloropyridazin-3(2H)-one (1.01 g, 6.34 mmol, 9%, 16), and was used
without further purification. 1H n.m.r. (CDCl3) 2.26, d, J 1.2 Hz, 3 H, 4-CH3; 3.74, s,
3 H, N-CH3; 6.80, q, J 1.2 Hz, 1 H, 5-H. Mass spectrum: m/z 161 (M+1, 34%), 159
(M+1, 100%), 125 (9%).
5.6.17. 2,5-Dimethylpyridazin-3(2H)-one
2,5-Dimethyl-6-chloropyridazin-3(2H)-one (50 mg, 0.315 mmol, 16) and palladium
on charcoal catalyst (10 mg) were added to methanol (5 mL) containing 0.5 mL
ammonia solution. The mixture was stirred overnight under hydrogen at 1 atm.
Slow absorption followed the initially rapid uptake of hydrogen over the first hour.
The mixture was filtered, evaporated to dryness under vacuum, and partitioned
between ethyl acetate and water (20 mL). The ethyl acetate layer was separated,
washed with a little extra water, dried over Na2SO4, and evaporated under vacuum
to leave 2,5-dimethylpyridazin-3(2H)-one (23 mg, 0.19 mmol, 59%, 17), sufficiently
pure by n.m.r. for structure identification, there being a number of minor
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components present up to around 5%. Irradiation of 5-methyl peak in n.O.e.
experiment gave equal enhancements of both aromatic protons, consistent with the
methyl being equidistant between ring protons and confirming 2,5-dimethyl-
substitution. 1H n.m.r. (CDCl3) 2.21, d, J 1.2 Hz, 3 H, 4-CH3; 3.76, s, 3 H, N-CH3;
6.70, dq, 1 H, 5-H; 7.60, d, J 2.2 Hz, 1 H, 3-H. 1H n.m.r. n.O.e. irradiation at 2.21 ppm;
enhancements at 6.70 (int. 29.3); 7.60 (int. 29.1). Mass spectrum: m/z 125 (M+1,
100%), 111 (6%).
5.6.18. 2,5-Dimethyl-6-ethoxypyridazin-3(2H)-one
Potassium hydroxide (11.22 g, 200 mmol) was dissolved in absolute ethanol (100
mL). 2,5-dimethyl-6-hydroxypyridazin-3(2H)-one (14.02 g, 100 mmol, 9) was added,
the slurry stirred, and ethyl iodide (31.2 g, 200 mmol) added. The mixture was held
at reflux with stirring overnight, whereupon most of the ethanol was removed in
vacuum. Water (250 mL) was added, and the mixture evaporated once more. More
water was added, and the aqueous suspension was extracted 4 times with 60 mL
portions of ethyl acetate. The combined extracts were washed with 50 mL portions
of brine and water, then evaporated to leave 10.79 g crude product. TLC (ethyl
acetate) showed the majority of the product and minimal starting material to have
been extracted. This product was recrystalised from 125 mL cyclohexane, with hot-
filtration to remove the last of the starting material, to give 8.45 g and a second crop
of 0.51 g 2,5-dimethyl-6-ethoxypyridazin-3(2H)-one (8.97 g total, 53 mmol, 53%, 18)
as large, slightly amber crystals. 1H n.m.r. (CDCl3) 1.37, t, J 7.0 Hz, 3 H, -CH2-CH3;
2.10, d, J 1.3 Hz, 3 H, 5-CH3; 3.62, s, 3 H, N-CH3; 4.18, q, J 7.0 Hz, 2 H, -CH2-CH3;
6.69, q, J 1.3 Hz, 1 H, 4-H. 13C n.m.r. (CDCl3=77.0) 13.9, CH2CH3; 15.4, 5-CH3; 38.4,
N-CH3; 62.3, CH2; 129.6, CH; 137.1, C-CH3; 151.7, C-OEt; 159.3, C=O.
The methoxy derivative 2,5-Dimethyl-6-methoxypyridazin-3(2H)-one 18a was
synthesised by a similar method, but employing methyl iodide. 1H n.m.r. (CDCl3)
2.10, d, 3 H, 5-CH3; 3.64, s, 3 H, N-CH3; 3.83, s, 3 H, O-CH3; 6.70, q, 1 H, 4-H.
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5.6.19. 2-Methyl-5-bromomethyl-6-ethoxypyridazin-3(2H)-one
2,5-Dimethyl-6-ethoxypyridazin-3(2H)-one (17.20 g, 102 mmol, 18) was dissolved in
CCl4 (300 mL), and N-bromosuccinimide (18.20 g, 102 mmol) added. The mixture
was stirred in a 500 mL round-bottomed flask fitted with a reflux condenser for 30
minutes, under a high intensity UV source at a distance of 10 cm (800W Lowel-Tota
lamp) which also heated the solution to reflux. A layer of floating succinimide
indicated that the reaction had proceeded. The mixture was allowed to cool, was
washed three times with 200 mL of water, dried over Na2SO4, and the CCl4 removed
in vacuum to leave 15.01 g of orange residue. TLC (ethyl acetate/toluene 1:1)
showed several spots, indicating that the reaction had not proceeded cleanly. The
mixture was chromatographed on a silica column, and the identity of some
components in addition to starting material established by 1H n.m.r. Among these
were: (a) 2-bromomethyl-5-(dibromomethyl)-6-ethoxypyridazin-3(2H)-one (Rf 0.81);
(b) 2,5-bis(bromomethyl)-6-ethoxypyridazin-3(2H)-one (Rf 0.73); (c) 2-bromomethyl-
5-methyl-6-ethoxypyridazin-3(2H)-one (Rf 0.61) which was shown to be the major
product (reaction of crude mixture with methanol saturated with ammonia at room
temperature overnight produced the white crystalline solid 2-methoxymethyl-5-
methyl-6-ethoxypyridazin-3(2H)-one, overall yield 37%, 1H n.m.r. (CDCl3) 3.45, s, 3
H, OCH3; 5.29, s, 2 H, NCH2O-; 
13C n.m.r. (CDCl3=77.0) 57.4, OCH3; 80.2, NCH2O-;
Mass spectrum: m/z 199 (M+1, 22%); 167 (100%). The 2-bromomethyl product (1H
n.m.r. (CDCl3) 5.75, s, 2 H, NCH2Br) was difficult to characterise since it was
unstable on silica and in moist air, and gave an extra TLC streak of low Rf perhaps
from the N-hydroxymethyl derivative; (d) 2-methyl-5-bromomethyl-6-
ethoxypyridazin-3(2H)-one (desired product, Rf 0.29, 2.218g, 8.98 mmol, 8.8%, 19).
1H n.m.r. (CDCl3) 1.40, t, J 7.1 Hz, 3 H, -CH2-CH3; 3.64, s, 3 H, N-CH3; 4.23, d, J 0.8
Hz, 2 H, 5-CH2Br; 4.25, q, J 7.1 Hz, 2 H, -CH2-CH3; 6.96, t, J 0.8 Hz, 1 H, 4-H.
5.6.20. 2-Methyl-5-aminomethyl-6-ethoxypyridazin-3(2H)-one
2-Methyl-5-bromomethyl-6-ethoxypyridazin-3(2H)-one (300mg, 1.21 mmol, 19) was
dissolved in methanol (50 mL), chilled to 0°C, and saturated with anhydrous
ammonia. The solution was allowed to stand overnight, then evaporated in vacuum
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to leave 360 mg of an amorphous amber residue. This was dissolved in dilute HCl
(30 mL, 0.3M), washed once with an equal volume of chloroform, basified with 1M
sodium hydroxide, and extracted with equal volumes of chloroform four times. The
combined extracts were dried over Na2SO4 and evaporated to leave 2-methyl-5-
aminomethyl-6-ethoxypyridazin-3(2H)-one, as an amber liquid (150 mg, 0.82 mmol,
68%, 20), which was pure by TLC and n.m.r. 1H n.m.r. (CDCl3) 1.38, t, J 7.1 Hz, 3 H,
-CH2CH3; 3.64, s, 3 H, N-CH3; 3.70, d, J 1.3 Hz, 2 H, -CH2NH2; 4.21, q, J 7.1 Hz, 2 H, -
CH2-CH3; 6.87, t, J 1.3 Hz, 1 H, 4-H.
5.6.21. 2-Methyl-5-aminomethyl-6-hydroxypyridazin-3(2H)-one
2-Methyl-5-aminomethyl-6-ethoxypyridazin-3(2H)-one (150 mg, 0.82 mmol, 20) was
dissolved in conc. HBr (3 mL), the solution heated at 140°C for 1 hour, then
evaporated. The brown residue was chromatographed on Dowex 50W (H+) ion
exchange resin, washing with water and eluting with pyridine. Evaporation of the
ninhydrin-positive pyridine fractions yielded solid 2-Methyl-5-aminomethyl-6-
hydroxypyridazin-3(2H)-one, (36 mg, 0.23 mmol, 28%, 21), contaminated with
about 5% starting material and degradation products according to n.m.r.
Recrystallisation from water-ethanol mixtures was unsuccessful, and due to the
small quantity recovered from low-yielding reactions, further purification was not
attempted. 1H n.m.r. (D2O, DOH=4.81) 3.54, s, 3 H, N-CH3; 4.03, d, J 0.9 Hz, 2 H, -
CH2NH2; 6.90, t, J 0.9 Hz, 1 H, 4-H.
5.6.23. Dimethyl pyridine-3,4-dicarboxylate
Pyridine-3,4-dicarboxylic acid (10.0 g, 59.8 mmol, 22) was refluxed in H2SO4 (20 mL)
and methanol (60 mL) for three hours. The mixture was poured onto ice (aprx. 200
mL) and 50 mL conc. ammonia solution was added to basify. On reaching room
temperature, the mixture was extracted three times with 75 mL portions of CHCl3,
which were pooled, dried over Na2SO4, and evaporated to give dimethyl pyridine-
3,4-dicarboxylate (10.29 g, 52.5 mmol, 88%, 23) as a pale yellow oil, which very
slowly darkened on standing. 1H n.m.r. (D2O, DOH=4.81) 3.93, s, 3 H, COOCH3;
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3.95, s, 3 H, COOCH3; 7.66, d, J 5.1 Hz, 1 H, 5-H; 8.79, d, J 5.1 Hz, 1 H, 6-H; 8.97, s, 1
H, 2-H.
5.6.24. Pyrido[3,4-d]pyridazine-1,4(2,3H)-dione
Dimethyl pyridine-3,4-dicarboxylate (4.52 g, 23.2 mmol, 23) and hydrazine hydrate
(3.34 g, 70 mmol) were added to methanol (8 mL), and the mixture stirred at room
temperature. Within minutes, yellow crystals appeared, and the reaction proceeded
to completion overnight. The mixture was evaporated, dissolved in 30 mL hot water
with 3 mL conc. ammonia solution, filtered hot, and the filtrate acidified with
glacial acetic acid, giving a fine, yellow precipitate. This was filtered, and the
residue washed with water, ethanol, ether, and dried, yielding pyrido[3,4-
d]pyridazine-1,4(2,3H)-dione (2.915 g, 17.9 mmol, 77%, 24). 1H n.m.r. (D2O,
DOH=4.81) 7.89, dd, J8-7 5.5 Hz, J8-5 1.1 Hz, 1 H, 8-H; 8.81, d, J7-8 5.5 Hz, 1 H, 7-H;
9.24, d, J5-8 1.1 Hz, 1 H, 5-H.
5.6.25. 5,6,7,8-Tetrahydropyrido[3,4-d]pyridazine-1,4(2,3H)-dione
Pyrido[3,4-d]pyridazine-1,4(2,3H)-dione 3 (1.00 g, 5.98 mmol, 24) was dissolved in
20 mL water with a few drops of conc. ammonia. Palladium on carbon catalyst (500
mg) was added, and the mixture stirred under hydrogen at atmospheric pressure
for 24 hours. The catalyst was removed by filtration, and the mixture evaporated, to
give 1.032 g of yellow residue. Recrystallisation from water gave 511 mg, followed
by a second crop from water/ethanol of 337 mg, of 5,6,7,8-tetrahydropyrido[3,4-
d]pyridazine-1,4(2,3H)-dione (848 mg, 5.07 mmol, 85%, 25). 1H n.m.r. (D2O,
DOH=4.81) 2.78, t, J 5.5 Hz, 2 H, C(8)H2; 3.48, t, J 5.5 Hz, 2 H, C(7)H2; 4.06, s, 2 H,
C(5)H2. 
13C n.m.r. (D2O, dioxane=67.4) 20.9, C(8)H2; 40.8, CH2; 41.1, CH2; 131.8, C;
135.9, C; 159.9, CO; 160.6, CO.
5.6.26. 1-Hydroxy-3-methylpyrido[3,4-d]pyridazin-4(3H)-one
5.6.27. 2-Methyl-4-hydroxypyrido[3,4-d]pyridazin-1(2H)-one
A mixture of dimethyl pyridine-3,4-dicarboxylate (8.0 g, 41 mmol, 23), methyl
hydrazine (5.67 g, 113 mmol) and methanol (15 mL) was stirred at room
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temperature in a sealed flask for seven days, by which time the reaction appeared to
be near complete by TLC. The mixture was evaporated, to leave a yellow solid. This
solid was disolved in 20 mL hot water, with the addition of 2 mL conc. ammonia
solution, and precipitated with 8 mL glacial acetic acid. By n.m.r., this was found to
contain two isomers 26 and 27, in roughly 2:1 proportions. The mixture was filtered,
and the residue washed twice with small portions each of water, ethanol, and
diethylether, leaving 6.29 g of yellow powder. This material was dissolved in 6000
mL boiling water, allowed to cool very slowly, and filtered, giving pure 1-hydroxy-
3-methylpyrido[3,4-d]pyridazin-4(3H)-one (3.42 g, 19.3 mmol, 47%, 26) as yellow-
orange crystals. 1H n.m.r. (D2O, DOH=4.81) 3.58, s, 3 H, N-CH3; 7.87, d, J 5.5 Hz, 1
H, 8-H; 8.85, d, J 5.5 Hz, 1 H, 7-H; 9.29, s, 1 H, 5-H. 13C n.m.r. (D2O+NaOD,
dioxane=67.4) 39.1, NCH3; 119.5, C(8)H; 123.8, C; 136.0, C; 149.1, C(5)H; 151.6,
C(7)H; 157.8, CO; 159.9, CO. Mass spectrum: m/z 178 (M+1, 100%). The filtrate was
evaporated, and the residue recrystalised twice from water (600 mL and 400 mL).
The concentration of 26 in the residues could not be decreased below 15% by
fractional crystallisation. The residue from the final recrystallisation was 85% 2-
methyl-4-hydroxypyrido[3,4-d]pyridazin-1(2H)-one (400mg total, aprx. 1.9 mmol,
5%, 27). 1H n.m.r. (D2O, DOH=4.81) 3.60, s, 3 H, N-CH3; 7.97, d, J 5.5 Hz, 1 H, 8-H;
8.81, d, J 5.5 Hz, 1 H, 7-H; 9.21, s, 1 H, 5-H. 13C n.m.r. (D2O+NaOD, dioxane=67.4)
39.6, NCH3; 119.5, C(8)H; 124.5, C; 134.9, C; 149.2, C(5)H; 150.4, C(7)H; 157.4, CO;
160.6, CO. Mass spectrum: m/z 178 (M+1, 100%), 162 (20%), 137 (43%), 119 (31%).
5.6.28. 1-Chloro-3-methylpyrido[3,4-d]pyridazin-4(3H)-one
A mixture of phosphorus oxychloride (1 mL, 11 mmol), phosphorus pentachloride
(0.42 g, 2 mmol) and 1-hydroxy-3-methylpyrido[3,4-d]pyridazine-4(3H)-one (356
mg, 2 mmol, 26) was refluxed for four hours. The mixture was poured into an ice /
ethyl acetate slurry (50 mL aprx) and dilute ammonia added until basic while
stirring. The ethyl acetate layer was separated, and evaporated to leave 37 mg of
residue, showing a single spot by TLC, Rf = 0.53, ethyl acetate. This was
recrystalised from boiling heptane to yield 1-chloro-3-methylpyrido[3,4-
d]pyridazin-4(3H)-one (26 mg, 0.13 mmol, 7%, 28). 1H n.m.r. (CDCl3) 3.85, s, 3 H,
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N-CH3; 7.76, d, J 5.3 Hz, 1 H, 8-H; 9.10, d, J 5.3 Hz, 1 H, 7-H; 9.72, s, 1 H, 5-H. 13C
n.m.r. (CDCl3=77.0) 39.5, NCH3; 117.295, C(8)H; 134.1, C(9 or 10); 135.5, C(10 or 9);
150.9 C(5)H; 152.1 C(1); 153.2 C(7)H; 157.9 C(4). Mass spectrum: m/z 196 (M+1,
100%), 182 (10%), 160 (6%), 135 (6%).
5.6.29. 3-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4(3H)-one
1-Chloro-3-methylpyrido[3,4-d]pyridazin-4(3H)-one (24 mg, 0.12 mmol, 28) was
hydrogenated for 18 hours at 1 atm, in a solution of 1.5 mL methanol, one drop of
conc. ammonia, with 24 mg of palladium on carbon catalyst. The solution was
filtered and evaporated to give a deep red residue, sufficient for n.m.r.
identification as 3-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4(3H)-one (23
mg, 80%, 29), rather than its positional isomer, 2-methyl-5,6,7,8-
tetrahydropyrido[3,4-d]pyridazin-1(2H)-one (not synthesised), by n.O.e.
experiments. TLC (butanol/acetic acid/water 4:1:1) showed one ninhydrin active
spot (Rf 0.22), and one minor contaminant (Rf 0.48). 
1H n.m.r. (CDCl3) 3.04, d, J 5.8
Hz, 2 H, C(8)H2; 3.47, d, J 5.8 Hz, 2 H, C(7)H2; 3.80, s, 3 H, NCH3; 4.20, s, 2 H, C(5)H2;
7.63, s, 1H, C(1)H. n.O.e. irradiation at 7.63 ppm (Ar-H); significant enhancement at
3.03 ppm only (CH2CH2C).
5.6.30. 1-Hydroxy-3-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-4(3H)-one
1-Hydroxy-3-methylpyrido[3,4-d]pyridazin-4(3H)-one (1.00 g, 5.64 mmol, 26), was
dissolved in methanol (50 mL) with the addition of a few drops of conc. ammonia.
Palladium on carbon catalyst was added (500 mg), and the mixture stirred under
hydrogen at atmospheric pressure for 48 hours. The catalyst was removed by
filtration, and the mixture evaporated, to leave 0.951 g. Recrystallisation from 15 mL
water gave pale yellow crystals (102 mg). Second (92 mg) and third (307 mg) crops
were obtained from water/ethanol, giving 1-hydroxy-3-methyl-5,6,7,8-
tetrahydropyrido[3,4-d]pyridazin-4(3H)-one (501mg, 2.77 mmol, 49%, 30). 1H n.m.r.
(D2O, DOH=4.81) 2.75, tt, J8-7 6.3 Hz, J8-5 1.8 Hz, 2 H, 8CH2; 3.45, t, J7-8 6.3 Hz, 2 H,
7CH2; 3.51, s, 3 H, N-CH3; 4.05, t, J5-8 1.8 Hz, 2 H, 5CH2. 
13C n.m.r. (D2O,
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dioxane=67.4) 21.5, C(8)H2; 39.5, CH3; 40.7, CH2; 40.9, CH2; 129.3, C; 136.9, C; 157.4,
CO; 161.4, CO.
5.6.31. 2-Methyl-4-hydroxy-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1(2H)-one
Impure 2-methyl-4-hydroxypyrido[3,4-d]pyridazin-1(2H)-one (400 mg, aprx. 85%,
1.9 mmol, 27) was dissolved in methanol (20 mL), with the addition of a few drops
of ammonia. Palladium on carbon catalyst (200 mg) was added, and the mixture
stirred under hydrogen at atmospheric pressure for 48 hours. The catalyst was
removed by filtration, and the mixture evaporated to leave 425 mg of residue. This
was dissolved in 15 mL hot water, filtered hot, and 15mL hot ethanol added to the
filtrate. On slow cooling, there was crystallisation of pale yellow translucent plates
of 2-methyl-4-hydroxy-5,6,7,8-tetrahydropyrido[3,4-d]pyridazin-1(2H)-one (191 mg,
1.05 mmol, aprx. 55%, 31), without detectable contamination by 30. 1H n.m.r. (D2O,
DOH=4.81) 2.78, t(br), J 6.3 Hz, 2 H, C(8)H2; 3.47, t, J 6.3 Hz, 2 H, C(7)H2; 3.54, s, 3 H,
N-CH3; 4.04, s(br), 2 H, 5CH2. 
13C n.m.r. (D2O, dioxane=67.4) 20.7 C(8)H2; 39.8, CH3;
40.8, CH2; 41.3, CH2; 132.0 C; 133.9 C; 158.5 CO; 160.3 CO.
5.6.32. Methyl 2-acetamido-2-carbomethoxy-3-(3,6-dimethoxypyridazin-4-
yl)propanoate
A dry sodium methoxide solution was prepared by dissolving sodium (690 mg, 30
mmol) in freshly dried and distilled methanol (30 mL). Of this solution, 1.5 mL was
pipetted into a 5 mL flask fitted with a drying tube and stirring bar, and containing
3,6-dimethoxy-4-bromomethylpyridazine (212 mg, 0.91 mmol, 5) and dimethyl
acetamidomalonate (189 mg, 1.00 mmol). Within half an hour, the solids had
dissolved to leave a clear, yellow solution. The mixture was left to stir at room
temperature overnight, then the solvent removed under vacuum. The residue was
suspended in 30 mL water, and extracted three times into equal volumes of ethyl
acetate. The pooled extracts were washed with 10 mL water, dried with Na2SO4,
and evaporated in vacuum to leave 220 mg of white solid. TLC showed three
components (Rf 0.56, 0.23, and 0.07, ethyl acetate/toluene 1:1). The mixture was
separated on a silica gel column, eluting with toluene/ethyl acetate (4:1) followed
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by pure ethyl acetate. The first component, a white crystalline solid, was found to
be a byproduct, 3,6-dimethoxy-4-methoxymethylpyridazine (43 mg, 0.23 mmol,
25%). 1H n.m.r. (CDCl3) 3.48, s, 3 H, CH2OCH3; 4.04, s, 3 H, OCH3; 4.06, s, 3 H,
OCH3; 4.38, d, J 1.4 Hz, 2 H, CH2OCH3; 7.02, t, J 1.4 Hz, 1 H, 5-H. The second
component, a white powder, was found to be the desired product, methyl 2-
acetamido-2-carbomethoxy-3-(3,6-dimethoxypyridazin-4-yl)propanoate (148 mg,
0.43 mmol, 47%, 32). 1H n.m.r. (CDCl3) 1.99, s, 3 H, COCH3; 3.65, s, 2 H, 4-CH2;
3.82, s, 6 H, (CO2CH3)2; 3.99, s, 3 H, OCH3; 4.02, s, 3 H, OCH3; 6.55, s, 1 H, N-H; 6.64,
s, 1 H, 5-H. 13C n.m.r. (CDCl3=77.0) 22.8, COCH3; 32.2, 4-CH2; 53.7, (CO2CH3)2; 54.5,
OCH3; 54.8, OCH3; 65.3, CH2C; 122.2, C(5)H; 129.5 C(4)CH2; 160.9, COMe; 162.2,
COMe; 167.7, (CO2Me)2; 169.3, HNCO. m.p. 151-2ºC. Mass spectrum: m/z 342 (M+1,
72%), 183 (16%), 155 (100%). The third component, a colourless crystalline residue,
was found to be the partially hydrolysed and decarboxylated product, methyl 2-
acetamido-3-(3,6-dimethoxypyridazin-4-yl)propanoate (4 mg, 0.014 mmol). 1H
n.m.r. (CDCl3) 1.98, s, 3 H, COCH3; 3.01, o, JAB 13.9 Hz, JAX 7.0 Hz, JAZ 0.7 Hz, 1 H,
RNHCHXR'CHAHBR"; 3.12, o, JBA 13.9 Hz, JBX 6.1 Hz, JBZ 0.7 Hz, 1 H,
RNHCHXR'CHAHBR"; 3.75, s, 3 H, CO2CH3; 4.03, s, 3 H, OCH3; 4.06, s, 3 H, OCH3;
4.86, o, 1 H, JXA 7.0 Hz, JXB 6.9 Hz, JXY 7.4 Hz, RNHYCHXR'CHAHBR"; 6.09, d(b), JYX 7.4
Hz, 1 H, N-HY; 6.74, t, J 0.7 Hz, 1 H, 5-HZ.
5.6.33. 2-amino-3-(pyridazine-3,6(1,2H)-dion-4-yl)propanoic acid
Methyl 2-acetamido-2-carbomethoxy-3-(3,6-dimethoxypyridazin-4-yl)propanoate
(70 mg, 0.205 mmol, 32) was refluxed for 90 minutes in 1 mL 48% HBr. The mixture
was evaporated in vacuum leaving 100 mg of amber liquid. This was absorbed onto
Dowex 50W (H+) ion exchange resin which was washed with several volumes of
water, followed by elution with 1M pyridine. The pyridine fractions were collected
and evaporated to leave 2-amino-3-(pyridazine-3,6(1,2H)-dion-4-yl)propanoic acid
(40 mg, 0.188 mmol, 92%). An analytical sample was obtained by recrystallisation
from water/ethanol. Rf 0.24 (Butanol/Acetic Acid/Water, 4:1:1). 
1H n.m.r. (D2O,
DOH=4.81) 3.04, q, JAB 14.6 Hz, JAX 7.6 Hz, 1 H, CHAHBCHX; 3.18, q, JBX 5.1 Hz, 1 H,
CHAHBCHX; 4.08, q, 1 H, CHAHBCHX; 7.11, s, 1 H, 5-H. 
13C n.m.r. (D2O+DCl,
161
dioxane=67.4) 31.8 (CH2), 52.1 (CH), 130.4 (CH), 140.0 (C), 157.5 (CO), 160.2 (CO),
171.3 (CO2H). m.p. >310ºC with decomposition. Mass spectrum: m/z 200 (M+1,
100%), 183 (16%), 154 (16%), 139 (28%).
5.6.34. Ethyl 2-acetamido-2-ethoxycarbonyl-3-(2-methyl-6-ethoxypyridazin-3(2H)-
on-4-yl)propanoate
A sodium ethoxide solution was prepared by dissolving sodium (0.369 g, 16.1
mmol) in 20 mL freshly dried ethanol. From this solution, 1.05 mL (0.84 mmol
ethoxide) was added to 2-methyl-4-bromomethyl-6-ethoxypyridazin-3(2H)-one (203
mg, 0.82 mmol, 13) and diethyl acetamidomalonate (176 mg, 0.81 mmol) under dry
conditions. Within a few minutes of stirring, a slightly yellow milky preciptate had
formed. The mixture was allowed to stir overnight, the ethanol evaporated, and the
products suspended in 20 mL water. Extraction twice into equal volumes of ethyl
acetate, drying over Na2SO4, and removal of solvent gave 300 mg of crude product.
This was recrystalised from 15-20 mL petroleum ether to give ethyl 2-acetamido-2-
ethoxycarbonyl-3-(2-methyl-6-ethoxypyridazine-3(2H)-on-4-yl)propanoate (245 mg,
0.64 mmol, 79%, 34). 1H n.m.r. (CDCl3) 1.28, t, J 7.1 Hz, 6 H, (CO2CHAHBCH3)2; 1.34,
t, J 7.1 Hz, 3 H, 6-OCH2CH3; 2.00, s, 3 H, COCH3; 3.56, s, 2 H, 4-CH2; 3.60, s, 3 H, N-
CH3; 4.13, q, J 7.1, 2 H, 6-OCH2CH3; 4.264, qq, JAX3 7.1 Hz, JAB 10.7 Hz, 2 H,
(CO2CHAHBCH3)2; 4.306, qq, JBX3 7.1 Hz, JBA 10.7 Hz, 2 H, (CO2CHAHBCH3)2; 6.75, s, 1
H, 5-H; 7.04, s, 1 H, N-H. 13C n.m.r. (CDCl3=77.0) 13.9, (CO2CH2CH3)2; 14.2, 6-
OCH2CH3; 22.9, COCH3; 34.0, 4-CH2; 39.6, NCH3; 62.7, 6-OCH2CH3; 62.8,
(CO2CH2CH3)2; 65.3, CH2C; 126.7, C(5)H; 140.0, C(4)CH2; 152.1, CO; 159.9, CO; 167.6,
(CO2Et)2; 169.3, HNCO. m.p. 123-5ºC. Mass spectrum: m/z 384 (M+1, 70%), 218
(11%), 197 (15%), 169 (100%). The byproduct ethyl 2-acetamido-3-(2-methyl-6-
ethoxypyridazin-3(2H)-on-4-yl)propanoate, which is also hydrolysable to the
glycine derivative, was detected in the crude product. 1H n.m.r. (CDCl3) 1.25, t, J
7.2 Hz, 3 H, CO2CH2CH3; 1.35, t, J 7.0 Hz, 3 H, OCH2CH3; 2.00, s, 3 H, COCH3; 3.02,
m, 2 H, 4-CH2CH; 3.67, s, 3 H, N-CH3; 4.16, q, J 7.0 Hz, 2 H, OCH2CH3; 4.19, q, J 7.2
Hz, 2 H, CO2CH2CH3; 4.67, m, 1 H, 4-CH2CH; 6.80, s, 1 H, 5-H; 7.66, d(b), J 6.6 Hz, 1
H, NHCOCH3.
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5.6.35. 2-Amino-3-(2-methyl-6-hydroxypyridazin-3(2H)-on-4-yl)propanoic acid
Ethyl 2-acetamido-2-ethoxycarbonyl-3-(2-methyl-6-ethoxypyridazine-3(2H)-on-4-
yl)propanoate (466 mg, 1.22 mmol, 34) was dissolved in 3 mL 48% hydrobromic
acid and held at reflux for 90 minutes. The acid was removed in vacuum to leave
375 mg of orange foamy residue. Ethyl 2-acetamido-3-(2-methyl-6-ethoxypyridazin-
3(2H)-on-4-yl)propanoate (144 mg, 0.46 mmol) was treated in the same way to leave
167 mg of residue. These combined products were absorbed onto Dowex 50W (H+)
ion exchange resin, washed with several volumes of water, and eluted with 1M
pyridine. The pyridine fractions were evaporated to leave 2-amino-3-(2-methyl-6-
hydroxypyridazine-3(2H)-on-4-yl)propanoic acid (281 mg, 1.32 mmol, 79%) as an
off-white powder. 1H n.m.r. (D2O, DOH=4.81) 3.05, q, JAB 14.6 Hz, JAX 7.1 Hz, 1 H,
CHAHBCHX; 3.19, q, JBX 4.9 Hz, 1 H, CHAHBCHX; 3.64, s, 3 H, N-CH3; 4.07, q, 1 H,
CHAHBCHX; 7.13, s, 1 H, 5-H. 
13C n.m.r. (D2O, dioxane=67.4) 32.9, CH2; 40.5, NCH3;
54.3, CH2CH; 127.6, C(5)H; 141.5, C(4); 154.8, CO; 161.5, CO; 173.6, CO2H. m.p. 256-
9ºC. Mass spectrum: m/z 214 (M+1, 100%), 197 (12%), 168 (16%).
5.6.36. Ethyl 2-acetamido-2-ethoxycarbonyl-3-(2-methyl-6-ethoxypyridazin-3(2H)-
on-5-yl)propanoate
Sodium (552 mg, 24 mmol) was dissolved in 40 mL dry ethanol. 2 mL of this
solution was added to diethyl acetamidomalonate (261 mg, 1.20 mmol), and the
mixture stirred. 2-Methyl-5-bromomethyl-6-ethoxypyridazin-3(2H)-one (300 mg,
1.21 mmol, 19) was added, whereupon the stirred solution turned dark instantly.
After stirring overnight, the solvent was removed in vacuum, the residue
suspended in 20 mL water, and extracted three times with 20 mL ethyl acetate. The
combined extracts were evaporated in vacuum to leave 555 mg of a crystalline solid,
which was recrystallised from cyclohexane to yield 220 mg of white crystals. The
residue after crystallisation was chromatographed on silica, eluting with ethyl
acetate:toluene, 1:1, affording a further 13 mg of ethyl 2-acetamido-2-
ethoxycarbonyl-3-(2-methyl-6-ethoxypyridazin-3(2H)-on-5-yl)propanoate (total
yield 233 mg, 0.61 mmol, 51%, 36). 1H n.m.r. (CDCl3) 1.28, t, J 7.1 Hz, 6 H,
(CO2CHAHBCH3)2; 1.34, t, J 7.0 Hz, 3 H, 6-OCH2CH3; 2.01, s, 3 H, COCH3; 3.55, s, 2 H,
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5-CH2; 3.61, s, 3 H, N-CH3; 4.14, q, J 7.05, 2 H, 6-OCH2CH3; 4.22, qq, JAX3 7.1 Hz, JAB
10.7 Hz, 2 H, (CO2CHAHBCH3)2; 4.32, qq, JBX3 7.1 Hz, JBA 10.7 Hz, 2 H,
(CO2CHAHBCH3)2; 6.60, s, 1 H, 4-H; 6.61, s(b), 1 H, NHCOCH3. 
13C n.m.r. 
(CDCl3=77.0) 13.9, (CO2CH2CH3)2; 14.1, 6-OCH2CH3; 22.9, COCH3; 31.5, 4-CH2; 39.0,
NCH3; 62.9, (CO2CH2CH3)2; 63.2, 6-OCH2CH3; 65.6, CH2C; 132.4, C(5)H; 135.2,
C(4)CH2; 151.5, CO; 159.1, CO; 167.2, (CO2Et)2; 169.2, HNCO.
5.6.37. 2-Amino-3-(2-methyl-6-hydroxypyridazin-3(2H)-on-5-yl)propanoic acid
Ethyl 2-acetamido-2-ethoxycarbonyl-3-(2-methyl-6-ethoxypyridazin-3(2H)-on-5-
yl)propanoate (223 mg, 0.58 mmol, 36) was dissolved in 3 mL conc. HBr, and heated
at 140ºC for a total of 12 hours, in three stages, between each of which the HBr was
evaporated and the product purified on Dowex 50W (H+) ion exchange resin,
eluting with pyridine, and the progress of the reaction followed by TLC
(butanol:acetic acid:water 4:1:1). Whilst hydrolysis of the acetamide and ethyl esters
was rapid, hydrolysis of the ring ethoxide was slow, incomplete, and by 12 hours it
was apparent that substantial degradation was occurring. The product was
evaporated and chromatographed on Dowex 50W. Removal of the pyridine in
vacuum yielded crude 2-amino-3-(2-methyl-6-hydroxypyridazin-3(2H)-on-5-
yl)propanoic acid (105 mg, 0.49 mmol, 85%, 37), as a beige powder, contaminated
with aprx. 8% 6-ethoxy derivative. Rf 0.24 (Butanol/Acetic Acid/Water, 4:1:1). 
1H
n.m.r. (D2O, DOH=4.81) 3.00, q, JAB 14.5 Hz, JAX 7.7 Hz, 1 H, CHAHBCHX; 3.16, q, JBX
5.2 Hz, 1 H, CHAHBCHX; 3.59, s, 3 H, N-CH3; 4.07, q, 1 H, CHAHBCHX; 6.92, s, 1 H, 4-
H.
5.6.39. 2-Methyl-6-hydroxypyridazin-3(2H)-one
Maleic anhydride (9.8 g, 0.1 mol, 38) and conc. hydrochloric acid (11.2 g, 0.1 mol)
were mixed in a 100 mL flask, and methyl hydrazine (4.6 g, 0.1 mol) was added
dropwise with caution. The mixture was heated at 100°C for three hours, cooled
and filtered. The residue was washed with several volumes of cold water, collected,
and dried to leave 8.25 g white crystals. The combined filtrates were concentrated,
yielding a second crop of 0.17 g 2-methyl-6-hydroxypyridazin-3(2H)-one (8.42 g,
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0.067 mol, 67%, 39). 1H n.m.r. (D2O, DOH=4.81) 3.60, s, 3 H, 1-CH3; 7.03, d, J 9.7 Hz,
1 H, 5-H; 7.20, d, J 9.7 Hz, 1 H, 4-H.
5.6.40. 2-Methyl-6-ethoxypyridazin-3(2H)-one
2-Methyl-6-hydroxypyridazin-3(2H)-one (8.00 g, 63 mmol, 39), potassium carbonate
(21.92 g, 317 mmol, 2.5 eq.), ethyl iodide (20.3 mL, 254 mmol, 4 eq.), and 150 mL
absolute ethanol were added to a 500 mL flask. The slurry was stirred and heated at
reflux (80°C) for 24 hours, cooled, and filtered. The residue was washed with
ethanol, and the filtrates evaporated to leave 14.10 g pale yellow residue.
Recrystallisation from 75 mL heptane, including hot filtration, yielded large off-
white oily crystals of 2-methyl-6-ethoxypyridazin-3(2H)-one (8.64 g, 56 mmol, 88%,
40). 1H n.m.r. (CDCl3) 1.37, t, J 7.1 Hz, 3 H, OCH2CH3; 3.65, s, 3 H, NCH3; 4.18, q, J
7.1 Hz, 2 H, OCH2CH3; 6.89, s, 2H, 4,5-H (coincident).
5.6.41. 2-Bromomethyl-6-ethoxypyridazin-3(2H)-one
2-Methyl-6-ethoxypyridazin-3(2H)-one (8.00 g, 52 mmol, 40), N-bromosuccinimide
(9.24 g, 52 mmol), and 200 mL CCl4, were stirred in a 500 mL flask fitted with a
reflux condenser. The mixture was irradiated for 30 minutes with a high intensity
UV source (800W Lowel-Tota lamp), at a distance of around 10 cm. The mixture
was washed twice with equal volumes of water to remove the floating succinimide
layer, dried over Na2SO4, and evaporated, to leave 8.78 g yellow residue. 60 mL of a
3:1 mixture of heptane and toluene was added, the mixture boiled, and decanted
from an insoluble orange oily layer. On cooling, 2-bromomethyl-6-ethoxypyridazin-
3(2H)-one was recovered as soft, yellow oily crystals (4.72 g, 20 mmol, 39%, 41). This
compound showed rapid degradation in moist air, presumably to the 2-
hydroxymethyl derivative (based on n.m.r. data, 1H n.m.r. (CDCl3) 5.54, s, 2H,
NCH2OH) conversion being substantially complete in 24 hours. Only minor
degradation was visible after 12 months in a sealed container at -15°C. 1H n.m.r. 
(CDCl3) 1.39, t, J 7.1 Hz, 3 H, -CH2-CH3; 4.24, q, J 7.1 Hz, 2 H, -CH2-CH3; 5.75, s, 2 H,
N-CH2Br; 6.87, d, J 9.8 Hz, 1 H, 5(or 4)-H; 6.93, d, J 9.8 Hz, 1 H, 4(or 5)-H. 
13C n.m.r.
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(CDCl3=77.0) 14.1, CH3; 46.1, CH2Br; 63.5, OCH3; 128.7, CH; 132.5, CH; 153.1, CO;
158.4, CO.
5.6.42. Ethyl 2-acetamido-2-ethoxycarbonyl-3-(6-ethoxypyridazin-3(2H)-on-2-
yl)propanoate
A sodium ethoxide solution was prepared by dissolving sodium (0.99 g, 43 mmol)
in 100 mL dry ethanol. Diethyl acetamidomalonate (2.33 g, 10.7 mmol) was
dissolved in 25 mL of this solution in a 50 mL flask fitted with a drying tube, and
allowed to stir for a few minutes. 2-Bromomethyl-6-ethoxypyridazin-3(2H)-one
(2.50 g, 10.7 mmol, 41) was added, and rapidly dissolved, whereupon the solution
turned to a pale orange-pink, and a mild exotherm was noted. The solution was
stirred for 18 hours, evaporated, suspended in 100 mL water, and extracted three
times with equal volumes of ethyl acetate. Drying of the ethyl acetate over Na2SO4,
followed by evaporation, gave 3.87 g residue, which was recrystallised from 200 mL
heptane containing a few mL of toluene to leave fluffy white needles of ethyl 2-
acetamido-2-ethoxycarbonyl-3-(6-ethoxy-pyridazin-3(2H)-on-2-yl)propanoate (2.87
g, 7.77 mmol, 73%, 42). 1H n.m.r. (CDCl3) 1.31, t, J 7.1 Hz, 6 H, (CO2CHAHBCH3)2; ]
1.34, t, J 7.1 Hz, 3 H, 3-OCH2CH3; 1.98, s, 3 H, COCH3; 4.09, q, J 7.1, 2 H, 3-OCH2CH3;
4.271, qq, JAX3 7.1 Hz, JAB 10.7 Hz, 2 H, (CO2CHAHBCH3)2; 4.332, qq, JBX3 7.1 Hz, JBA
10.7 Hz, 2 H, (CO2CHAHBCH3)2; 4.91, s, 2 H, N-CH2-, 6.59, s (br), 1 H, NHCOCH3;
6.83, d, J 9.8 Hz, 1 H, 5(or 4)-H; 6.87, d, J 9.8 Hz, 1 H, 4(or 5)-H. 13C n.m.r. 
(CDCl3=77.0) 13.9, (CO2CH2CH3)2; 14.2, 6-OCH2CH3; 22.8, COCH3; 51.8, N-CH2; 62.8,
6-OCH2CH3; 62.8, (CO2CH2CH3)2; 64.6, CH2C; 127.0, CH; 132.5, CH; 152.4, CO; 159.4,
CO; 166.9, (CO2Et)2; 169.0, HNCO.
5.6.43. 2-Amino-3-(6-hydroxypyridazin-3(2H)-on-2-yl)propanoic acid
Ethyl 2-acetamido-2-ethoxycarbonyl-3-(6-ethoxypyridazine-3(2H)-on-2-
yl)propanoate (2.5 g, 6.77 mmol, 42) was dissolved in hydroiodic acid (10 mL, 57%),
and refluxed 15 hours. Evaporation of excess acid, followed by chromatography on
Dowex 50W (H+ ion-exchange resin, eluting with pyridine, and evaporation of the
pyridine fractions, gave 1.13 g of buff-coloured solid. TLC (butanol/acetic
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acid/water, 4:1:1) and n.m.r. showed that only a modest proportion the material
was fully deprotected (Rf 0.24), with the major product being 2-amino-3-(6-
ethoxypyridazine-3(2H)-on-2-yl)propanoic acid (Rf 0.31) along with some
degradation. 1H n.m.r. (D2O, DOH=4.81) 1.34, t, J 7.1, 3 H, -OCH2CH3; 4.19, dd, 1
H, NCHAHBCH; 4.23, q, J 7.1, 2 H, 6-OCH2CH3; 4.46, dd, 1 H, NCHAHBCH; 4.64, dd,
1 H, NCHAHBCH; 7.03, d, J 9.9 Hz, 1 H, 5(or 4)-H; 7.18, d, J 9.9 Hz, 1 H, 4(or 5)-H.
This material was redissolved in 10 mL fresh hydroiodic acid, and refluxed for a
further 9 hours, by which time conversion appeared substantially complete by TLC,
and the free amino acid was recovered as before by ion-exchange chromatography,
leaving 771 mg of residue. This was recrystalised from 30 mL of boiling
ethanol/water (1:1), yielding fluffy white needles of 2-Amino-3-(6-
hydroxypyridazin-3(2H)-on-2-yl)propanoic acid (612 mg, 3.07 mmol, 45% overall,
43). Rf 0.28 (Butanol/Acetic Acid/Water, 4:1:1). 
1H n.m.r. (D2O, DOH=4.81) 4.21,
dd, JXB 3.8 Hz, JXA 6.9 Hz, 1 H, NCHAHBCHX; 4.50, dd, JAX 6.9 Hz, JAB 14.8 Hz, 1 H,
NCHAHBCHX; 4.56, dd, JBX 3.8 Hz, JBA 14.8 Hz, 1 H, NCHAHBCHX; 7.08, d, J 9.9 Hz, 1
H, 5(or 4)-H; 7.23, d, J 9.9 Hz, 1 H, 4(or 5)-H. 13C n.m.r. (D2O, dioxane=67.4) 51.1,
NCH2; 54.6, CH2CH; 129.2, CH; 133.5, CH; 155.2, CO; 161.8, CO; 172.0 CO2H.
5.6.48. 3,6-Dimethoxy-4-(dibromomethyl)pyridazine
3,6-Dimethoxy-4-methylpyridazine (11.56 g, 75 mmol, 4) was dissolved in CCl4 (200
mL) and N-bromosuccinimide (26.70 g, 150 mmol) added. The stirred mixture was
fitted with a reflux condenser, and irradiated for 40 minutes with an 800W "Lowel-
Tota" high intensity lamp at a distance of 10 cm. The mixture was allowed to cool,
filtered to remove excess succinimide, washed once with water (200 mL) and
evaporated to leave 23.6 g dark residue. The residue was triturated with three
approximate 50 mL volumes of hot heptane, discarding a tarry residue. The heptane
extracts were pooled, and allowed to stand. Further tar being deposited, the extract
was filtered, evaporated, and recrystallised from heptane to give 3,6-dimethoxy-4-
(dibromomethyl)pyridazine (13.09 g, 42 mmol, 56%, 48) as large soft pale beige
waxy crystals. 1H n.m.r. (CDCl3) 4.08, s, 3 H, OCH3; 4.14, s, 3 H, OCH3; 6.70, d, J 1.1
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Hz, 1 H, 5-H; 7.39, d, J 1.1 Hz, 1 H, CHBr2. 
13C n.m.r. (CDCl3=77.0) 31.5, CHBr2;
54.8, OCH3; 55.2, OCH3; 119.9, C(5)H; 134.0, C(4); 156.0, COMe; 162.0, COMe.
5.6.49. 3,6-Dimethoxypyridazine-4-carboxaldehyde
Attempted hydrolysis of the methyl pyridazine dibromide in water, THF/water,
dioxane/water, or alcohol/water, with or without the addition of mineral acids or
bases, with prolonged reflux, generally either returned starting material or baseline
products, along with traces of the aldehyde. The following was the best of several
methods trialled: 3,6-dimethoxy-4-(dibromomethyl)pyridazine (13.1 g, 42 mmol, 48)
was dissolved in ethanol (80 mL) and sodium acetate trihydrate (14.3 g, 105 mmol)
added. Upon heating, the mixture became homogeneous, and reflux was
maintained for five days. TLC (toluene/EtOAc 4:1) indicated substantial
destruction of starting material (Rf 0.55), the presence of 3,6-dimethoxypyridazine-
4-carboxaldehyde 49 and its diethoxy acetal 50 (Rf 0.30 and 0.33 respectively) along
with baseline or low Rf material. Addition of water (200 mL) and extraction twice
into ether (200 mL) followed by vacuum removal of the ether afforded 3.89 g of pale
yellow liquid residue. 1H n.m.r. indicated that the ratio of diacetal to aldehyde was
5:1. Dilute hydrochloric acid (0.1M, 100 mL) was added, and the mixture shaken for
ten minutes at 70°C, converting most of the diacetal to the aldehyde, with some
degradation. The mixture was again evaporated, and the residue chromatographed
on silica (toluene/EtOAc 9:1) to give crude 3,6-dimethoxypyridazine-4-
carboxaldehyde (819 mg, 4.8 mmol, 12%, 49) as a somewhat volatile and low-
melting white crystalline solid, the major contaminant being the diethoxy acetal.
This mixture could be further purified by repeating the hydrolysis step, and
triturating the residue with chloroform, with reduced yields due to further
degradation. The aldehyde is unstable at room temperature in air, but can be
maintained sealed at lower temperatures for reasonable periods. Rf 0.38
(toluene/ethyl acetate, 4:1). 1H n.m.r. (CDCl3) 4.10, s, 3 H, OCH3; 4.21, s, 3 H,
OCH3; 7.30, s, 1 H, 5-H; 10.37, s, 1 H, 4-CHO. 
13C n.m.r. (CDCl3=77.0) 55.11, OCH3;
55.14, OCH3; 118.0, C(5)H; 125.1, C(4)CH; 160.0, COMe; 163.1, COMe; 188.2, 4-CHO.
The acetal appears more stable, and the relative success of the reaction in ethanol
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vs. other solvents, and with mildly basic buffered conditions may be attributed to
its formation. 3,6-Dimethoxy-4-(diethoxymethyl)pyridazine 50: Rf 0.43
(toluene/ethyl acetate, 4:1). 1H n.m.r. (CDCl3) 1.23, t, J 7.1 Hz, 6 H, (OCH2CH3)2;
3.59, qq, JAX 7.1 Hz, JAB 9.3 Hz, 2 H, (OCHAHBCH3)2; 3.64, qq, JBX 7.1 Hz, 2 H,
(OCHAHBCH3)2; 4.05, s, 3 H, OCH3; 4.09, s, 3 H, OCH3; 5.54, d, J 0.75 Hz, 1 H, 4-
CH(OEt)2; 7.16, d, J 0.75 Hz, 5-H. 
13C n.m.r. (CDCl3=77.0) 15.1, (OCH2CH3)2; 54.5,
OCH3; 54.7, OCH3; 62.4, (OCH2CH3)2; 95.7, 4-CH(OEt)2; 118.1, C(5)H; 131.7, C(4)CH;
159.7, COMe; 162.6, COMe. Mass spectrum: m/z 243 (M+1, 100%), 229 (12%), 213
(23%), 197 (48%).
5.6.53. Ethyl 2-(3,6-dimethoxypyridazin-4-yl)acetate
A dry 100 mL 3-neck flask was prepared under nitrogen. Freshly distilled THF (30
mL) was introduced by syringe, as was diisopropylamine (0.56 mL, 405 mg, 4
mmol) which had been freshly distilled from calcium hydride. The mixture was
cooled to -30°C. Butyl lithium in hexane, recently titrated at 2.2M with 2,5-
dimethoxybenzaldehyde, was added (1.82 mL, 4 mmol). The mixture was stirred 30
minutes at 0°C and then cooled to -70°C. A solution of carefully dried 3,6-
dimethoxy-4-methylpyridazine (308 mg, 2 mmol, 4) in 10 mL dry THF was
introduced, whereupon a pale yellow colour developed. The temperature was
maintained below -50°C and stirred for 90 minutes. Freshly distilled ethyl
chloroacetate (0.19 mL, 217 mg, 2 mmol) in 10 mL dry THF was introduced,
whereupon a deep red colour developed, and the solution was allowed to warm
slowly to 0°C. 15 mL 1M HCl was added to quench, the solution returning to pale
yellow, followed by 10 mL ethanol. The solution was neutralised with saturated
sodium bicarbonate solution, and rotary evaporated. The residue was extracted
twice with chloroform (50 mL portions), dried over sodium sulfate, and evaporated
to leave 413 mg. The crude product was recrystalised from heptane, to give ethyl 2-
(3,6-dimethoxypyridazine-4-yl)acetate (244 mg, 1.3 mmol, 65%, 53). 1H n.m.r. 
(CDCl3) 1.26, t, 3 H, J 7.1 Hz, OCH2CH3; 3.55, d, 2 H, J 0.8 Hz, ArCH2; 4.04, s, 3 H,
OCH3; 4.05, s, 3 H, OCH3; 4.18, q, 2 H, J 7.1 Hz, OCH2CH3; 6.87, t, 1 H, J 0.8 Hz, ArH.
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13C n.m.r. (CDCl3=77.0) 14.1, OCH2CH3; 35.0, ArCH2; 54.5, OCH3; 54.7, OCH3; 61.3
OCH2CH3; 120.9, C(5)H; 128.4, C(4)R; 160.6, COMe; 162.1, COMe; 169.1, COOEt.
5.6.54. Ethyl 2-bromo-2-(3,6-dimethoxypyridazin-4-yl)acetate
Ethyl 2-(3,6-dimethoxypyridazin-4-yl)acetate (55 mg, 0.24 mmol, 53) was dissolved
in 2 mL CCl4, and N-bromosuccinimide added (43.3 mg, 0.24 mmol). The mixture
was stirred, and irradiated for 20 minutes with an 800W "Lowel-Tota" high intensity
UV lamp at a distance of 10 cm. A layer of floating succinimide indicated the
reaction had proceeded, and TLC indicated clean conversion. The mixture was
filtered, and evaporated, to leave crude ethyl 2-bromo-2-(3,6-dimethoxypyridazin-
4-yl)acetate (82 mg, (112%), 54). 1H n.m.r. (CDCl3) 1.30, t, J 7.1, 3 H, OCH2CH3; 4.07,
s, 3 H, OCH3; 4.09, s, 3 H, OCH3; 4.26, q, J 7.1 Hz, 2 H, OCH2CH3; 5.42, s, 1 H, CHBr;
7.28, s, 1 H, Ar-H.
5.6.56. Ethyl 2-hydroximino-2-(3,6-dimethoxypyridazin-4-yl)acetate
Ethyl 2-(3,6-dimethoxypyridazin-4-yl)acetate (49 mg, 0.22 mmol, 53), was dissolved
in acetic acid (330 mg, 5.5 mmol) and stirred at 0°C. A solution of sodium nitrite (84
mg, 1.2 mmol) in 2 mL water was slowly added dropwise over a 20 minute period.
The solution turned pale yellow, and a creamy solid begain to form. The mixture
was maintained at 0°C for several hours. After stirring overnight, 10 mL water was
added, and the solution extracted three times with 5 mL portions of CHCl3. The
pooled extracts were evaporated to give a very pale yellow liquid which crystallised
on standing to a yellow solid: ethyl 2-hydroximino-2-(3,6-dimethoxypyridazin-4-
yl)acetate (48 mg, 0.18 mmol, 85%, 56) of fair purity by TLC and n.m.r. 1H n.m.r. 
(CDCl3) 1.31, t, J 7.1 Hz, 3 H, OCH2CH3; 4.04, s, 3 H, OCH3; 4.08, s, 3 H, OCH3; 4.33,
q, J 7.1 Hz, 2 H, OCH2CH3; 6.99, s, 1 H, Ar-H; 8.8 (aprx), s (broad), 1 H, CNOH.
13C
n.m.r. (CDCl3=77.0) 14.0, CH2CH3; 54.8, OCH3; 55.0, OCH3; 62.5, OCH2CH3; 121.4,
C(5)H; 123.0, C(4)R; 144.4, CNOH; 158.3, CO; 161.7, COMe; 161.9, COMe.
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6. Theoretical studies on the free-radical bromination
of methyl pyridazines
Abstract
Free-radical bromination by N-bromosuccinimide has been performed on a range of methyl 3-
methoxypyridazine derivatives. Depending on the substitution pattern, various products and
selectivities have been observed, including atypical N-methyl bromination. The hypothesis that
selectivity is dependent primarily on the stability of the free-radical intermediate formed in the
reaction is examined, and a range of semi-empirical and ab initio molecular orbital methods used
to calculate these stabilities and evaluated for agreement with experiment. Semi-empirical
calculations using the PM3 Hamiltonian gave the best qualitative predictions of the methods
trialed, thus providing a rapid method for predicting the selectivity of reactions used in the
synthesis of novel heterocyclic analogues of the neurotransmitters GABA and glutamate.
"Theoretical studies on free-radical bromination of methyl pyridazines in the synthesis of novel
heterocyclic analogues of neurotransmitters", JR Greenwood, G Vaccarella, HR Capper, KN
Mewett, RD Allan, GAR Johnston. Journal of Molecular Structure (Theochem) 368, 235-243
(1996)
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6.1 Introduction
The Wohl-Zeigler reaction has long been used as a general means of brominating
unsaturated compounds at an allyl or aromatic methyl position [1].
This reaction is believed to take place by a free-radical mechanism [2], is generally
conducted in carbon tetrachloride as a solvent, and is catalysed by light and
peroxides. N-bromosuccinimide is used as a source of low-concentration bromine,
which produces bromine radicals which initiate the reaction. [3]
Scheme 6.1: Mechanism of the Wohl-Zeigler reaction
The rate limiting step is believed to be the formation of the aromatic methylene free-
radical, and the stability of this radical and the ease of breaking the carbon-
hydrogen bond are crucial to the ease of bromination and the selectivity of the
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reaction [4], outweighing other factors such as steric effects. The focus of the
calculations presented here is on predicting the thermodynamics of this step as the
best indicator of the course of the overall reaction.
The Wohl-Zeigler reaction has been used to produce intermediates for the synthesis
of conformationally restricted bioactive analogues of the neurotransmitters GABA
and glutamic acid [5]. In the course of the synthesis of such analogues, based on the
pyridazine heterocycle, of which there were a number of examples in Chapter 5, it
has been found that this essential step is unreliable; unexpected products have been
formed, and some compounds fail to brominate. In particular, the formation of N-
bromomethyl derivatives of methyl pyridazinones (9,10,11) appears unprecedented.
The single account found of the bromination of a similar system, 2,4-dimethyl-6-
phenyl-3(2H)-pyridazinone, describes the formation of the 4-bromomethyl
derivative [6], although the elemental analysis and infra-red spectroscopy
employed to identify the product may not have detected the presence of a 2-
bromomethyl substituted derivative.
The aim of this work is to study these reactions further by comparing experimental
results with a variety of computational methods, and develop a convenient and
preferably rapid theoretical means of predicting selectivity.  
6.2 Method
In order to study the stability of the free-radical intermediates in the Wohl-Ziegler
reaction by theoretical calculations, an appropriate theory and method must be
chosen.
Since the reaction being considered is a neutral one, and since the solvent used is
non-polar, it is a fair assumption that solvent effects will be minimal, and gas-phase
calculations will reflect properties of species in solution.
Semi-empirical theories provide rapid results, which although unlikely to be
quantitatively accurate, may provide useful qualitative information, especially
when relative energies are compared with one another, so as to cancel out as far as
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possible inherent errors. Among commonly used semi-empirical parametisations,
the PM3 Hamiltonian has previously been found to give the most reliable results for
calculations on pyridazinones [7]. Here, the results of AM1, MNDO and PM3 are
compared with experimental observations for all the systems studied.
High level ab initio calculations, while much more computationally demanding,
hold the promise of definitive and quantitative results. Wong and Radom [8]
suggest that large basis sets and advanced correlation methods such as UQCISD(T)
are necessary for accurate descriptions of the energy barriers and enthalpies in
radical reactions. Since methyl-pyridazines are relatively large molecules, such
calculations are at present prohibitively expensive. Ab initio optimisations have
been carried out on all of the systems studied, with restricted Hartree-Fock theory
(RHF) for singlet species, and unrestricted Hartree-Fock theory (UHF) for doublets,
using the 3-21G or 3-21G(d) basis sets. In addition, optimisations have been
performed on pyridazinone systems of particular interest (9,10) with restricted
open-shell Hartree-Fock theory (ROHF) and second-order Møller-Plesset
perturbation theory (MP2), using the 6-31G(d) basis set.
6.3 Results
Table 6.1 summarises the experimental products observed for each of the
bromination reactions considered, and correlates mono-brominated derivatives
with free-radical intermediates. Secondary bromination reactions, producing di-
bromides as minor products, have not been considered.
Table 6.2 lists the relative energies of these radicals and the heats of formation or
total energies of parent species, calculated by MOPAC [11] and Gaussian [12]. Also
included for reference are the same calculations performed on hydrogen bromide
and bromine radicals.
Table 6.3 lists the heats of reaction, calculated by subtracting the calculated energy
of formation of bromine radicals from hydrogen bromide, from the calculated
relative energies of the free-radical intermediates.
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Geometries optimised at HF / PM3 are available in Protein Data Bank (.pdb)
format.
6.4 Discussion
In the case of the methoxy pyridazines (1, 2, 3, 4) and pyridazine N-oxides (5, 6, 7, 8)
studied experimentally, bromination of methyls ortho to the methoxy substituent is
consistently favoured. Every theoretical method trialled on these systems predicted
the greater stability of methylene radicals at the ortho vs. the meta position, with a
typical energy difference for parallel reactions being around 1-4 Kcal. Of the semi-
empirical methods, PM3 gave magnitudes for the heat of reaction in closest
agreement with ab initio results. PM3 also gave relative radical stabilities calculated
from total energies (E(R.)-E(RH)) in closest agreement with HF / 3-21G.
The chlorinated methoxy pyridazines (2, 3, 4) react normally with NBS, although a
significant amount of tar is produced from 2 and 3 indicating that side-reactions are
occurring. Most importantly, 3 is observed to react at approximately five times the
rate of 2. This is reflected in the relatively small (1-3 Kcal) differences in the
calculated heats of reaction for these species. This modest energy difference appears
to be sufficient to ensure the selective bromination of 3 at position 5, and shows the
sensitivity of this theory for predicting selectivity.
The methods trialed did not fully describe the observed failure of 3-methoxy-5-
methylpyridazine N-oxide (6) to react in a normal fashion. The most reliable semi-
empirical method, PM3, gave a larger heat of reaction for this species than for any
other, although HF / 3-21G did not. Also, the reaction of 6 was found to be
generally more unfavourable compared with 5 than was the case for the other
parallel systems. Since ring bromination has been observed in this case, it seems
likely that the methylene radical at position 4 is sufficiently high in energy for a
more favoured ring radical species to be produced, possibly involving
rearrangement. This hypothesis is further supported by the fact that while the
calculated energetics of the more substituted 7 are very similar to those of 5 and 6,
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traces of the 5-bromomethyl product, but no ring brominated products were
observed in this case, implicating the 4-position of 6 in the side reaction.
The observed reactivities of the N-methyl pyridazinones studied (9, 10, 11) were not
well reproduced, particularly by ab initio SCF calculations. Experimentally, the
unexpected N-bromomethyl products were formed in all cases to some extent, and
in the case of 10, this product predominates, although a mixture is formed. No
method gave energies which entirely reflect the observed product distributions,
although PM3 performs well, according to which 10(2) and 10(5) are very close in
energy, suggesting a mixture. This method also gave good qualitative agreement
with experiment for 11. While all SCF methods correctly predicted 9(4) to be
favoured over 9(2), the large differences in energy observed, particularly for HF / 3-
21G and HF / 6-31G(d), do not reflect the substantial proportion of the N-
bromomethyl product formed in this reaction. On the other hand, all methods
favour 9(4) over 10(5), as well as 11(4) over 11(2) and 11(5), in agreement with
experiment.
The greater ability of semiempirical methods to qualitatively predict selectivity
compared with ab initio Hartree-Fock calculations in these cases may be attributed
to the implicit consideration of electron correlation inherent in the empirical
parametisation of these methods. The post-SCF calculations performed indicate that
electron correlation leads to substantially increased stability of N-methylene
radicals. MP2 / 6-31G(d) // HF / 6-31G(d) single point energies, with or without
the inclusion of zero-point energies, give 9(2) and 10(2) as more stable than 9(4) and
10(5). However, these calculations also attribute 9(2) greater stability vs. 9(4) than
10(2) vs. 10(5), in conflict with experiment. This trend appears to be reversed under
geometry optimisation at MP2 / 6-31G(d), and therefore presumably an artefact of
the Hartree-Fock geometry, but convergence failure for N-methylene radical
structures has prevented inclusion of these results. It would appear likely that MP2
is overcompensating for deficiencies in the Hartree-Fock model, and higher level
correlation is required.
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The fact that substituting ROHF theory for UHF greatly increases the stability of N-
methylene radicals vs. 4- or 5- methylene radicals, in closer agreement with the
observed products, indicates that spin contamination may be significantly
contributing to the failure of Hartree-Fock theory to model these systems. The UHF
calculations show high spin contamination, and S**2 is generally within the range
0.8-1.2. UHF is known to greatly overestimate spin-polarisation, which is neglected
by ROHF theory, and hence UHF may be overestimating the stability of allylic
radicals of high spin polarisation. Significantly, the MP2 calculations show reduced
spin contamination, concurrent with destabilisation of 9(4) and 10(5).
In summary, PM3 gave the best qualitative predictions of the methods trialed.
Figure 6.1 Image and PM3 energies of 9(2), 9(4), 10(2), 10(5)
Figure 6.2 Wavefunction map of HOMO of 9(2), 9(4), 10(2), 10(5)
6.5 Experimental
Method A exemplified for 9:
2,4-Dimethyl-6-methoxy-3(2H)-pyridazinone (100 mg, 0.65 mmol) (9) was dissolved
in carbon tetrachloride (2 ml), and N-bromosuccinimide (115 mg, 1 equivalent)
added. The mixture was stirred in a round-bottomed flask fitted with a reflux
condenser for 30 minutes, under a high intensity light source (800W Lowel-Tota
lamp). A layer of floating succinimide indicated that the reaction had proceeded.
Method B exemplified for 2:
3-Chloro-4-methyl-6-methoxypyridazine (3.18 g, 20 mol) (2) was dissolved in
carbon tetrachloride (250 ml), and N-bromosuccinimide (3.60 g, 1 equivalent), and
benzoyl peroxide (25 mg) were added. The mixture was stirred at reflux until no
NBS remained and a layer of floating succinimide indicated completion of the
reaction.
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Both methods:
The reaction mixtures were allowed to cool, filtered to remove most of the
succinimide and evaporated rapidly under vacuum, except in the case of the N-
oxides, where products and starting material co-precipitated with succinimide.
Instead, N-oxides were purified by column chromatography.
Components of the crude reaction mixtures were identified by 1H n.m.r.
spectroscopy.
Isolation of all individual products was generally not attempted since some
components, particularly N-bromomethyl compounds, were found to be very
susceptible to hydrolysis. More stable components could be separated by column
chromatography on silica, eluting with ethyl acetate/toluene, dichloromethane, or
dichlormethane/hexane.
Ambiguities in the interpretation of the spectra of isomeric products were resolved
by a combination of derivatisation of the bromides (4, 11) or precursors (9, 10),
nuclear Overhauser effect (n.O.e.) 1H n.m.r. spectroscopy experiments (1, 4, 7, 8, 9,
10), and X-ray crystallography (11).
6.6 Calculation Details
Structures were initially modelled using Chem-X [9], which, together with RasMol
[10], was also used for post-calculation visualisation. Semi-empirical geometry
optimisations were performed using Mopac 6.0 [11]. The gradient norm (GNORM)
requirement was set at 0.01 throughout, and the SCF criterion (SCFCRT) was set at
10-6. Ab initio geometry optimisations were performed using Gaussian 92/DFT for
Windows, Gaussian 94/DFT for Windows, and Gaussian 94 [12]. Symmetry was
constrained to Cs for all ab initio calculations, other than 9(2) and 10(2), where a
slightly pyramidal N-CH2 (dihedral angles ~ 10°) induced a loss of symmetry with
6-31G(d) basis set. Minima up to HF / 6-31G(d) were checked with analytical
frequency calculations. Polarisation (d) functions were added to the 3-21G basis set
for chlorine atoms only. RHF and UHF theories were used for the calculation of
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singlet and doublet species respectively throughout, except where ROHF is
specified for doublets. The platforms used were an Intel Pentium 66 with 16 Mb
RAM and 800 Mb scratch space under Windows 3.1, an IBM RS/6000 with 24 Mb
RAM and 1.8 Gb scratch space under AIX 3.2, and a Silicon Graphics Power
Challenge with 8 R8000 processors under IRIX 6.2.
6.7 Conclusion
The selectivity of free-radical brominations of methyl 3-methoxy-pyridazine
derivatives via the Wohl-Zeigler reaction is confirmed to be related to the stability
of the free-radicals formed in the rate-limiting step.
Studying these intermediates is difficult experimentally, but is amenable to
theoretical calculations.
Semi-empirical calculations using the PM3 Hamiltonian generally give relative
energies which qualitatively reproduce the selectivities observed experimentally.
Thus, a rapid method for predicting the selectivity of these reactions has been
found. This technique has application to the syntheses of novel heterocyclic
neurotransmitter analogues.
Small to moderate basis set ab initio Hartree-Fock calculations do not reproduce
experimental trends reliably, particularly with respect to the pyridazinones studied.
Spin contamination is high for these systems. MP2 theory performs better, but
appears to over-correct HF deficiencies. Higher level calculations incorporating
large basis sets and further electron configuration interaction may be necessary for
quantitative results.
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Table 6.1. Summary of the experimental products of bromination
reactions
No Structure Method Products a Ratio (%) Radical
Intermediate
Reference
starting
material
-  
 
4 80 1(4) [14]
5 15 1(5)  
    
1 A
    
starting
material
22  
 
4 15 2(4) [14]
4,4 16   
c    
2 B b
    
starting
material
38  
 
5 36 3(5) [14]
5,5 26   
    
3 B b
    
starting
material
11  
 
4 10 4(4) [14]
5 79 4(5)  
    
4 A
    
starting
material
10  
 
4 60-70 5(4) [14]
4,4 10   
5 B
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starting
material
10  
 
5 - d 6(5) [14]
    
    
6 B
    
starting
material
12  
 
4 81 7(4) [13]
5 4-6 7(5)  
    
7 A
    
starting
material
10-15  
 
5
major (~
65%) e
8(5) [13]
7 - 8(7)  
    
8 A
    
starting
material
23  
 
2 21 9(2) [15]
4 38 9(4)  
2,4 10   
9 A
4,4 8   
starting
material
8-12  
 
2 48 e 10(2) [15]
5 8-10 10(5)  
2,2 6   
10 A
2,5 6   
starting
material
12  
 
2 5-8 11(2) [13]
4 65 11(4)  
5 4-6 11(5)  
11 A
polybromo 12-17   
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Notes:
a Reaction products as determined by 1H NMR; position of mono- or di- bromo
methyls
b (2) NBS consumed in 96 hours; (3) NBS consumed in 18 hours
c substantial (~ 45%) degradation products
d ring substitution, polymerization with heating
e unstable to air/moisture
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Table 6.2: Energies relative to singlet species (and heats of formation
or total energies)
Hf - Hf[RH] ( Hf[RH] ) MOPAC, Kcal/mol
E - E[RH] ( E[RH] ) Gaussian, Hartree
Reactant Product Method
  HF /
AM1
HF /
MNDO
HF /
PM3
HF / 3-
21G(d)
ROHF /
3-21G(d)
HF /
6-31G(d)
ROHF /
6-31G(d)
MP2/
6-31G(d)//
HF/
6-31G(d)
Best a
 HBr 0
(-10.50)
0 (3.64) 0 (5.31) 0
(-2560.62078)
0
(-2560.62078)
0
(-2570.46555)
0
(-2570.46555)
0
(-2570.58099)
0
(-2570.57462)
Br.  37.24 23.10 21.43 0.58016 0.58022 0.59910 0.60259 0.62516 0.61878
1  0 (2.40) 0
(-14.44)
0 (-1.44) 0
(-415.11051)
     
 1(4) 24.10 19.88 25.71 0.59637      
 1(5) 25.33 21.15 27.00 0.60131      
2  0 (4.34) 0
(-15.66)
0 (0.19) 0
(-870.06901)
     
 2(4) 25.39 21.25 26.36 0.60085      
3  0 (4.81) 0
(-15.31)
0 (1.44) 0
(-870.06918)
     
 3(5) 23.87 19.89 25.28 0.59571      
4  0 (-1.70) 0
(-19.26)
0 (-7.07) 0
(-908.89074)
     
 4(4) 24.68 20.39 27.27 0.59872      
 4(5) 23.93 19.52 25.49 0.59621      
5  0 (27.47) 0 (6.21) 0 (2.34) 0
(-487.61144)
     
 5(4) 17.51 12.14 25.39 0.57142      
6  0 (26.51) 0 (6.18) 0 (0.45) 0
(-487.61112)
     
 6(5) 22.52 15.11 28.85 0.58459      
7  0 (20.13) 0 (1.67) 0 (-6.40) 0
(-526.43421)
     
 7(4) 17.48 11.11 25.32 0.57204      
 7(5) 22.01 15.01 28.68 0.58507      
8  0 (25.94) 0 (-0.32) 0 (-0.62) 0
(-564.08960)
     
 8(5) 16.36 9.37 21.16 0.57181      
 8(7) 20.21 12.55 23.42 0.58180      
9  0
(-18.99)
0
(-45.37)
0
(-37.70)
0
(-526.54045)
0
(-526.54045)
0
(-529.49803)
0
(-529.49803)
0
(-531.06189)
0
(-530.87845)
 9(2) 25.23 24.77 25.83 0.62109 0.62879 0.62536 0.63115 0.65986 0.64285
 9(4) 20.79 17.75 22.32 0.59801 0.62423 0.60322 0.62663 0.66154 0.64526
10  0
(-18.99)
0
(-44.95)
0
(-37.00)
0
(-526.53879)
0
(-526.53879)
0
(-529.49644)
0
(-529.49644)
0
(-531.06018)
0
(-530.876750
 10(2) 25.59 24.81 25.92 0.62114 0.62875 0.62540 0.63112 0.66111 0.64412
 10(5) 24.84 20.37 25.83 0.60339 0.62532 0.60716 0.62751 0.66247 0.64624
11  0
(-24.61)
0
(-48.47)
0
(-44.38)
0
(-565.36271)
     
 11(2) 24.32 24.82 25.91 0.62101      
 11(4) 19.93 18.01 20.82 0.59654      
 11(5) 22.61 19.05 24.66 0.60155      
a Best energy = ZPE(HF / 6-31G(d)) + E(MP2 / 6-31G(d) // HF / 6-31G(d))
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Table 6.3: Heats of Reaction (Kcal/mol )
E(R.) + E(HBr) - E(RH) - E(Br.)
Reactant Product Method
  HF /
AM1
HF /
MNDO
HF /
PM3
HF /
3-21G
(d)
ROHF /
3-21G(d)
HF /
6-31G(d)
ROHF /
6-31G(d)
MP2 /
6-31G(d)
// HF /
6-31G(d)
Best a
1 1(4) -13.14 -3.22 4.28 10.17      
 1(5) -11.91 -1.95 5.57 13.27      
2 2(4) -11.85 -1.85 4.93 12.98      
3 3(5) -13.37 -3.21 3.85 9.76      
4 4(4) -12.56 -2.71 5.85 11.64      
 4(5) -13.31 -3.58 4.06 10.07      
5 5(4) -19.73 -10.96 3.96 -5.48      
6 6(5) -14.73 -7.99 7.42 2.77      
7 7(4) -19.77 -11.99 3.89 -5.1      
 7(5) -15.23 -8.09 7.25 3.08      
8 8(5) -20.89 -13.73 -0.27 -5.24      
 8(7) -17.03 -10.55 1.99 1.03      
9 9(2) -12.01 1.67 4.41 25.68 30.48 16.55 18.42 21.77 15.1
 9(4) -16.45 -5.35 0.89 11.2 27.61 2.59 15.09 22.83 16.62
10 10(2) -11.65 1.71 4.49 25.72 30.45 16.6 18.44 22.56 15.9
 10(5) -12.4 -2.73 4.4 14.58 28.3 5.06 15.64 23.41 17.23
11 11(2) -12.92 1.73 4.48 25.63      
 11(4) -17.31 -5.09 -0.61 10.28      
 11(5) -14.63 -4.05 3.23 13.42      
a Best energy = ZPE(HF / 6-31G(d)) + E(MP2 / 6-31G(d) // HF / 6-31G(d))
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Figure 6.1 Image and PM3 energies of 9(2), 9(4), 10(2), 10(5)
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Figure 6.2 Wavefunction map of HOMO of 9(2), 9(4), 10(2), 10(5)
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Chapter 6. pdb files of structures, optimised at HF / PM3
1.pdb
3-methoxy-4,5-dimethyl-pyridazine
1(4).pdb
4-methylene radical
1(5).pdb
5-methylene radical
2.pdb
3-chloro-4-methyl-6-methoxy-pyridazine
2(4).pdb
4-methylene radical
3.pdb
3-chloro-5-methyl-6-methoxy-pyridazine
3(5).pdb
5-methylene radical
4.pdb
3-chloro-4,5-dimethyl-6-methoxy-pyridazine
4(4).pdb
4-methylene radical
4(5).pdb
5-methylene radical
5.pdb
3-methoxy-4-methyl-pyridazine 1-oxide
5(4).pdb
4-methylene radical
6.pdb
3-methoxy-5-methyl-pyridazine 1-oxide
6(5).pdb
5-methylene radical
7.pdb
3-methoxy-4,5-dimethyl-pyridazine 1-oxide
7(4).pdb
4-methylene radical
7(5).pdb
5-methylene radical
8.pdb
3-methoxy-6,7-dihydro-5H-cyclopenta[d]pyridizine 1-oxide
8(5).pdb
5-methylene radical
8(7).pdb
7-methylene radical
9.pdb
2,4-dimethyl-6-methoxy-3(2H)-pyridazinone
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9(2).pdb
2-methylene radical
9(4).pdb
4-methylene radical
10.pdb
2,5-dimethyl-6-methoxy-3(2H)-pyridazinone
10(2).pdb
2-methylene radical
10(5).pdb
5-methylene radical
11.pdb
2,4,5-trimethyl-6-methoxy-3(2H)-pyridazinone
11(2).pdb
2-methylene radical
11(4).pdb
4-methylene radical
11(5).pdb
5-methylene radical
191
7. Pharmacological screening in vitro
Abstract
The ten pyridazine-3,6-dione amino acid analogues whose design was proposed in Chapter 4
and synthesis described in Chapter 5 were screened for activity: three analogues 1,2,3 of
muscimol 4, three analogues 5,6,7 of THIP 8, and four analogues 9,10, 11, 12 of AMPA 13 and
HIBO 14. The muscimol and THIP analogues were screened for GABAA activity using a guinea-
pig ileum preparation, and found to be inactive. Additionally, two compounds 1 and 5 were
tested for GABAC activity at receptors expressed in Xenopus oocytes and found to be inactive.
The glutamate analogues were tested for NMDA and AMPA activity on rat cortical wedge
preparation. Compound 9 was found to be a weak non-specific EAA receptor agonist.
Compound 10, although weaker still, was more specific for the AMPA receptor.
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7.1 GABAA activity: Guinea-pig isolated ileum preparation
7.1.1 Results
The guinea-pig isolated ileum preparation is a standard assay for activity at the
GABAA class of GABA receptors [1,2,3,4], a receptor at which both muscimol 4 and
THIP 8 are known to have high potency as agonists [5]
Compounds 1,2,3,5,6,7 were tested on this assay, as described in Section 7.1.3,
following the method described by Ong and Kerr [4] and Apostopoulos [6].
No evidence for either agonist activity of these compounds was found at a bath
concentration of 1000 µM, ten times the concentration of GABA producing a
maximal tissue response. No evidence of antagonist activity was found, although
weak antagonist activity cannot strictly be ruled out on the basis of the experiments
conducted.
Traces:
• Trace 7.1 1 followed by GABA
• Trace 7.2 2 followed by GABA
• Trace 7.3 3 followed by GABA
• Trace 7.4 5 followed by GABA
• Trace 7.5 6 followed by GABA
• Trace 7.6 7 followed by GABA
• Trace 7.7 GABA followed by TACA
7.1.2 Discussion
It is concluded that these pyridazinedione analogues of muscimol 4 and THIP 8 are
inactive at GABAA receptors. The pyridazine-3,6-dione base does not mimic
carboxylate at this receptor in the way that the 3-isoxazolol base does. Given that
little is known about the precise environment of the GABAA receptor, it is difficult
to pin-point the reason for the loss of activity on exchange of a ring oxygen
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heteroatom for a lactam. One possibility is that the pyridazine-3,6-dione is simply
too large to be accommodated in the receptor. Another is that the position of the
extra carbonyl group is disturbing the electronic complementarity of the ring for the
receptor.
This lack of activity may be considered in the light of previous attempts to find
heterocyclic carboxylate bioisosteres other than 3-isoxazoles with activity at this
receptor. Close analogues of muscimol 4, such as dihydromuscimol 15 and
thiomuscimol 16 retain moderate to high agonist potency [7]. More substantial
changes, e.g. replacing ring oxygen with nitrogen (azamuscimol 17) or transposing
oxygen and nitrogen (isomuscimol 18) result in a considerable loss of potency [7].
Departing further from the isoxazole structure, is quisqualamine 19, which is
closely related to the potent EAA agonist quisqualate 20, and may be considered an
analogue of the weakly active homomuscimol 21, as well as of THIP 8. It is
described in the Tocris Catalogue (http://www.tocris.com) as a weak GABAA
agonist, based on the work of Evans et al. [8], and Herrero [9]. Quisqualamine is
derived from the strongly acidic five-membered heterocycle, 2-methyl-3,5-dioxo-
1,2,4-oxadiazolidine, which has structural and electronic similarity to 3-isoxazolol
(see Chapter 8). It is also, like the pyridazinediones, a doubly oxygen-substituted
heterocycle. A hydantoin analogue 22 of quisqualamine is inactive [7], suggesting
receptor sensitivity to small changes in structure.
Another muscimol analogue with reported GABAergic activity is kojic amine 23,
derived from the six-membered heterocycle, 3-hydroxy-4H-pyran-4-one. [1,10]. This
structure is of particular interest, because it is the only known active 6-membered
hydroxy-heterocycle, and like the pyridazine-3,6-diones and quisqualamine 19, is
doubly oxygen substituted. Little information is available about this compound; it is
unknown whether its activity is sensitive to bicuculine antagonism (GABAA).
Atkinson et al. [10] report a range of modifications, all leading to a loss of activity:
homologisation to the aminoethyl derivative 24, substitution of nitrogen for the ring
oxygen forming pyridone derivatives 25, 26, and shifting the position of the
hydroxyl substituent ortho- to the aminomethyl chain 27.
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These examples serve to underscore the very particular and still poorly understood
requirements for carboxylate bioisosterism at the GABAA receptor. There is
considerable scope for further investigation in this area, including the incorporation
of ortho- and meta- substituted dioxo-pyridazines, whose electronic and tautomeric
properties were described in detail in Chapters 2 and 3. In particular, the fact that
kojic amine 23 appears to show GABAergic activity suggests that the GABAA
receptor may accommodate six-membered dioxo-heterocycles, and that such
structures are worthy of further investigation.
7.1.3 Experimental
Guinea pig isolated ileum preparation, from the descriptions of Ong and Kerr [4]
and Apostopoulos [6]:
Three female guinea-pigs weighing 500 g, 570 g, and 660 g were killed by cervical
dislocation. Segments of distal ileum approximately 3 cm in length, taken at least 10
cm from the ileo-caecal valve were removed, emptied of their contents using a
syringe, and allowed to relax in Krebs solution for at least two hours at room
temperature, or refrigerated overnight. When ready, the segments were mounted
vertically in a 20 mL organ bath containing modified Krebs-bicarbonate solution of
composition (mM): Na+ 151.0, K+ 4.6, Mg2+ 0.6, Ca2+ 2.5, Cl- 134.9, HCO3
- 24.9, H2PO4
-
1.3, SO4
2- 0.6, glucose 7.7, (pH 7.4 at 35°C). The Krebs solution was continuously
gassed with a mixture of 95% O2 and 5% CO2.
The effects of drug treatments were examined on resting tissue. Isotonic
contractions of the longitudinal muscle were recorded using a Curken polygraph
recorder. Tissues were placed under a resting tension of 1g and left to equilibrate
for 30 - 60 min before drugs were applied. A standard solution of GABA, 2 mg/mL
was used to test the tissue, a 100 µL injection corresponding to a bath concentration
of 100 µM, and producing a rapid spontaneous contraction, followed by relaxation.
The potent GABAA agonist, trans-4-aminocrotonic acid (TACA) 20 mg/mL, 100 µL,
1000 µM bath concentration, was tested for comparison.
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Tissue response to known agonists having been established, 1,2,3 and 5,6,7 were
tested at least 3 times on separate preparations in the following manner: 100 µL of a
200 mM solution was injected, for a bath concentration of 1000 µM. After 3 minutes,
100 µM GABA solution was introduced, the response recorded, and the preparation
washed twice and allowed to re-equilibrate for at least 10 minutes. In this fashion,
test compounds were rapidly screened for agonist activity, and also for any
indication of potent antagonist activity.
7.2 EAA activity: Cortical wedge preparation
7.2.1 Results
A standard assay for activity at NMDA and AMPA classes of EAA receptors is the
cortical wedge preparation [11,12].
Compounds 9,10,11,12 were tested on this assay, as described in Section 7.2.3
Compound 12 showed no agonist response at concentrations up to 1000 µM, nor
inhibition of 10 µM NMDA or 5 µM AMPA responses at 500 µM, and is concluded
to be without activity.
Compound 11 caused a slight attenuation in spontaneous activity of the wedge at
1000 µM, but this effect on spontaneous actibity was sufficiently weak as to be
unquantifiable. No antagonist activity was observed, and the substance is
presumed to be without significant activity.
Compound 9 was found to be a weak non-specific EAA agonist. At 500 µM, its
activity was almost completely blocked by 10 µM CPP, and attenuated by 5 µM
CNQX, potent and selective antagonists for NMDA and AMPA respectively. An
EC50 value of 481 µM was determined for 9. It was not found to decrease tissue
response to AMPA or NMDA, except in as much as it appeared to be cumulatively
toxic to the tissue at levels above 500 µM. Its low activity did not allow the
maximum response to be determined, but there is no clear evidence for antagonist
activity based on these experiments.
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Compound 10 was found also to be a very weak agonist at EAA receptors, with an
EC50 greater than 1000 µM. At these concentrations, lack of solubility, and toxicity to
the tissue hampered investigation, as previously found with poorly active
pyridazinones [13]. Its response showed little or no change with CPP (10 µM), but
was attenuated by CNQX (5 µM), indicating greater activity at AMPA receptors
compared with NMDA receptors.
Neither 9 nor 10 were capable, at the highest doses tested (1000 µM), of producing a
maximal depolarisation, compared with high doses of NMDA or AMPA.
Graph 7.1. log[Dose] - response curves for compounds 9 and 10, compared with AMPA and
NMDA (including data from Vaccarella [14])
Traces:
• Trace 7.8 9
• Trace 7.9 CPP plus 9
• Trace 7.10 CNQX plus 9
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• Trace 7.11 10
• Trace 7.12 CPP plus 10
• Trace 7.13 CNQX plus 10
7.2.2 Discussion
The AMPA receptor structure-activity implications of the observed lack of activity
of 11 and 12, and the poor activity of 9 and 10, are discussed in detail in Section
8.4.3, in the context of modelling a range of AMPA agonists. Their activity is
compared with a number of other alanino-pyridazinones in Table 8.1.
The NMDA activity of 9 is worthy of note. This compound is capable of existing in
two tautomeric forms in solution; which of the two predominates is not possible at
present to determine. A number of other alanino-heterocycle EAA agonists having
mixed AMPA / NMDA activity are known (Table 8.1), quisqualate 20 being one
example. So it may simply be the case that only one of the tautomeric forms of 9 is
active, and this form is of non-specific activity. On the other hand, it is possible that
one tautomer is largely responsible for the NMDA activity, and the other is
responsible for AMPA activity. This hypothesis is supported by the observation that
the N-methylated 10, with fixed position of carboxylate-like function, shows a loss
of NMDA activity. It should also be noted that alanino-hydroxy heterocycles are
known to have varying specificity depending on stereochemistry, and the current
work has considered racemic mixtures of pyridazinediones only. The fact that the
other isomer, 11, is inactive at both AMPA and NMDA, is presumed to be a result
of an unfavourable hydrophobic interaction between the N-methyl group and these
receptors.
The lack of activity of 12 can be attributed to the unfavourable orientation of the
carboxylate-like region with respect to the alanine substituent.
• Chart 7.2 AMPA (13), AMAA (14), and tested glutamate analogues
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7.2.3 Experimental
Rat cortical wedge preparation, following the methods described by Harrison and
Simmonds [11], Allan et al. [12] and Apostopoulos [6]:
Slices of rat neocortex and corpus callosum were obtained from Sprague-Dawley
rats weighing 200 - 300 g, as previously described [11,12]. A minimum of three
preparations from each of three separate animals was used to screen for activity.
Cerebral wedges were prepared and placed between layers of absorbent fibre
supported on an inclined block at room temperature, superfused with a
magnesium-free Krebs solution oxygenated with 95% oxygen and 5% carbon
dioxide, at a rate of 1 mL / min. DC potentials between the cingulate cortex and
corpus callosum were monitored by Ag / AgCl electrodes via agar / saline bridges
and a high impedance DC amplifier and were displayed on a chart recorder. All
compounds tested were made up in magnesium-free Krebs buffer. Testing for
agonist activity involved application to the cortex for a period of one minute.
Testing for antagonist activity involved application to the cortex for four minutes,
followed by one minute of a solution containing the test compound plus a standard
agonist (10 µM NMDA). Testing for selectivity involved application of an
antagonist compound (10 µM CPP for NMDA receptor, 5 µM CNQX for AMPA
receptor) to the cortex for four minutes, followed by application for one minute of a
solution containing the test compound plus the antagonist. With this arrangement,
recording cortex against corpus callosum, activity was measured as a depolarising
response (an upward deflection from the baseline in which amplitude was
measured in mV). The attenuation of repetitive spontaneous discharge of the tissue
was also noted as evidence of agonist activity.
7.3 GABAC activity
Compounds 1 and 5 were tested by Dr Mary Collins on the GABAC ( 1) receptor
[15] expressed in Xenopus oocytes as part of a routine screening program at this
receptor. Whereas muscimol 4 and THIP 8 are active at GABAC, the compounds
showed no activity and no further investigation was warranted.
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7.4 Conclusion
The observed lack of activity at GABAA receptors of 1,2,3 and 5,6,7 has ended the
pursuit of pyridazine-3,6-diones as GABA analogues. Further attempts to find
novel heterocyclic derivatives binding at GABAA receptors would better be directed
towards 6-membered structures with ortho- or meta- dioxo substitution, and
hydroxy- or dioxo- 5-membered structures. The increasing range of heterocycles
known to yield active AMPA analogues (see Chapter 8) provides several untested
leads in this regard.
The lack of activity of 11,12 and poor activity of 9,10 at EAA receptors has
contributed to abandoning the evaluation of pyridazine-3,6-diones as glutamate
analogues. However, this study has taken place within the context of the evaluation
of a range of pyridazinone-derived structures for EAA activity, and has assisted in
leading research towards AMPA analogues with higher potencies. This research is
examined in detail in the next chapter.
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8. Heterocycles as bioisosteres for the -carboxylate
moiety of glutamate in AMPA receptor agonists: A
review and theoretical study.
Abstract
(S)-2-Amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) is the prototypical
selective agonist for the AMPA subtype of excitatory amino acid (glutamate) receptors. Several
3-hydroxy-isoxazole analogues are known to have activity at this receptor, as do a number of
other alanine-substituted heterocyclic phenols, the acidic heterocycles being bioisosteres for the
-carboxylate moiety of glutamate. The increasingly diverse range of known AMPA agonists is
reviewed, including a number of novel pyridazine-based analogues. By removal of a common
glycine unit, the parent heterocycles 3-hydroxy-4,5-dimethylisoxazole, 3-hydroxy-4,5-
dimethylisothiazole, 4-methyl-5-isoxazolone, 3-hydroxy-4-methyl-1,2,5-thiadiazole, 2-methyl-
3,5-dioxo-1,2,4-oxadiazolidine, 1-methyl uracil, 6-aza-1-methyl uracil, and 3-hydroxy-4-
methylpyridazine 1-oxide are modelled as representative of the known -carboxylate
bioisosteres. In addition, heterocyclic fragments of inactive hydantoin and 3,5-dioxotriazole
quisqualate analogues, and pyridazinone fragments with derivatives of varying potency are
considered. These structures and their conjugate bases are subjected to high level ab initio
calculations up to G2(MP2) theory, and semi-empirical aqueous phase calculations using the
AM1-SM2 model. Their tautomerism and aqueous pKa behaviour are studied in detail, and
compared with experimental data. Molecular geometries and electrostatic potential-derived
charge distributions are presented. Electrostatic properties at the Van der Waals surface are
compared. Calculated properties are discussed with respect to structural requirements for
AMPA receptor activity. Tridentate models of AMPA receptor binding are presented.
"Heterocycles as bioisosteres for the -carboxylate moiety of glutamate in AMPA receptor
agonists: A review and theoretical study" JR Greenwood, G Vaccarella, HR Capper, RD Allan,
and GAR Johnston. Internet Journal of Chemistry 1, 38 (1998)
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8.1. Introduction
8.1.1 Carboxylate bioisosterism and drug design
The concept and study of bioisosterism is a central theme in drug design and
development [1]. It has been defined as "groups of molecules which have chemical
and physical similarities producing broadly similar biological properties" [2]. Both
major reviews of the subject [1,2] discuss bioisosteres for carboxylic acids, and in
particular 3-isoxazolols (26) as bioisosteres for the -carboxylate moiety of the
inhibitory neurotransmitter - aminobutyric acid (GABA), the latter work also
drawing attention to the potential carboxylate bioisosterism of 3,5-dioxo-1,2,4-
oxadiazolidines (30). It is now known that both of these heterocycles, when
appropriately substituted, among several others, display carboxylate bioisosterism
at Excitatory Amino Acid (EAA) receptors [3,4]. The current work examines
heterocyclic carboxylate bioisosterism at the AMPA subclass of EAA receptors. In
particular it examines the agonist pharmacophore. The range of structures known
to possess carboxylate-like properties at this receptor, as evidenced by their binding
constants and potency as agonists is reviewed and expanded. Theoretical
calculations on these structures are presented with a view to increasing the
understanding of structure-activity relationships and aiding the design of novel
ligands.
8.1.2 EAA and AMPA receptors
Glutamate is the major excitatory neurotransmitter in the brain [3]. EAA receptors,
which bind (S)-glutamate, consist of a number of subtypes. Three main ionotropic
subtypes have been classified on the basis of neurochemistry, pharmacology, and
molecular biology: NMDA, AMPA, and kainate receptors. Much effort has been
directed towards the production of specific ligands for these receptors, both as
research tools, and as potential leads to novel therapeutic compounds for use in the
treatment of disorders in which EAA receptors are believed to play a role, for
example excitotoxicity caused by cerebral ischaemia, and neurodegenerative
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conditions such as Huntington's Chorea, AIDS-related dementia, and
schizophrenia. [4,5,6]
AMPA receptors are named after the highly selective potent agonist (S)-2-amino-3-
(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (1a) (Chart 8.1). This compound is
a conformationally restricted analogue of glutamate, in which the acidic 3-
isoxazolol heterocycle behaves as a bioisostere for the -carboxylate moiety. An
extensive and expanding series of 3-isoxazolol derivatives have subsequently been
found to have agonist or antagonist activity at AMPA receptors (Table 8.1) [4].
Structure-activity studies have revealed that modifications of the -carboxylate
group of AMPA substantially reduces or abolishes activity at these receptors [3].
Likewise, little modification of the amino group is tolerated, other than
incorporation into a bicyclic system. By contrast, several analogues with various
heterocycle replacements for the 3-isoxazolol of AMPA retain activity. Such
derivatives are a fertile area in the search for receptor characterisation tools and
novel therapeutics.
8.1.3 Alanino heterocycles active as agonists at AMPA receptors
AMPA agonists of this type are alanine- and oxygen- substituted acidic
heterocycles, with or without further ring substitution or other modification. The
following classes are representative of the known spectrum of heterocycles from
which potent AMPA receptor ligands may be formed: AMPA and derivatives (1),
and homoibotenic acid (HIBO) and derivatives (2), from 3-isoxazolol; isothiazole
analogues of AMPA and HIBO (3,4 respectively), TAN-950A and its derivatives
from 5-isoxazolol (5); LY-262466 from 3-hydroxy-1,2,5-thiadiazole (6); quisqualic
acid from 3,5-dioxo-1,2,4-oxadiazolidine (7); willardiine and derivatives from uracil
(10); 6-aza willardiine and derivatives from 6-aza uracil (14, 15), and 2-amino-3-(3-
hydroxypyridazin-1-oxide-4-yl)propionic acid and other derivatives of 3-
hydroxypyridazine (9). The structures of these compounds are presented in Charts
8.1 along with closely related less active or inactive heterocycles in Chart 8.2. Their
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activities are summarised in Table 8.1. Where possible, both binding data and
electrophysiology have been included for comparison.
The lack of a single standard assay for AMPA activity across all tested structures
hampers direct comparison, but qualitative trends may be perceived by comparing
values obtained from different preparations, electrophysiology and binding assays.
8.1.4 The theoretical study of heterocycles related to AMPA receptors
With the fairly recent proliferation of structures tested as AMPA receptor ligands, it
is of interest to make a uniform and detailed study of the various heterocycles
which are now known to act as -carboxylate bioisosteres at this receptor. In
particular, it is hoped that accurate geometrical and electrostatic data for known
ligands, previously unavailable but now accessible via quantum chemical
simulations, will benefit future ligand design, and lay the groundwork for
modelling such as QSAR, 3D-QSAR (CoMFA) and molecular dynamics simulations.
The theoretical study of heterocycles has long been a challenge for quantum
chemistry, since relatively expensive calculations involving large basis sets and
thorough treatment of electron correlation are required in order to consistently treat
aromatic and semi-aromatic ring atoms of unusual or variable atom hybridisation,
and capable of complex tautomerism [7]. The treatment of aromatic anions is even
more problematic. The study of heterocyclic tautomerism has been historically been
pursued by a variety of experimental techniques on account of the major
importance of heterocycles in biological systems, as well as being a rich chemical
discipline in its own right [8]. This chapter employs ab initio gas phase molecular
orbital methods in conjunction with semi-empirical aqueous phase calculations to
characterise the range of heterocycles known to produce active AMPA receptor
agonists. The study of tautomeric preferences, both gas and aqueous phase
behaviour, pKa, and electronic structure, are considered useful for understanding
these compounds and their activity.
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8.2. Methods and results
8.2.1 Choice of model compounds
In order to simplify computation, and facilitate comparison of different -
carboxylate bioisosteres over the range of known AMPA agonists, a representative
simplest set of heterocyclic structures was chosen. Removal of the -amino acid
function of prototypical ligands, that is a glycine unit, being common to all
structures (1–25), leaves a series of methyl- substituted heterocycles forming such a
set (26–38, neglecting some duplicate heterocycles differing only by a methyl
group). This approach was originally adopted for this kind of system by Jackson et
al. [9], to simplify theoretical comparisons between quisqualate analogues (7, 8, 9),
and it is a reasonable first assumption that the removal of the glycine unit has only
modest impact on the properties of the heterocyclic fragment. A similar approach
(glycine or alanine removal) was recently adopted by Frydenvang et al. in their
stimulating ab initio and X-ray crystallography study of 3-isoxazolol and 3-
isothiazolol as carboxylate bioisosteres [10].
It is well established from pKa data that at physiological pH, glutamate is tri-ionised
[11]. The heterocyclic analogues under consideration here also appear to be
predominantely tri-ionised. It cannot be said for certain that the anionic base is the
heterocyclic form interacting with the AMPA receptor, since localised effects within
the receptor such as desolvation in a low dielectric environment are largely
unknown and a proton might be transferred to the ligand on binding. On the other
hand, the variety of strong tautomeric preferences of the heterocycles under
consideration would suggest that proton transfer at a particular position to an anion
would be favourable for some structures but not for others.
Therefore, it is of particular interest to model the anionic conjugate bases, present in
solution. It is also of interest to model the tautomerism and pKa behaviour of the
neutral conjugate acids. Regardless of the form involved in binding and activation,
it is likely that transport across membranes, and hence to some extent in vivo
activity of these amino acids depends on the neutral forms [12]. Frydenvang et al.
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[10] emphasise the importance of the interaction between the anion and the
receptor, and hence the study of pKa.
Thus, the base of 4,5-dimethyl-3-isoxazolol ( 26-) is a model compound for both
AMPA (1a) and its derivatives, and 4-methyl homoibotenic acid (2b) and its
derivatives. The base of 4,5-dimethyl-3-isothiazolol (27-) is used as a model for
isothiazole-based ligands (3– 4). 4-Methyl-5-isoxazolol base (28-) represents the
known 5-isoxazolol ligands (5), 3-hydroxy-4-methyl-1,2,5-thiadiazole base ( 29-)
represents LY-262466 (6), 2-methyl-3,5-dioxo-1,2,4-oxadiazolidine base ( 30-)
represents quisqualate (7), 1-methyl uracil base (31-) represents the willardiine
series (10,11–13), 6-aza-1-methyl uracil base (32-) represents the aza willardiines
(14,15) and 3-hydroxy-4- methyl-pyridazine 1-oxide base (33- ) represents newly
discovered ligands derived from this structure (16–17,18). In addition, we have
examined a number of less active heterocyclic systems tested at AMPA receptors:
the bases of 2-methyl-3,5-dioxotriazole (34a- ) and 1-methyl hydantoin (35a- )
representing the apparently inactive quisqualate analogues (8–9), 2,4,5-trimethyl- 6-
hydroxy-pyridazine-3(2H)-one base ( 36-) representing a series of weakly active
analogues based on pyridazine-3,6-dione (21–23), 6-hydroxy-7-methyltetrazolo[1,5-
b]pyridazine base (37-) for alanino heterocycles derived from this ring system
(19–20), and 4,5-dimethylpyridazin-3(2H)-one base (38-) representing the alanino
pyridazin-3(2H)-ones (24–25). These thirteen anionic structures are presented in
Chart 8.3.
Well established [7,13,14,15,16] theoretical techniques were used to model these
structures as follows:
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8.2.2 Structure determination
Gas-phase geometries were determined by optimisation at MP2 / 6-31G(d,p) ab
initio theory. The structures are illustrated in Charts 8.3 and 8.4, and have
geometries as follows (.pdb format):
26- 26a 26b  
27- 27a 27b  
28- 28a 28b 28c
29- 29a 29b 29c
30- 30a 30b 30c
31- 31a 31b 31c
32- 32a 32b 32c
33- 33a 33b 33c
34a- 34b-   
35a- 35b-   
36- 36a 36b  
37- 37a 37b  
38- 38a 38b  
8.2.3 Gas phase thermochemistry and tautomerism
Optimisation and frequency calculations were performed at RHF / 6-31G(d), to
calculate zero point energy and thermochemical parameters at 298.15 K, using a
frequency scaling factor of 0.8929.
Single point energies were calculated at MP2 / 6-311+G(3df,2p) // MP2 / 6-
31G(d,p), a large basis set, including diffuse functions for improved treatment of
anions. The combination of these results with thermochemistry calculations for
systems 26–33 are presented in Table 8.2a. Relative energies of tautomers of systems
34–38 are discussed in Section 8.4.1.9.
Single point energies were calculated at QCISD(T) / 6-311G(d,p) // MP2 / 6-
31G(d,p) for anions 26- to 33-, as well as neutral tautomers of 27, 28, 29, 31, 32 and
33. The energies at 0 K and free energies at 298.15 K according to G2(MP2) theory
[14] for 27, 28, 29, 31, 32 and 33 calculated from these results are presented in Table
8.2b.
217
Due to the expense of QCISD(T) calculations on relatively large molecules in C1
symmetry, G2 theory energies were calculated using a double-  rather than triple-
 reduced basis set, i.e. QCISD(T) / 6-31G(d,p) // MP2 / 6-31G(d,p) for some
tautomers of 26 and 30. This theory is intermediate in level between G2(MP2)
theory [14], and the G2(MP2, SVP) theory of Curtiss et al. [17]. The higher-level
correction energy (HLC) for this reduced basis set has not been published, and so
while 26 and 30 may be compared, having equal numbers of alpha and beta valence
electrons, direct comparison with the other systems can not be made from the
results presented in Table 8.2c.
8.2.4 Point charges and dipoles
Gas phase point charges and dipoles derived from the molecular electrostatic
potential were calculated using the Merz-Kollman-Singh scheme [18,19]. These
results, as well as molecular geometries, are depicted for anions 26- to 38- in Figures
8.1.26 – 8.1.38.
8.2.5 Aqueous phase modelling and tautomerism
The AM1-SM2 theory of Cramer and Truhlar [20] was used to predict free energies
of solvation for systems 26–33. Whereas gas phase geometries are considered
sufficiently accurate for aqueous phase calculations on neutral species, and indeed
likely to yield more accurate results for unusual systems such as these due to poor
AM1 geometries, the same is not necessarily true of ionic species [16,21].
Accordingly, the free energies of solvation of neutral species were calculated as
single point energy differences between AM1 and AM1-SM2 theory using MP2 /6-
31G(d,p) optimised geometries, whereas free energies of solvation for anions were
calculated using semi-empirical geometry optimisation. These results are
summarised in Tables 8.2a – 8.2c.
AM1-SM2 theory was used to generate electrostatic potential contour plots in the
heterocyclic ring planes, and electrostatic potential maps at the Van der Waals
surface of anions 26- to 38-, and these results are presented in Figures 8.2.26 – 8.2.38.
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Electrostatic potential contour plots of 26- to 33- calculated by this method and
superimposed are depicted in Figure 8.3.
Aqueous phase tautomeric behaviour of 26 to 38 is summarised in Chart 8.4, as
determined from theory and some experiments as discussed in Section 8.4.1.
8.2.6 pKa estimation
Table 8.3 reports free energies of solvation and pKa estimation for systems 26–33.
Relative pKa values, calculated entirely from theory, and corrected for 1-methyl-
uracil = 9.75, are compared with an empirical pKa determination technique [22,23],
and experimental literature values for the systems under investigation, or their near
analogues. Comparisons of pKa predictions are shown in Graphs 8.1–8.3. For those
structures for which the pKa is unknown experimentally, the next nearest structure's
pKa is used.
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8.3. Key to tables, graphs, charts and figures
Table 8.1 Summary of AMPA analogue activities
Table 8.2 Energies and tautomerism of model heterocycles
Table 8.3 Solvation energies, pKa predictions and literature values
Graph 8.1 Experimental pKas vs. ab initio predictions
Graph 8.2 Experimental pKas vs. empirical predictions
Graph 8.3 pKas: ab initio vs. empirical predictions
Chart 8.1 Structures with moderate to high potency
Chart 8.2 Structures with reduced or abolished potency
Chart 8.3 Model des-glycino heterocyclic conjugate base anions
Chart 8.4 Tautomerism of model heterocycles
Chart 8.5 The tridentate binding hypothesis of heterocycles at the AMPA
receptor, illustrated for AMPA (1a) and two possible models of
tridentate binding of bromo-HIBO (2c) and bromo- willardiine
(10d).
Chart 8.6 A plausible tridentate binding of bromo- willardiine (10d) to the
bidentate hydrogen bond donor arginine and another hydrogen
bond donor. Two possible modes of binding of AMPA (1a) to the
same residues, with and without the mediation of a water
molecule.
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Figure 8.1.26
Figure 8.1.27
Figure 8.1.28
Figure 8.1.29
Figure 8.1.30
Figure 8.1.31
Figure 8.1.32
Figure 8.1.33
Figure 8.1.34
Figure 8.1.35
Figure 8.1.36
Figure 8.1.37
Figure 8.1.38
Conjugate base anions of model acidic heterocycles (26- to 38-) are
presented as CPK models, with MP2/6-31G(d,p) optimised
geometry. From electrostatic properties calculated at MP2/6-
311+G(3df,2p)//MP2/6-31G(d,p), point charges assigned using
the Merz-Kollman-Singh method [18,19] are indicated in yellow.
The dipole and its magnitude calculated at this level of theory are
indicated as a yellow arrow, displaced by 1.5 Å in the z- direction
for visibility. The most favoured position of protonation is
indicated by H+, and the magnitude of the point charge on the
proton calculated by the above method for the neutral species
indicated. The methyl group(s) at which glycine substitution
results in an AMPA analogue is indicated by white GLY-, there
being two such positions in the case of the isoxazol-3ol 26- and
isothiazol-3ol 27-. Thio 4-methyl-homoibotenic acid is apparently
unknown, although both 4-unsubstituted and 4-bromo
derivatives are tested, hence 27- is taken to model both series 3
and 4, as 26- models both 1 and 2 in the present work. Similarly,
31- represents uracils 11–13 as well as 10. 32- represents aza-
uracils 14 and 15. 33- may be considered as representative not
only of 16a, but the analogues 16b, 17 and 18, allowing for
varying position of methyl substitution. Likewise 36-, being
desglycino 22b, may be taken to represent the ring structures of
series 21–23, 37- to represent 19 and 20, and 38- to represent 24
and 25.
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Figure 8.2.26
Figure 8.2.27
Figure 8.2.28
Figure 8.2.29
Figure 8.2.30
Figure 8.2.31
Figure 8.2.32
Figure 8.2.33
Figure 8.2.34
Figure 8.2.35
Figure 8.2.36
Figure 8.2.37
Figure 8.2.38
Conjugate base anions of model acidic heterocycles (26- to 38-),
presented as wire-frame models, with MP2/6-31G(d,p) optimised
geometry. The Van der Waals surface is depicted, with
electrostatic potential calculated using AM1-SM2 mapped onto
the surface in colour. The electrostatic potential in the plane of the
ring (or near plane for puckered 30-) is shown by colour contour
plot.
Figure 8.3 Conjugate base anions (26- to 33-) are overlayed such that regions
of similar electrostatic potential coincide. Electrostatic potentials
in the ring planes are depicted by coloured contour plot. The
orientation of 26- and 27- is chosen to correspond to AMPA (1a)
and thio-AMPA (3a) with respect to overlap of side chain.
Figure 8.4 1-methyl uracil anion ( 31-), methyl guanidinium cation (arginine
fragment), and methanol (serine fragment), optimised as a
complex, using AM1-SM2 theory, as a model of direct residue
tridentate binding of willardiine to the AMPA receptor.
Electrostatic potential is mapped on to a dot representation of the
Van der Waals surface.
Figure 8.5 4,5-dimethyl-3-isoxazolol anion (26-), methyl-guanidinium cation,
water, and methanol, optimised as a complex, using AM1-SM2
theory, as model of water-mediated tridentate binding of AMPA
(1a) or 4-methyl-HIBO (2b)
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8.4. Discussion
8.4.1 Tautomerism of model heterocyclic phenols
The tautomerism of systems 26 to 38, taking into account both literature and
theoretical predictions, is summarised in Chart 8.4. Several of these systems, or
closely related ones, have been experimentally studied by a variety of means [8].
The predicted tautomeric behaviour from ab initio and semi-empirical calculations is
presented in Tables 8.2a, 8.2b and 8.2c. Systems 34- and 35- are exceptional, being
capable of anionic tautomerism, as presented.
The significance of tautomerism to AMPA receptor binding is an open question:
whether or not and at what position heterocycles might be protonated upon
binding to the receptor remains unknown. The plasma form of glutamate analogues
are believed to be anionic, that is immediately prior to binding, whereas neutral
tautomers are probably involved in transport across membranes.
However, the study of heterocyclic tautomerism is a challenging application for
theoretical chemistry in its own right. Tautomerism is complimentary to the study
of pKa. It is likely to effect in vivo transport behaviour of these molecules, as well as
providing insight into preferred sites and strengths of hydrogen bonding
interactions or protonation within the receptor.
8.4.1.1 3-hydroxy-4,5-dimethylisoxazole (26)
3-Isoxazolols are widely reported to prefer a hydroxy (26a) over a keto (26b)
structure, with an experimental pKT = -0.72±0.07 reported for the dimethyl
derivative (26) [8, 24], however the authors stress that this is most likely an
underestimate. Woodcock et al. [25] report that the unmethylated 3-isoxazolol is
favoured by 7.1 Kcal at MP4/6-31G(d,p)//3-21G, and also examine SCRF, PCM,
and free energy perturbation theories as means of estimating aqueous phase
properties, finding the latter two in good agreement and the former overestimating
the effect of large dipole on solvation. The calculations presented here give a
difference of 2.96 Kcal in favour of the hydroxy form at the highest level of theory
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trialed, being the reduced-basis set G2(MP2) calculation, corresponding to pKT = -
2.2 in the aqueous phase. Refining these figures to G2(MP2) theory was not
attempted because of the high cost of QCISD(T) calculations on C1 symmetry
structures, however better treatment of electron correlation may further lower the
energy of the keto tautomer (c.f. 27).
8.4.1.2 3-hydroxy-4,5-dimethylisothiazole (27)
Elguero [8] describes the tautomerism of the parent structure, 3-hydroxy-
isothiazole, citing the UV and NMR studies of Chan et al. [26], and also SCF-LCAO
calculations [27]. The hydroxy form is claimed to be favoured in non-polar
solutions, with the NH ketone becoming more prominent as the polarity increases
(KT(aq) = 0.3). The current results at G2(MP2) theory for the dimethyl derivative are
in very good agreement with this data, the hydroxy form (27a) being strongly
favoured in the gas phase (KT(gas) = 280) and the two forms being very close in
energy in the aqueous phase (KT(aq) = 1.5). Of particular note is the sensitivity of
geometries of both the OH and NH tautomers with respect to increased basis size,
the NH tautomer (27b) preferring a puckered structure at MP2/6-31G(d,p), but a
planar structure at MP2/6-311+G(3df,2p). The structural preference of both
tautomers is predicted to be planar in gas phase and aqueous solution.
8.4.1.3 4-methyl-5-isoxazolone (28)
The tautomerism of the 5-hydroxy isoxazoles is less clear, despite this heterocycle
being heavily studied by experimental and ab initio methods [7,25]. NH , (4)CH and
OH tautomers must all be considered, and apparently the position of equilibrium is
strongly dependent on solvent [8]. Generally, for 5-hydroxy-isoxazoles, polar
solvents tend to favour NH tautomers over CH tautomers, and the occurrence of
OH tautomers is rare. However, 4- substitution decreases the stability of CH
tautomers. The aqueous behaviour of the 4-methyl derivative (28) is not reported,
however the presence of the NH form only (28a) is reported in aqueous sulfuric
acid [8,28], and a mixture of 28a and 28b reported in cyclohexane (ratio 1:3) and
chloroform. Cramer and Truhlar [7] provide an extensive theoretical study and
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review the tautomerism of methyl- and unsubstituted 5-isoxazolones. High level
calculations (up to 345 basis functions with a triple-  basis set, and CCSD treatment
of electron correlation) were applied to the parent compound, as well as aqueous
phase modelling using semi-empirical (AM1-SM2, SM1a) and cavity models.
Methyl derivatives were examined using semi-empirical corrections applied to the
parent compound, and (28) was concluded in aqueous solution to prefer the NH
(28a) tautomer over the CH (28b) tautomer using AM1-SM2, and CH over NH
using AM1-SM1a, with the 5-OH (28c) tautomer substantially less favourable. Their
results are generally in accordance with known experimental trends, but doubt
exists as to the tautomeric behaviour of 28. They noted fairly poor convergence of
gas phase calculations with respect to increasing levels of theory and basis size,
emphasising the need for high quality calculations. The G2(MP2) calculations on 28
reported here are of comparable level to those of Cramer and Truhlar [7] on 5-
hydroxy-isoxazole. Without the inclusion of higher-level electron correlation
(QCISD(T)), the results suggest a mixture of all three tautomers, in proportions
NH>OH>CH in aqueous phase, and CH>OH>NH in gas phase. However, at
G2(MP2) theory, the OH tautomer proves substantially less favourable, in
accordance with experiment. An increase in stability of the NH tautomer with
respect to the CH tautomer from gas to aqueous phase is also noted, in accordance
with experiment. These results suggest a mixture of tautomers in the aqueous
phase, the CH tautomer being favoured by half a Kcal, within the expected error
range for this method. Further experimental and theoretical work would be
necessary to establish more accurately proportions of these two tautomers in
aqueous solution.
8.4.1.4 3-hydroxy-4-methyl-1,2,5-thiadiazole (29)
There is little experimental or theoretical data available on this compound. The
synthesis and pKa of 29 are known [29,30], and the claim is made on the basis that
there is no carbonyl peak observed in the IR spectrum in CHCl3, that the preference
is for a hydroxy tautomer (29a). The zwitterionic (5)NH structure suggested by
Elguero et al. [8] was found to be highly unfavourable energetically for 29 at
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MP2/6-31G(d,p) (by 33 Kcal) and not considered further. The results at G2(MP2)
theory support the experimental conclusion that 29a is the predominant tautomer in
the gas phase. However, an increase in the relative stability of the NH tautomer
(29b) in water indicates that it may play a role in the aqueous behaviour of this
system. Significant quantities of 29b would not be expected in non-polar solution.
8.4.1.5 2-methyl-3,5-dioxo-1,2,4-oxadiazolidine (30)
This unusual ring system seems to have been poorly studied, despite the well-
known activity of the natural product derived from it, quisqualate (7). Jackson et al.
[9] describe in detail X-ray crystal data of 7, and use 30 as a model for theoretical
studies in a similar fashion to the present work. They describe MNDO calculations
of the energy barrier of inversion of 30a. The current calculations support their
experimental and theoretical conclusions that 30 prefers a non-planar structure, the
substituted nitrogen being markedly pyramidal. Using reduced-basis set G2(MP2)
theory, it is predicted that the dioxo tautomer 30a is strongly preferred over either
OH tautomers, 30b and 30c, in gas and aqueous phases, in accordance with the X-
ray crystal structure.
8.4.1.6 1-methyl uracil (31)
The tautomerism of 1-methyl uracil is well studied and understood, as would be
expected from its biological importance [8,31,30,33]. The dioxo tautomer 31a has
been firmly established as strongly preferred in solution and solid phases. The
present study strongly supports only the presence of 31a in appreciable quantities
in the gas phase and in aqueous solution.
8.4.1.7 1-methyl 6-azauracil (32)
Elguero et al. [8] conclude that the tautomeric behaviour of 1-methyl 6-azauracil (32)
in solution closely parallels that of 1-methyl uracil (31), i.e. a preference for the 3-
NH tautomer 32a, citing [34]. A diketo structure was proposed and the pKa of 32
determined by Gut et al. [35]. The crystal structure of 6-azauracil is known to be a
diketone [36], supporting the presence of 32a in the solid phase. 6-Azauracil was the
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subject of quantum chemical studies as early as 1962 [37], and was included in an ab
initio tautomerism study [38] concluding the (3)NH tautomer to be preferred over
the 4-OH tautomer in the gas phase by 10.2 Kcal/mol uncorrected. The G2(MP2)
theory calculations gave a preference of 9.9 Kcal/mol for the corresponding 1-
methyl structures 32a vs. 32c. in the gas phase. Despite the fact that these aqueous
calculations show substantial preferential stabilisation of hydroxy tautomers, there
is no indication that any structure other than the diketo 32a is present in any phase.
8.4.1.8 3-hydroxy-4-methylpyridazine 1-oxide (33)
Despite the superficial similarity between 31 and 33, these two systems are found to
have quite different tautomeric behaviour. The parent compound 3-
hydroxypyridazine 1-oxide has been extensively studied experimentally [39,40,41].
A thorough ab initio investigation of this unmethylated heterocycle [15] was
presented in Chapter 2, supporting the 3-OH tautomer as most favoured in gas
phase and in solution. The tautomerism of 33 is previously unexamined, although
the compound is known synthetically [42,43]. It is found here to be very similar in
behaviour to 3-hydroxy-pyridazine 1-oxide, i.e. that the hydroxy tautomer 33a is
substantially more favourable than the N-OH (33b) or NH (33c) tautomers.
8.4.1.9 Model systems 34–38
Thorough analysis of the tautomerism of these structures is beyond the scope of this
work. The tautomerism of the triazole 34 is particularly complex, and its conjugate
base, 34- is capable of tautomerism. The (4)NH dioxo tautomer 34a- is predicted to
be preferred over the (1)NH dioxo tautomer 34b- by 0.99 Kcal in the gas phase at
MP2/6-311+G(3df,2p)//MP2/6-31G(d,p), in accordance with the available
literature [44]. Likewise, the conjugate base of the hydantoin, 35-, is capable of
tautomerism. The (5)CH2 dioxo tautomer 35a- is favoured by 15.72 Kcal over the
(5)CH, (3)NH dioxo tautomer 35b- at the same level, in accordance with the
literature [8]. Pyridazine-3,6-diones (36) are well known to prefer a lactam-lactim
structure [45,46], as examined in detail in Chapter 3, and N-methylation fixes the
position of the ketone and hydroxy substituents. The planar hydroxy-keto form 36a
227
is found to be preferred over the non-planar keto-keto form 36b by 7.96 Kcal at
MP2/6-31G(d,p). The tetrazole 37 would be expected by analogy to prefer a
hydroxy tautomer, and this is found to be the case, the hydroxy form 37a being
preferred by 6.23 Kcal over the keto form 37b at MP2/6- 311+G(3df,2p)//MP2/6-
31G(d,p). However 38 is believed from previous work to strongly favour the keto
(2)NH tautomer 38a [46,47,48], and a preference of 5.73 Kcal over 38b is found at
this level of theory.
8.4.2 pKa prediction, behaviour and activity
Table 8.3 compares ab initio, empirical, and experimental predictions of pKa for the
model compounds 26–33, corresponding to the ring structures known to give rise to
the most potent AMPA agonists. To a certain extent, interpretation of Table 8.3 is
hampered by the fact that the experimental literature is incomplete with respect to
pKa determination of the compounds under investigation. Moreover,
inconsistencies often occur between different methods applied to the same
compound by different authors. The development of easily applied and consistent
approaches to determining aqueous pKa is an ongoing area of research.
In their extensive study of compounds from series 1–4, several results of which
have been incorporated into Tables 8.1 and 8.3, Matzen et al. [12] devoted
considerable attention to determining and analysing the pKas of these analogues.
Their method of determining pKa was 
13C nmr titration. Their conclusion was that
"no simple correllation... was apparent" between pKa and in vitro activity. On the
other hand, a slightly more recent theoretical paper from the same group by
Frydenvang et al. [10] states "it appears that the difference in the acidity is the
primary factor affecting the activity" of isoxazolols vs. isothiazolols. Unfortunately,
it now seems that some early measurements underestimated the potency of the
isothiazolols [49] and thus these conclusions may need revision. The question of the
relationship between pKa and AMPA receptor activity remains wide open.
All of the structures considered by Matzen et al. [12], and Frydenvang et al. [10] are
predicted to be substantially ionised at physiological pH, the highest pKas for amino
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acids being for thio-AMPA (3a) and thio-ATPA (3b), i.e. pKa = 7.0, and for
heterocyclic fragments, 7.54 for 4-methyl 3-isothiazolol. This is in accordance with
the hypothesis that it is the tri-ionised anionic species which proceeds to interact
with the AMPA receptor. The suggestion is also made [12] that the observed
disparity between trends in the in vitro data and the in vivo data (uncertainty
regarding the activity of the isothiazolols not withstanding) namely that the thio
analogues are apparently more active in vivo as convulsants vs. the isoxazolols than
would be expected from electrophysiology, is the result of the fact that compounds
of higher -carboxylate bioisostere pKa may more easily cross lipid membrane
barriers such as the blood-brain barrier (BBB), due to the greater ease of formation
of neutral species. Significant proportions of the isothiazolol amino acids will be
present as neutral zwitterions in plasma.
The major anomaly with respect to activity and pKa, evident from Tables 8.1 and
8.3, is willardiine (10a). Based on literature pKas, the heterocycle portion of
willardiine is not expected to be substantially ionised at physiological pH. The
literature pKa of methyl-uracil (31) is 9.75 [50] , meaning that it is not expected to
ionise to a significant degree in plasma. The published pKas of willardiine are 9.3 or
9.97 for the ring proton, and 7.98 for the amino group [51,52]. If this is to be
believed, it would indicate that the tri-ionised anion should never exist at any pH in
appreciable quantities. One possible explanation is that the pKa measurements are
inaccurate, or that the order of protolysis has been confused; the pKa of glutamate
amino group being 9.7. While willardiine itself is of moderate potency, when
substituted with electron withdrawing groups, the potency is greatly increased. It
should also be noted that substitution of willardiine with electron withdrawing
groups (10b–10i), which decrease pKa, generally results in considerable increases in
in vitro activity, with some correspondence between the degree of electron
withdrawal and the activity. It may be the case then, that the ionisation of
willardiine is borderline for activity, and that analogues with pKas above this are
unlikely to be active.
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At the other end of the scale, there are strongly active analogues with pKas around
4. Glutamate itself has a pKa of 4.2, and aspartate 3.9. We do not yet have any
indication of what the lower limit of the pKa of the -carboxylate bioisostere is for
retaining activity.
In summary, the current results lend support to the conclusions of Matzen et al. [12]
regarding the AMPA receptor, i.e. that no clear relationship between pKa and
activity has yet been found. Better experimental data are needed. Compounds with
pKas between 4 and 8 are known to be active. With respect to the design of AMPA-
targetted pharmaceuticals, in vivo activity is likely to be higher with higher pKa;
design of a prodrug being an alternative strategy in this regard.
The claim is made of ACD/pKa [23], the empirical package used to estimate pKas in
Table 8.3, "The accuracy of calculation is usually better than ± 0.2 pKa units (for very
complex structures, better than ± 0.5)" [23]. These results, compared with
experimental data, do not bear out this claim - there are substantial disparities
between pKas predicted by this method, and experimental values, most notably for
the isoxazole (26) and oxadiazole (30). Although the precise method of empirical
calculation is not discussed by the manufacturer, it is clear that it is based on a
database of experimental compounds. Given that every heterocycle is a new story
with respect to pKa, the poor performance of an empirical scheme for heterocycles
outside its database is to be expected. The RMS deviation for the empirical method
vs. experiment was found to be approximately 2.0 (Graph 8.2), allowing for
incomplete experimental data. By comparison, the ab initio theoretical methods fare
slightly worse, with an RMS value of 2.4 (Graph 8.1), and in particular do a poor job
with the triazole (32). The deviation between empirical and theoretical methods is
substantially poorer at 3.5 (Graph 8.3).
The fact that both empirical and theoretical methods perform particularly poorly for
the oxadiazole may be attributed to the unusual character of this anion, with its
clear preference for a non-aromatic non-planar structure. It should also be noted,
that the authors expressed ambiguity in their experimental determination of the pKa
of quisqualate (7) by potentiometric titration [53].
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To the credit of the empirical method, it is able to evaluate absolute rather than
relative pKas, and for compounds included in its database such as 1-methyl uracil
(31) the results are in good agreement with experiment, whereas theoretical
technique employed is applicable only to relative estimates within a homologous
series. However, neither method may be judged sufficiently reliable in order to
predict pKa data to the accuracy required for activity relationships to be
determined. With regard to the theoretical calculations, the main source of error
resides in the consistency of the treatment of the anions. The quoted RMS error in
anion solvation by AM1-SM2 is 4.0 Kcal [54], but the relative treatments of
analogous anions is probably better than this. The treatment of anionic electron rich
heterocycles is known to require very large basis sets and extensive treatment of
correlation; inconsistencies in this treatment across heterocycles are most likely
where the bulk of the error lies. It may be hoped that as the quality of the
calculations able to be performed on heterocycles of this kind increases with
increased computing power, and with improved aqueous phase modelling, the
theoretical approach will become more viable for the ab initio prediction of pKa.
8.4.3 Observations on the requirements for - carboxylate bioisosterism at the
AMPA receptor: a tridentate model.
Being a trans-membrane protein, the 3D structure of the AMPA receptor and its
agonist binding site are unlikely to be solved within the near future. Attempts to
map the agonist binding site based on ligand properties must necessarily be
considered speculative. Previous work on AMPA agonists has tended to consider
only one or other class of heterocycles at a time. It is worthwhile making some
qualitative observations here, based on the whole range of bioisosteres, in
expectation of a more thorough future quantitative treatment.
Noting that known AMPA ligands (other than endogenous excitatory amino acids
aspartate and glutamate) are generally heterocyclic and exhibit charge
delocalisation, might suggest that a complementary receptor moiety would be a
positively charged heterocycle, such as a protonated histidine residue. In addition
to electrostatic interactions, such a model would suggest – stacking interaction
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between adjacent heterocyclic rings. Preliminary studies using AM1-SM2
calculations have not shown this kind of interaction to be favourable, the histidine
residue preferring to lie co-planar rather than parallel to the anionic heterocycle.
An examination of Figures 8.2.26 – 8.2.33, and especially Figure 8.3, being an
overlay of the electrostatic potentials of these structures 26–33 which represent the
classes of heterocyclic phenols from which the most potent AMPA agonists known
are derived, indicate three main regions of electrostatic minima. Most clearly seen
in Figures 8.2.30, 8.2.31 and 8.2.33, are three co-linear minima near the Van der
Waals surface of the heterocycles. Those active heterocycles carrying only one
oxygen substituent, 26–29, show a deep negative potential well surrounding this
atom, and a broader region in the space corresponding to the other two minima of
the dioxo- heterocycles, but with steric and electrostatic properties favourable for
interaction with more than one electropositive group. Proposed, therefore, is a
tridentate binding model hypothesis, involving three electropositive complements,
+1, +2 and +3, corresponding to the three co- linear electrostatic minima
observed, for example three proton interactions with the AMPA receptor (see Chart
8.5, Chart 8.6), with or without actual proton transfer to the anion. Previous authors
have tended to consider only one or two points of binding interaction with the ring.
The interactions between 3- and 5-isoxazolol ions and methyl guanidinium cations
(as arginine residue fragments) were studied in detail using semi-empirical
methods by Boulanger et al. [55], in connection with the inhibitory GABAA receptor,
which shows many parallels with EAA receptors. Their work suggested a bidentate
interaction of the GABAA receptor with these heterocycles. A tridentate binding
model at the AMPA receptor could be satisfied by an arginine as a bidentate
complementary residue, and in addition a third hydrogen bond donor. A flexible,
neutral hydrogen bond donor, for example serine, would accommodate both the
monoxo- and dioxo- heterocycles producing powerful agonists. Another possibility
which would assist in explaining both the binding of singly and doubly oxygen-
substituted heterocycles is the presence or absence of a binding site water molecule
mediating hydrogen bonding at position +1. These two possibilities are illustrated
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in Chart 8.6. An optimised complex between 31-, methyl-guanidinium, and
methanol, is depicted in Figure 8.4, as an example of the tridentate binding model
without water mediation. Figure 8.5 depicts an optimised complex between 26-,
methyl-guanidinium, water and methanol, an example of the water-mediated
tridentate binding model. This kind of ligand-water- residue mediation of binding
is well documented in other systems, e.g. the binding of dihydrofolate to
dihydrofolate reductase [56].
Preliminary studies of complexes between 26–33 and hydrogen bond donors using
geometry optimisation and AM1-SM2 theory are promising (e.g. Figures 8.4, 8.5)
indicating a preference for hydrogen bonding interactions within a few degrees of
the plane of the heterocyclic ring.
A binding model must not only be consistent with the activities of the closely
homologous singly oxygen-substituted series 1, 3, 5, 6, and the doubly substituted
series 7, 10, 14, 15, 16 and 17 for which an oxygen substituent lies - to the alanino
substituent, it must also be consistent with those systems for which the alanino
substituent lies - to an oxygen substituent, e.g. series 2 and 4.
Chart 8.5 illustrates two possible models of the way in which these two homologies
may be reconciled, namely that there are two possible orientations of the
heterocyclic ring of known potent ligands which satisfy tridentate binding . Both
models assume consistent (S) stereochemistry about the chiral centre. Model 1
places importance on the consistent interactions of +2 and +3 with strongly
electronegative regions of the carboxylate bioisostere, presuming that
conformational flexibility will allow the -amino acid portion of the molecule to
align with its receptor complement despite the difference in relative substitution
position. Model 2 places more importance on the relative position of alanino
substitution with respect to +2 and +3, and less importance on dipole direction.
Chart 8.5 compares the potent agonists bromo-willardiine (10d) and bromo-HIBO
(2c) with AMPA. The binding orientation of willardiines is ambiguous under Model
1, a reason to prefer Model 2; 10d is depicted here with bromine substituent
isosteric with that of 2c.
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The tridentate hypothesis should also be consistent with, and assist in explaining
the reduction in activity observed with other compounds in Table 8.1. Firstly, the
decreased electronegativity surrounding the sulfur atom in the thio- analogues of
AMPA and HIBO, 3 and 4, and the decreased hydrogen bond accepting character of
the isothiazoles, is consistent with the reported decrease in in vitro activity observed
for these compounds (Figure 8.2.27). The hydantoin 9, although ostensibly capable
of accepting three hydrogen bonds, probably owes its lack of activity to its high pKa
and hence, lack of ionisation in vivo, and lack of aromatic character or electron
delocalisation. 8, While fairly acidic (pKa = 4.7 [53]), prefers an anionic tautomer
with a proton in position to interrupt binding (Figure 8.2.34), and a dipole in an
unfavourable direction for receptor alignment (Figure 8.1.34).
The reduced activity of 18 vs. 17 and 16 is not necessarily expected from Model 1,
but lends weight to Model 2 by confirming the importance for activity of the
positioning of the -amino acid moiety with respect to the electronegative regions
of the molecule. While the activity of 17 is less than 16, it is still fairly active for a
compound without hydrophobic substituent, c.f. 2b, 2a, 5a et al.
While the tetrazoles 19 and 20 appear to potentially support tridentate interaction
(Figures 8.1.37, 8.2.37), their activities are low. Whether this is because these bicyclic
systems are approaching the size limit which may be accommodated by the AMPA
receptor binding pocket, whether because of unfavourable electrostatic interaction,
or because of insufficiently low pKa, is unknown. It is worth noting that the degree
of negative charge assigned to the tetrazole nitrogen attached to the pyridazine ring
nitrogen from electrostatic potential derived charges (Figure 8.1.37) is substantially
lower than that assigned for the homologous N-oxide (Figure 8.1.33). The relative
positions of the alanino substituent and anionic regions of 19 vs. 20 are reflected in
their activities in analogous fashion to 16b vs 18.
The pyridazine-3,6-dione AMPA analogues, series 21–23, are particularly
interesting illustrations of the requirements for activity. The non-N-methylated
compounds 21a and 21c, are weak and non-specific glutamate agonists [67,Chapter
7]; two hydrogen bond acceptor regions are available in these cases, but the
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presence of a protonated ring nitrogen prevents a third point of binding. Their
weak activity as NMDA agonists may be related to the alternate tautomeric forms
available to the anions, and may be compared with the lack of specificity of
quisqualate (7). The second ring oxygen substituent, situated para- to the first, is
poorly placed to interact with the AMPA receptor under the tridentate hypothesis.
N-methylation para- to the alanino substituent (21b) completely abolishes activity,
despite the superficial similarity between this compound and 1a, the difference
being replacement of ring oxygen with methyl-lactam. This clearly indicates that
the AMPA receptor cannot tolerate a hydrophobic group in this region, i.e. +1. The
low and moderate activities of 22a and 22b parallel the reduced activity of 18 vs
16b, and compared with 21b, seem to indicate a greater tolerance for hydrophobic
substituents close to position +3 than for position +1. None the less, the potency
of 22b is unexpectedly high under the present hypothesis, and may indicate some
latitude of binding orientation. The orientation of the regions of electrostatic
potential minima of 23 vs the location of the amino acid substituent correspond
very poorly with the current models of the AMPA receptor, and unsurprisingly,
this compound is without activity.
The pyridazin-3-ones 25 and particularly 24 also fit within the tridentate binding
hypothesis, but show poor or nil activity. The electrostatics appear favourable
(Figures 8.1.38 and 8.2.38), but most likely it is the relatively high pKa = 10.5 [57] of
this heterocycle which is preventing binding. It would be most interesting to
examine the effect of ring substitution with an electron withdrawing group on
activity. As with 18 vs. 16, shifting the position of the alanino substituent reduces
activity, in this case abolishing it entirely.
8.5. Conclusion
The available literature on the activities of alanino heterocycles as agonists at the
AMPA excitatory amino acid receptor has been summarised, and structure-activity
data on novel pyridazinone AMPA analogues presented. This catalogue of
structures is expected to continue to proliferate in the future.
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Des-glycino parent heterocycles of AMPA active compounds have been modelled
using high level ab initio gas phase and semi-empirical aqueous phase calculations.
Structure, tautomerism, electrostatic properties, and pKa behaviour have been
modelled and discussed with respect to experimental literature. Neither empirical
nor ab initio methods of pKa determination are yet satisfactory for confident
extrapolation to novel heterocycles. Models of a tridentate binding hypothesis of -
carboxylate bioisosteres at the AMPA receptor have been presented, as a means to
rationalising the whole range of alanino heterocycles known to activate the
receptor.
The design of new -carboxylate bioisosteres based on hydroxy heterocycles
should take into consideration tautomerism and pKa behaviour such that ionisation
at physiological pH is significant and structure favours hydrogen bonding
interactions. The tridentate binding hypothesis suggests that the presence of steric,
neutral, or positive groups in any of the three binding regions is likely to decrease
potency. All known bioisosteres are five- or six-membered heterocycles possessing
two or more adjacent heteroatoms, monoxo- or dioxo- substituted, with a
heteroatom - to an oxygen substituent.
8.6. Calculation details
QCISD(T) energies were calculated using Molpro 96 [58]. All other ab initio
calculations were performed using Gaussian 94, revision D.3 [59]. AM1-SM2
calculations were performed using AMSOL 5.4 [54] and Spartan 4 [60]. Empirical
pKa estimates were calculated with ACD/pKa [23]. Platforms used were SGI R4000
O2 and SGI R10000 Power Challenge (IRIX 6.2) and IBM RS6000 (AIX 3.2).
Visualisation and rendering were performed with Spartan 4, and Povray [61].
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Table 8.1. Activities of alanine-substituted heterocycle AMPA analogues
Structurea,
Class
Substituents
(Chart 1,2)
Activity,
electrophysiolog
y b
Activity,
binding c
Selectivity and
stereoselectivity
References
3-isoxazolols
1a R = Me 3.5 µM I
5.4µM I
5.4µM II
1 µM III
0.040 µM *
0.02µM (S) *
76µM (R) *
0.28 &
14.23µM(S) **
82.80µM (R) **
AMPA>>NMDA, KAIN
(S) >> (R)
[3, 4, 12, 62,
63, 64, 65, 66,
67, 68, 69]
1b R = H 900µM I 0.27µM * AMPA>>NMDA, KAIN [69]
1c R = Et 2.3µM I 0.03µM * AMPA>>NMDA, KAIN [70]
1d R = C(CH3)3 34µM 
I
~50µM I
2.1µM *
10µM *
AMPA>>NMDA, KAIN [3, 12, 70]
[72]
1e R = Pr 5.0µM I 0.09µM * AMPA>>NMDA, KAIN [69]
1f R = CH(CH3)2 9.0µM 
I 0.19µM * AMPA>>NMDA, KAIN [69]
1g R = cyclopropyl 5.5µM I 0.035µM * AMPA>>NMDA, KAIN [70]
1h R = (CH2)3CH3 32µM 
I 1.0µM * AMPA>>NMDA, KAIN [69]
1i R = CH2CH(CH3)2 23µM 
I 0.61µM * AMPA>>NMDA, KAIN [69]
1j R = C(CH3)3 34µM 
I
~50µM I
2.1µM *
10µM *
AMPA>>NMDA, KAIN [3, 12, 70]
[72]
1k R = (CH2)2 CH(CH3)2 >1000µM 
I >100µM *  [69]
1l R = CH2C (CH3)3 420µM 
I 55µM * AMPA>>NMDA, KAIN [69]
1m R = phenyl 230µM (S) I
(R) is weak
antagonist
6µM (S) * AMPA>> NMDA, KAIN (S)
AMPA, KAIN antagonist (R)
[71]
1n R = CH((CH2)2CH3)2 >1000µM 
I 99µM *  [69]
1o R = benzyl >1000µM I >100µM *  [69]
1p R = CH2Br 13µM 
I 0.03µM *  [3, 73]
1q R = thiazole,-2-yl d 2.3µM I 0.094µM * AMPA > KAIN > NMDA [68]
1r R = imidazole,-2-yl 550µM I 48µM * AMPA > KAIN > NMDA [68]
1s R = imidazole,1-
methyl-2-yl
> 1000µM I > 100µM * KAIN > AMPA,NMDA [68]
1t R = 1,2,4-triazole,-3-
yl
63µM I 1.5µM * AMPA > KAIN > NMDA [68]
1u R = 1,2,4-triazole,2-
methyl-3-yl
93µM I 5.8µM * AMPA,KAIN > NMDA [68]
1v R = 1,2,4-triazole,1-
methyl-3-yl
11µM I 0.7µM * AMPA >> KAIN,NMDA [68]
1w R = tetrazole,5-yl > 1000µM I 72µM * AMPA > KAIN,NMDA [68]
1x R = tetrazole,-1-
methyl-5-yl
> 1000µM I 54µM * AMPA > KAIN,NMDA [68]
1y R = tetrazole,-2-
methyl-5-yl
0.92µM I 0.03µM * AMPA > KAIN > NMDA [68]
1z R = pyridin-2-yl e 7.4µM I
4.5µM (S) I
(R) is weak
antagonist
0.57µM *
0.19µM (S) *
 [74]
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2a R = H 370µM I 1.5µM * AMPA>>NMDA, KAIN
(S) >> (R)
[4,12,62]
2b R = Me ~20µM I 0.6µM *  [62 ,72]
2c R = Br 22µM I
23µM I
21µM (S) I
>1000 (R) I
0.65µM *
0.60µM *
0.34 µM(S) *
32µM(R) *
 [12,62,75]
2d R = (CH2)3CH3 ~40µM 
I
37µM I
17µM (S)I
>1000 (R) I
2µM *
1.8µM *
0.48µM (S)*
>1000 (R) I
AMPA &GT;&GT;
NMDA,KAIN
[72,75]
2e R = CH2CH2OH ~90µM 
I 2µM * AMPA &GT;&GT;
NMDA,KAIN
[72]
3-isothiazolols
3a R = Me 15µM I f 1.8µM *  [12]
3b R = C(CH3)3 14µM 
I 0.63µM *  [12]
4a R = H 380µM I 5.8µM *  [12]
4b R = Br 500µM I 17µM *  [12]
5-isoxazolols
5a R = H 300µM III 0.28µM * AMPA>KAIN>NMDA (S)
NMDA>AMPA>KAIN (R)
[4,64]
5b R = Me 1µM III 0.30µM *  [64]
5c R = Et 1µM III 0.67µM *  [64]
5d R = cyclopropyl 0.3µM III 0.12µM *  [64]
5e R = cyclopentyl 0.3µM III 0.31µM *  [64]
5f R = isopropyl 3µM III 3.8µM *  [64]
5g R = phenyl 30µM III 15µM *  [64]
3-hydroxy-1,2,5-thiadiazole
6  "potent"  AMPA [4,49,76]
3,5-dioxo-1,2,4-oxadiazolidine
7  8µM II
0.9 µM(S) IV
25 µM V
15 µM (S) V
120 µM (R) V
0.0086 µM *
0.26µM (S) **
AMPA,KAIN>NMDA [53, 64, 65,
66, 77, 78, 79]
3,5-dioxo-1,2,4-triazole
8  nil at 1000 µM V   [53]
hydantoin
9  nil at 1000 µM V
"potent" g
 "depolarisation in the
mammalian EAA system" g
[53]
[51, 80]
uracils
10a R = H 1/3 to 1/2 vs 7a
VI
44.8µM (S)IV
3.40µM(S) **
> 1000µM(R) **
AMPA,KAIN >>NMDA
(S)>>(R)
[4,81,82,83,
84]
10b R = F 1.47µM (S) IV 0.02 &
30.39µM(S) **
 [4,82,83, 84]
10c R = Cl 7.28µM (S) IV 0.39µM(S) **  [82,83, 84]
10d R = Br 8.82µM (S) IV 0.56µM(S) **
41.00µM(R) **
 [82,83, 84]
10e R = I 19.2µM (S) IV 19.45µM(S) **
> 1000µM(R) **
 [82, 83, 84]
10f R = NO2 4.10µM (S) 
IV 0.20µM(S) **  [82, 83, 84]
10g R = CN 3.75µM (S) IV 1.64µM(S) **  [83, 84]
10h R = CF3 4.00µM (S) 
IV 0.37µM(S) **  [83, 84]
10i R = CH3 251µM (S) 
IV 68.5µM(S) **  [83, 84]
11   23.46µM**  [83]
12   > 1000µM **  [83]
13   > 1000µM **  [83]
243
6-aza-uracils
14a R = H 3.99 (S) VI
3645 (R) VI
1.6µM(S)
>1000µM(R) **
KAIN,AMPA >> NMDA
(S)>>(R)
[85, 86, 87]
14b R = Cl 0.07 (S) VI 53.0µM(S) ** KAIN,AMPA >> NMDA [85, 86, 87]
14c R = Br 0.08 (S) VI 19.0µM(S) ** KAIN,AMPA >> NMDA [85, 86, 87]
14d R = I 0.15 (S) VI 0.5µM(S) ** KAIN,AMPA >> NMDA [85, 86, 87]
14e R = Me 1.90 (S) VI 2.5µM(S) ** KAIN,AMPA >> NMDA [85, 86, 87]
15  4.62 (RS) VI 5.4µM(RS) ** KAIN,AMPA >> NMDA [85,87]
3-hydroxy-pyridazine 1-oxides
16a R = H 9.28µM II  AMPA>>NMDA [63,67]
16b R = Me 8.74µM II  AMPA>>NMDA [67]
17  65µM II   [63,67]
18 R = Me 588µM II   [67]
6-hydroxy-tetrazolo[1,5- b]pyridazines
19  299µM II  AMPA>>NMDA [67, 89]
20  610µM II  AMPA,NMDA [67, 89]
pyridazine-3,6-diones
21a (=22c) h R1 = R2 = H 481µM 
II  AMPA, NMDA [67, 88]
21b R1 = H
R2 = Me
nil at 1000 µM II   [67, 88]
21c (=22d) h R1 = Me
R2 = H
289µM II  AMPA, NMDA [67, 88]
22a R1 = H
R2 = Me
low ( 1000 µM) II  AMPA>>NMDA [67, 88]
22b R1 = R2 = Me 81.4µM 
II  AMPA>>NMDA [67, 88]
23  nil at 1000µM II   [67, 88]
pyridazine-3-ones
24  837µM II   [67]
25  nil at 1000 µM II   [67]
a unless otherwise indicated, values refer to racemic mixture.
b electophysiological assays
I EC50, cortical wedge preparation, Krogsgaard-Larsen et al. [12, 68, 70, 73 ,72 90]
II EC50, cortical wedge preparation, Vaccarella, Allan, et al. [67, 90,91]
III Minimum effective concentration required to excite rat hippocampal CA1
neurones in vitro [64]
IV Steady-state EC50 values, whole-cell recording from mouse embryonic
hippocampal neurons [82, 84]
V Equipotency of inhibition of retractor unguis muscle of Schistocerca gregaria vs
L-glutamate at 100 µM [53]
VI Depolarisation of motoneurones from ventral roots of hemisected spinal-cord
preparations [81]. Equieffective molar concentrations relative to (S)-AMPA=1
[87]
c IC50, µM, inhibition of AMPA binding.
* (RS)[3H]AMPA. One site model, in the presence of KSCN. [ 64, 70, 83 et al.]
** (S)[3H]AMPA. One or two site models, in the absence of KSCN. [83].
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d The thiophene-2-yl isomer of 1q is reportedly active, EC50 of 5.8 µM; and the furan-
2-yl isomer apparently also known. [49, 92]
e The pyridin-3-yl isomer of 1z is reportedly inactive, and the pyridin-4-yl isomer a
weak agonist. [74]
f 3a has apparently been found to be substantially more active than the published
figures suggest [49]
g While inactive in the locust glutamatergic system [53], 7c potentiates
depolarisation by L-AP4 in mamalian hippocampal CA1 neurones, and is suggested
to act via the AMPA receptor [51, 80]
h Structures 21a and 21c may be regarded also as structures 22c, 22d by
tautomerism.
245
Table 8.2a. 26–33 at MP2/6- 311+G(3df,2p)//MP2/6-31G(d,p)
Structure Symmetry E0 
a G298, gas
b
Gas phase
Ratio c
Gaq 
d Aqueous
Ratio c
26a Cs -344.27 -343.44 99.97% - 276.66 99.98%
26b C1 -339.53 -338.70 0.03% - 271.59 0.02%
27a Cs 
e -344.46 -344.17 99.99% -284.27 98.90%
27b Cs 
f -338.58 -338.41 0.01% -281.61 1.10%
28a C1 -327.64 -326.53 5.62% - 268.80 55.36%
28b C1 -329.13 -327.99 65.68% - 269.06 8.92%
28c Cs -328.33 -327.50 28.71% - 267.98 35.72%
29a Cs -335.64 -334.87 100.00% - 279.13 100.00%
29b Cs -325.57 -325.20 0.00% - 271.92 0.00%
30a C1 -326.59 -326.04 100.00% - 271.03 100.00%
30b C1 -311.48 -310.86 0.00% - 259.06 0.00%
30c C1 -309.95 -309.28 0.00% - 256.70 0.00%
31a Cs -344.53 -343.70 100.00% - 282.59 100.00%
31b Cs -326.00 -325.17 0.00% - 268.39 0.00%
31c Cs -334.29 -333.12 0.00% - 274.48 0.00%
32a Cs -334.22 -332.11 100.00% - 272.13 99.99%
32b Cs -319.34 -318.28 0.00% - 262.86 0.00%
32c Cs -324.97 -323.33 0.00% - 266.28 0.01%
33a Cs -330.96 -330.21 99.78% - 276.36 100.00%
33b Cs -322.66 -322.02 0.00% - 270.16 0.00%
33c Cs -327.63 -326.60 0.22% - 268.25 0.00%
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Table 8.2b. Tautomerism at G2(MP2) theory
Structure Symmetry E0 
g G298, gas 
b Gas phase
Ratio c
Gaq 
d Aqueous
Ratio c
27a Cs e -345.22 -344.93 99.64% - 285.04 60.45%
27b Cs f -342.03 -341.59 0.36% - 284.79 39.55%
28a C1 -331.96 -330.85 0.54% - 273.38 28.13%
28b C1 -335.09 -333.94 99.36% - 273.93 71.23%
28c Cs -330.67 -329.84 0.10% - 271.14 0.64%
29a Cs -336.65 -335.88 100.00% - 280.15 99.71%
29b Cs -330.33 -339.96 0.00% - 276.68 0.29%
31a Cs -346.55 -345.71 100.00% - 284.61 100.00%
31b Cs -338.14 -337.31 0.00% - 270.52 0.00%
31c Cs -336.19 -335.02 0.00% - 276.38 0.00%
32a Cs -336.58 -334.48 100.00% - 274.50 100.00%
32b Cs -321.78 -320.72 0.00% - 265.30 0.00
32c Cs -326.65 -325.01 0.00% - 267.96 0.00
33a Cs -332.91 -332.16 99.18% - 278.31 100.00%
33b Cs -324.73 -324.10 0.00% - 272.24 0.00%
33c Cs -330.36 -329.32 0.82% - 270.98 0.00%
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Table 8.2c. Tautomerism at reduced basis set G2(MP2) theory
Structur
e
Symmetry E0 
h G298, gas
b
Gas phase
Ratio c
Gaq 
d Aqueous
Ratio c
26a Cs -345.06 -344.22 99.33% - 277.45 99.62%
26b C1 -342.09 -341.26 0.67% - 274.15 0.38%
30a C1 -328.56 -328.00 100.00% - 272.99 100.00%
30b C1 -314.13 -313.51 0.00% - 261.70 0.00%
30c C1 -312.86 -312.19 0.00% - 259.61 0.00%
a Eelec = E{MP2/6-311+G(3df,2pd)//MP2/6-31G(d,p)}
E0 = Eelec + 0.8929*ZPE{HF/6-31G(d)}
All energies in Kcal/mol, relative to conjugate base anion
b G298 = Eelec + Ethermal + RT - TS
Thermochemistry calculated at HF/6-31G(d) minima, 298.15 K.
c HAi <=> HAj ; Kj,i = [HAj]/[HAi] = exp((Gi-Gj)/RT) ; [HA] = 1
d For neutral species:
Gaq = G298 + E{AM1-SM2//MP2/6-31G(d,p)}-E{AM1//MP2/6-31G(d,p)}
For anions:
Gaq = G298 + E{AM1-SM2}-E{AM1}
e Minimum in Cs symmetry at MP2/6-31G(d,p). Cs symmetry is not a minimum at
HF/6- 31G(d). C1 structure used for thermochemistry calculation.
f C1 optimised structure favoured over Cs optimised structure at MP2/6-31G(d,p) by
0.21 Kcal. However, Cs symmetry favoured by 0.10 Kcal at MP2/6-
311+G(3df,2pd)//MP2/6-31G(d,p). C1 optimised structure used for
thermochemistry.
g Modified G2(MP2) theory [14] incorporating optimisation at MP2/6-31G(d,p):
Eelec = E{MP2/6-311+G(3df,2pd)//MP2/6-31G(d,p)}
+ E{QCISD(T)/6-311G(d,p)//MP2/6-31G(d,p)}
- E{MP2/6-311G(d,p)//MP2/6-31G(d,p)}
+ EHLC
E0 = Eelec + 0.8929*ZPE{HF/6-31G(d)}
h Reduced basis set G2(MP2) theory (cf [14, 17]), neglecting EHLC:
Eelec = E{MP2/6-311+G(3df,2pd)//MP2/6-31G(d,p)}
+ E{QCISD(T)/6-31G(d,p)//MP2/6-31G(d,p)}
- E{MP2/6-31G(d,p)}
E0 = Eelec + 0.8929*ZPE{HF/6-31G(d)}
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Table 8.3. Solvation energies, pKa predictions and literature values*
Structure Gsolv
single point a
Gsolv
optimised b
G298, aq 
c
pKa
theoretical d
pKa
empirical
e
pKa
experimental
reference
26- -74.62 -75.41 - 398.74839 4.41 8.05 ± 0.44 4.8 f
5.12 f
5.07 g
5.85 h
[93]
[11]
[11]
[10]
26a -8.64 -8.84 - 399.19032
27- -73.09 -74.45 - 721.39789 9.99 9.84 ± 0.42 8.15 i
7.00 j
6.69 k
7.54 l
[94]
[12]
[12]
[10]
27a -14.56 -17.62 - 721.85213
27b -17.64 -23.93 - 721.85173
28- -67.11 -67.21 - 359.53390 1.80 5.80 ± 0.50 4.5 [28]
28a -9.74 -9.72 - 359.96957
28b -7.21 -7.22 - 359.97045
28c -8.52 -8.85 - 359.96599
29- -74.18 -74.71 - 698.23865 6.48 6.35 ± 0.44 5.1 [30]
29a -18.97 -19.64 - 698.68509
29b -21.43 -25.56 - 698.67956
30- -67.26 -66.53 - 450.75033 1.23 7.41 ± 0.40 4.2 m [53]
30a -11.52 -11.67 - 451.18534
31- -73.85 -75.07 - 452.89612 9.75 d 9.24 ± 0.40 9.75
9.3 n
9.97 n
[50]
[51]
[52]
31a -13.96 -14.93 - 453.34967
31b -18.28 -18.94 - 453.32723
31c -16.43 -16.54 - 453.33656
32- -71.43 -72.12 - 468.92181 2.34 7.69 ± 0.40 6.99 [95]
32a -12.15 -12.79 - 469.35925
32b -16.70 -17.21 - 469.34459
32c -15.07 -15.25 - 469.34884
33- -67.54 -66.69 - 452.78955 5.14 6.31 ± 0.45 4.1 o [40]
33a -12.84 -12.09 - 453.23307
33b -14.83 -15.91 - 453.22339
33c -8.35 -8.39 - 453.22139
* See also Graphs 1- 3.
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a Free energy of solvation at MP2/6- 31G(d,p) geometry in Kcal / mol
Gsolv = E{AM1-SM2//MP2/6-31G(d,p)}- E{AM1//MP2/6-31G(d,p)}
b Free energy of solvation at semi- empirical geometry in Kcal / mol
Gsolv = E{AM1-SM2}-E{AM1}
c Absolute G298,aq free energies in Hartree, from modified G2(MP2) theory,
thermochemistry at HF/6-31G(d) , and AM1-SM2 solvation energy as follows
Eelec = E{MP2/6-311+G(3df,2pd)//MP2/6-31G(d,p)} + E{QCISD(T)/6-
311G(d,p)//MP2/6-31G(d,p)} - E{MP2/6- 311G(d,p)//MP2/6-31G(d,p)} + EHLC
E0 = Eelec + 0.8929*ZPE{HF/6-31G(d)}
G298 = Eelec + Ethermal + RT - TS
Thermochemistry calculated at HF/6-31G(d) minima, 298.15 K.
For neutral species:
G298,aq = G298 + E{AM1-SM2//MP2/6- 31G(d,p)}-E{AM1//MP2/6-31G(d,p)}
For anions:
G298,aq = G298 + E{AM1-SM2}-E{AM1}
d pKa = (- log10(exp(- G298,aq/RT))), Relative to pKa (31) = 9.75
Where more than one tautomer is significant, i.e. 28, 29, 30, free energy at
equilibrium is determined as a weighted average:
G298,aq = aiG298,aq,i - G298,aq,anion ; such that ai = 1
e Modified Jaffe method [22] of estimating parameters for the Hammet equation, as
implemented in ACD/pKa program [23]
f pKa of AMPA (1a)
g pKa of HIBO (2a)
h pKa of 3-isoxazolol
i pKa of 4-methyl-3- isothiazolol
j pKa of thio-AMPA (3a)
k pKa of thio-HIBO (4a)
l pKa of 3- isothiazolol
m pKa of quisqualate (7) as determined by Boden et al. [53] and apparently
misquoted as 4.5 by Hill et al. [51]
n pKa of willardiine (10a) as determined by Lidak et al [51] and Hill et al. [52]
respectively. Interestingly, Lidak also quotes ammonium protolysis pKNH3+ for
willardiine as 7.98.
o pKa of 3-hydroxy- pyridazine 1-oxide
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Figures 8.1.26 to 8.1.31 Conjugate base anions of model acidic
heterocycles, CPK rendering, point charge distributions
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Figures 8.1.32 to 8.1.37 Conjugate base anions of model acidic
heterocycles
252
Figure 8.1.38, Figures 8.2.26 to 8.2.30 Conjugate base anions of model
acidic heterocycles, Van der Waals surfaces, electrostatic potentials
253
Figures 8.2.31 to 8.2.36 Conjugate base anions of model acidic
heterocycles, Van der Waals surfaces, electrostatic potentials
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Figures 8.2.37 to 8.2.38 Conjugate base anions of model acidic
heterocycles, Van der Waals surfaces, electrostatic potentials
Figure 8.3 Conjugate base anions 26- to 33- overlayed
Figure 8.4 1-methyl uracil anion, methyl guanidinium cation, and
methanol complex
Figure 8.5 4,5-dimethyl-3-isoxazolol anion, methyl-guanidinium
cation, water, and methanol complex
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Chart 8.1. Alanino hydroxy-heterocycles with moderate to high
agonist activity at AMPA receptors
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Chart 8.2. Alanino hydroxy-heterocycles showing reduced or
abolished activity at AMPA receptors
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Chart 8.3. Model heterocyclic conjugate bases
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Chart 8.4. Tautomerism of model heterocycles
Optimised geometries at MP2/6-31G(d,p) linked
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Chart 8.5. Tridentate binding models at AMPA receptors
The tridentate binding model hypothesis suggests two possible binding orientations
of heterocyclic domains.
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Chart 8.6. Tridentate binding to two putative residues, with and
without water mediation
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Graph 8.1.: Experimental pKas vs ab initio predictions (Table 3)
RMS deviation = 2.4
Graph 8.2.: Experimental pKas vs empirical predictions (Table 3)
RMS deviation = 2.0
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Graph 8.3.: pKas: ab initio vs. empirical predictions (Table 3)
RMS deviation = 3.5
